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Since ultrasound was introduced for diagnostic purposes in medicine, it has become an imaging 
modality with many applications in internal and vascular medicine, obstetrics and gynaecology, 
and cardiology. Developments in ultrasound technology during the last decades, have 
significantly contributed to the implementation of ultrasound for diagnostic purposes. Ultrasound 
contrast agents, that are gas-filled microspheres with specific acoustic properties, were introduced 
initially to opacify the right ventricle. Later, microbubbles with improved stability and survival 
were developed that pass the pulmonary capillary bed, and thus reached the left side of the heart. 
The use of these contrast agents for left ventricular opacification has significantly improved the 
diagnostic accuracy of (stress) echocardiography. However, the most important application is the 
non-invasive assessment of myocardial perfusion with intravenous myocardial contrast 
echocardiography. In patients with both acute and chronic ischemic heart diseases, this technique 
has proven its important clinical value.  
At the same time, experimental studies investigated the ability to use microbubbles, that are pure 
intravascular tracers, for therapeutic purposes. Chemical properties of microbubbles allow them 
to bind drugs or genes, and local delivery in body tissue can be achieved by intravenous injection 
and localized ultrasonic destruction. Insonified ultrasound contrast agents appear to produce 
mechanical effects, that can be used for e.g. lysis of blood clots. This sonothrombolytic effect is a 
promising application of ultrasound contrast.  
This thesis describes several clinical studies on intravenous myocardial contrast 
echocardiography, and reviews the existing literature on the use of myocardial contrast 
echocardiography for assessment of myocardial perfusion in patients with acute and chronic 
ischemic heart disease. Furthermore, an experimental study on the effects of insonified 
microbubbles on a cellular level is presented, toghether with a review on the use of ultrasound 
contrast agents for therapeutic purposes. 
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Abstract 
The development of ultrasound contrast agents, containing encapsulated microbubbles, has 
increased the possibilities for diagnostic imaging. Ultrasound contrast agents are currently used to 
enhance left ventricular opacification, increase Doppler signal intensity, and in myocardial 
perfusion imaging. Diagnostic imaging with contrast agents is performed with low acoustic 
pressure using non-linear reflection of ultrasound waves by microbubbles. Ultrasound causes 
bubble destruction, which lowers the threshold for cavitation, resulting in microstreaming and 
increased permeability of cell membranes. Interestingly, this mechanism can be used for delivery 
of drugs or genes into tissue. Microbubbles have been shown to be capable of carrying drugs and 
genes, and destruction of the bubbles will result in local release of their contents. Recent studies 
demonstrated the potential of microbubbles and ultrasound in thrombolysis. In this article, we will 
review the recent advances of microbubbles as a vehicle for delivery of drugs and genes, and 
discuss possible therapeutic applications in thrombolysis. 
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Introduction                     
For the past decades ultrasound has been an imaging modality with multiple applications. 
Ongoing developments improved diagnostic possibilities remarkably whereas ultrasound also 
became of interest as a therapeutic tool in interventional cardiology e.g. for intravascular 
sonotherapy of coronary arteries and non-invasively for induction of thrombolysis (1;2). The first 
use of contrast agents in echocardiography was already reported by Gramiak and Shah in 1968 
(3). Intracardiac injection of saline improved aortic delineation, probably by reflection of 
ultrasound by mini bubbles present in the contrast medium. Since then, microbubbles have 
rapidly developed to an ultrasound contrast agent in echocardiography (4;5). Microbubbles are 
small gas-filled microspheres that have specific acoustic properties that make them useful as a 
contrast agent in ultrasound imaging. First-generation microbubbles are room air microspheres 
(6). However, air microbubbles disappear in a few seconds after intravenous administration as the 
solubility of air in blood is high and the lungs filter microbubbles, especially those with higher 
diameters (7;8). Therefore, they are not useful to opacify the left cardiac chamber. Improved 
stability and survival was reached by stabilizing microbubbles with a thin shell, like albumin 
(Albunex) or galactose palmitic acid (Levovist). These microbubbles are capable of passing the 
pulmonary capillary bed, but cannot resist arterial pressure gradients. To increase stability of 
microbubbles further, second-generation contrast agents are filled with a heavy-molecular-weight 
gas like e.g. sulphur hexafluoride, which decreases solubility, thus improving survival and 
stability under higher pressure. Surfactants, sonicated albumin and (phospho)lipids are used to 
improve stabilization of the shell (6). For example, Sonovue, a second-generation contrast agent, 
is a phospholipid coated, sulphurhexafluoride gas-containing microbubble used in diagnostic 
imaging. These microbubbles have much smaller diameters than room air-filled bubbles (about 
2.5 µm), which improves passage of the pulmonary capillary bed.  
Low acoustic pressure, i.e. a mechanical index (MI) lower than 0.05, causes linear oscillations of 
microbubbles and the frequency of ultrasound reflection is equal to the transmitted frequency. 
Increase of acoustic pressure (MI>0.05) causes non-linear expansion and compression of 
microbubbles, resulting in emission of non-linear harmonic signals at multiples of the transmitted 
frequency (9). Diagnostic imaging with contrast agents uses acoustic pressure higher than MI 
0.05 and the harmonic imaging modality, which improves signal-noise ratio by transmitting a 
fundamental frequency and receiving multiples of this frequency. This creates an acoustic 
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impedance mismatch between body tissue and fluids containing microbubbles and makes them 
useful in diagnostic ultrasound imaging (10). 
Microbubbles and their bioeffects: potential use for drug delivery                                                       
Microbubbles have been proposed as a new vehicle for delivery of drugs and genes (7;9;11-17). 
Several properties of microbubbles make them a promising tool for drug and gene delivery to 
cells. Microbubbles have specific acoustic properties that make them useful for this goal. 
Whereas low or intermediate acoustic pressure results in linear and non-linear oscillations of 
microbubbles respectively, high pressure ultrasound (MI>1.0) causes forced expansion and 
compression of microbubbles, leading to bubble destruction. Several studies have shown that 
destruction of microbubbles leads to permeability of cell membranes. Skyba et al. demonstrated 
that microbubble destruction during ultrasound exposure caused rupture of microvessels with 
extravasation of red blood cells (18). Price et al. showed that microbubble destruction with 
ultrasound followed by infusion of 200 nm and 500 nm polymer microspheres resulted in red 
blood cells and polymer microspheres moving into the interstitium (19). Although various 
mechanisms by which microbubbles increase cell permeability have been proposed, the exact 
mechanism remains to be resolved. Ultrasound applied to fluid causes cavitation, i.e. the creation, 
vibration and collapse of small gas-filled bodies by the ultrasound beam. The effect of ultrasound 
alone has been studied and has been shown to increase cell permeability (20) on its own, without 
the addition of microbubbles. However, microbubbles in the presence of ultrasound with high 
acoustic pressure has an additional effect in increasing cell permeability (21).  First, 
microbubbles, by acting as cavitation nuclei, can lower the threshold for cavitation. Stride et al 
made an analysis of the conditions in the shell of the microbubble under influence of ultrasound 
and concluded that extremely high shell stresses and ‘bubble like behaviour’, including cavitation 
may be expected (22). In body tissue or blood, cavitation sets fluid in motion and creates small 
shock waves that give rise to microstreaming along the endothelial cell. Destruction of 
microbubbles may cause high-energy microstreams, or microjets, that will cause shear stress on 
the membrane of an (endothelial) cell and increases its permeability (13) (Fig 1). This increase in 
permeability is probably due to transient holes in the plasma membrane and possibly the nuclear 
membrane. A second proposed mechanism, the generation of reactive oxygen species in 
endothelial cells under influence of ultrasound, was investigated by Basta et al. (23). A 
significant, time-dependent increase in intracellular radical production after exposure to 
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ultrasound was demonstrated. As the use of microbubbles together with ultrasound lowers the 
threshold for cavitation, this could possibly result in an increased production of free radicals, 
which are associated with cell killing in vitro and, as a consequence, may be also involved in 
enhancement of permeability of endothelial cell layers. A third interesting aspect is the rise in 
temperature in tissue following the application of high pressure ultrasound (24). Bubble collapse 
following high energetic ultrasound can create high velocity jet streams that may cause a local, 
transient increase in temperature. As a rise in temperature influences the fluidity of phospholipid 
bilayer membranes, cell membrane permeability could possibly be changed directly as a 
consequence of the increased bilayer fluidity. Fourth, endocytosis or phagocytosis, active 
membrane transport mechanisms, may also be involved in the uptake of the bubble, bubble 
fragments or material entrapped in microbubbles. Preliminary studies of our group showed 
increased uptake of fluorescent 20 nm nanospheres in myocardial cells exposed to microbubbles 
loaded with these nanospheres. Nanospheres were dissolved in 5 ml NaCl 0.9 %. Sonovue 
microbubbles were prepared with NaCl 0.9 % containing the same concentration of nanospheres. 
Cultured myocardial H9C2 cells, placed in a live-cell observation chamber, were exposed to 0.5 
ml nanospheres or to 0.5 ml Sonovue microbubbles loaded with nanospheres during 5 minutes at 
a temperature of 37°C. After 5 minutes all solutions were removed from the cell cultures and 
residual nanospheres or microbubbles were washed out. Even in absence of ultrasound, 
myocardial cells exposed to microbubbles loaded with nanospheres showed a significantly higher 
uptake of nanospheres per cell, as measured by the product of mean intensity of fluorescence and 
area of fluorescence, in comparison with exposure to nanospheres alone (p=0.002) (Fig 2). This 
suggests that active processes like endocytosis or phagocytosis may be enhanced when 
microbubbles are used as a vehicle for nanospheres. A fifth mechanism by which the use of 
microubbles could facilitate the deposition of drugs or genes in a cell is exchange or fusion of the 
phospholipid microbubble coating with the phospholipid bilayer of a cell membrane. This could 
result in delivery of the cargo of the microbubble directly into the cytoplasm of the cell with the 
possibility of further uptake in endosomes or delivery to the cell nucleus. 
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Figure 1. Above: Destruction of microbubbles by ultrasound resulting in increased membrane permeability 
by shear stress, temperature and activation of reactive oxygen species. Lower: Drug delivery by 
microbubbles by a: transient holes induced by shearstress, b: increase in membrane fluidity, c: endocytosis 
of microbubbles, d: fusion of the microbubble membrane with the cell membrane.  
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Figure 2: Uptake of red fluorescent nanospheres by cultured H9C2 myocardial cells after exposure to left) 
nanospheres and right) microbubbles loaded with nanospheres. Nucleus: blue staining; nanospheres: red 
staining. 
 
Unger et al. described that drugs and genes can be attached to microbubbles (9) (Fig. 3). Since 
microbubble shell constituents mainly exist from protein-, polymer- or lipid based coatings, 
several ways of attachment of drugs to a microbubble have become available. Drugs can be 
conjugated to the microbubble membrane with the use of a charge dependent, noncovalent 
binding. Especially DNA that is a large negatively charged molecule is suitable for attachment to 
a positively charged membrane. Another mechanism to load a bubble with drugs is to incorporate 
the drug in the shell. This process is importantly influenced by the nature of the drug, in terms of 
lipophilicity and hydrophilicity. Although it seems difficult  to enclose material within the 
microbubble itself, as it is a gas filled microsphere, theoretically a drug containing powder may 
be attached to the inside of the bubble wall. Furthermore, drugs can be bound by ligands that are 
embedded in the membrane. With respect to this type of conjugation, a specific technique which 
is based on a avidin-biotin model, used for binding of antibodies in other studies, may be of 
importance for the binding of certain drugs. Finally, even microbubbles with multiple layers can 
be constructed, in which drugs can be solved. In conclusion, loading of microbubbles with a 
certain drug depends on several important factors like molecular weight, lipophilicity and charge.   
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Figure 3: Several mechanisms to attach drugs to microbubbles. a: incorporation in the bubble; b: 
incorporation in the bubble membrane; c: attachment to the membrane; d: attachment to a ligand; e: 
incorporation in multi layer microbubble. 
 
Recent experiments have shown that it is possible to create targeted microbubbles by 
incorporating monoclonal antibodies into the membrane. Microbubbles targeted to GPIIbIIIa 
receptors and to ICAM-I have already been used in experimental studies (25-28). These studies 
clearly suggest that microbubbles can be used as a vehicle for drugs, and bubble destruction by 
high acoustic pressure ultrasound can be used for local delivery of materials attached to or 
entrapped in the bubble. As mentioned earlier, cavitation is probably the mechanism by which 
destruction of microbubbles enables extravasation of red blood cells and increases cell 
permeability, however, the exact process is not clear and needs further investigation. Adverse 
effects like a rise in blood temperature or hemolysis when using ultrasound and microbubbles, has 
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been a cause of concern for several investigators (24;29;30). In theory, microbubbles exposed to 
ultrasound could cause mechanical stress to act on cells and consequently lead to cell injury. 
Bioeffects are influenced importantly by factors like ultrasound frequency and amplitude, and 
although these factors are generally  different in diagnostic imaging than in experimental testing, 
temporary and persistent effects on cell function may not be ruled out and deserve attention. 
Delivery of drugs and genes with microbubbles is a promising technique, however, possible side 
effects on tissue and organ level in humans -as well as their clinical importance- will remain a 
relevant issue and need further investigation. 
Delivery of genes and drugs 
As a consequence of the identification of thousands of genetic factors, in the near future gene 
therapy will become an important factor in treatment of several (cardiovascular) diseases. A few 
genes that could be important in the management of cardiovascular disease, e.g. the gene for 
VEGF, have already been studied in animals and in humans (31;32). To be effectively expressed 
a gene must be delivered in tissue, taken up by the cell and incorporated into the genome in the 
nucleus of the cell, without being digested. An important limitation in gene therapy is to find an 
adequate carrier to deliver genes into specific target cells. DNA consists of large molecules and 
direct intravascular injection will result in removal of the DNA from the blood. Furthermore, as 
genes are too large to enter the cell passively, they need an active carrier. Baumgarter et al. 
demonstrated that direct injection of VEGF in human skeletal muscle resulted in transient 
increase in serum level of VEGF and induced arteriogenesis in patients with critical limb 
ischemia (31). However, direct injection of DNA in myocardial tissue of the human ischemic 
heart would require a possibly dangerous procedure with the subsequent risk of complications. 
Viral vectors, particularly lentiviruses, retroviruses and adeno-associated viruses have been 
extensively used as a vehicle for gene delivery (33). However, viral vectors have the disadvantage 
of being antigenic and may cause an immune response. A few years ago an 18-year old patient 
died as a direct consequence of severe complications caused by an adenoviral vector used in gene 
therapy (33). Another way of non-viral gene delivery is the use of DNA plasmids, that can carry 
relatively large DNA molecules. Nevertheless, intramuscular injections of plasmids are known to 
cause side effects like local inflammation and are still a cause of concern (34). 
Ultrasound in combination with microbubbles can provide a new, safe method of delivering genes 
into the cell. Microbubbles are metabolically inert, i.e. they do not cause an immune response of 
 22
the host. Unlike naked DNA that is injected directly intravascularly, genes that are bound to 
microbubbles can be carried to the tissue without being digested. Using gel electrophoresis, it was 
demonstrated that DNA carried by microbubbles was stable and intact after DNA release by 
destruction of the microbubbles with ultrasound (9). Several studies have shown the effectiveness 
of gene delivery enhanced by ultrasound and microbubbles (20;35-38) (Table 1). Shohet et al. 
demonstrated that albumin-coated microbubbles in combination with ultrasound destruction can 
be used to effectively deliver an adenoviral transgene to rat myocardium. Microbubbles with β-
galactosidase transgene attached to their surface were infused in the jugular vein of rats and 
underwent ultrasound-mediated destruction. 
 
 
Nucleair staining showed that in the group with β-galactosidase containing microbubbles, rat 
hearts over which ultrasound destruction was applied, had a 10-fold higher β-galactosidase 
activity than control groups. Interestingly, in one of five control groups, microbubble destruction 
followed by infusion of the transgene, β-galactosidase activity was 2-fold higher than in other 
control groups, indicating that disruption of the membrane is an important factor in viral 
transduction (38). Similar results were obtained by Bekeredjian et al with the use of microbubbles 
containing CMV-luciferase plasmids and ultrasound (35). Luciferase activity was seen in rat 
hearts after application of ultrasound, with negligible expression in other organs. Porter et al. 
demonstrated that perfluorocarbon-exposed sonicated dextrose albumin (PESDA)-microbubbles 
can target the delivery of synthetic antisense oligodeoxynucleotides to the carotid artery, an 
 23
antisense nucleotide preventing restenosis. The concentration of oligodeoxynucleotides taken up 
within the carotid vascular wall was found to be significantly increased when they were 
administered bound to PESDA-bubbles and while transcutaneous ultrasound was applied over the 
carotid artery, which resulted in a significant lower rate of restenosis (37). Another study, 
performed by Vannan et al., showed the expression of plasmid chloramphenicol acetyltransferase 
(pCAT) in canine hearts after intravenous injection of a relatively low concentration of pCAT 
(39). An interesting point is that this study used positively charged, phospholipid bilayer vesicles, 
called liposomes that bind the negatively charged DNA.  
During the last decades, much attention has been focused on the use of liposomes as a vehicle for 
drug and gene delivery (40). Liposomes were a promising tool as they can be loaded with 
material and injected intravenously to deliver their contents in target tissue.  Especially DNA, that 
is negatively charged, can bind to positively charged liposomes, forming a compex called 
lipoplex. These lipoplexes are thought to bind specific receptors on the cell membrane, which 
subsequently can facilitate endocytosis. To promote local release of drugs or genes carried by 
liposomes, several techniques like acidification, enzymatic, thermal or photochemical release 
were used (40). However, although studies in an in vitro setting showed good results, in vivo 
studies were disappointing (41). Microbubbles create new options. Several studies demonstrated 
that microbubbles alone in combination with ultrasound can be used as an effective vehicle for 
gene delivery and could possibly take over the role of liposomes. A major advantage is the 
possibility of a targeted microbubble, as local release of material is dependent on local destruction 
by ultrasound. Another challenging option may consist of a combination of these two techniques. 
Co-administration of liposomes with microbubbles creates the possibility to increase cell 
permeability with ultrasound in target regions, which could prepare specific tissue for the uptake 
of liposomes. Furthermore, liposomes could be directly conjugated to microbubbles.  
All forms of drug therapy in which drugs are administered systemically require plasma 
concentrations within the therapeutic range. Although many diseases as cancer, inflammatory 
diseases or thromboembolic processes may require higher concentrations of certain drugs, plasma 
concentrations are limited by occurence of potentially dangerous side effects. After systemic 
administration, (targeted) microbubbles loaded with drugs can rupture under influence of 
localized ultrasound and drug release will result in higher local concentrations in comparison with  
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systemic administration. Besides a higher availability of the drug for receptor binding, the drug 
may be pushed directly into the cell as a concequence of higher membrane permeability. 
Recent studies performed by Pislaru et al and Li et al investigated the effect of different 
microbubbles on the enhancement of ultrasound mediated gene transfer (42;43). Unexpectedly, 
these studies demonstrated that different transfection rates were reached when using other 
microbubbles. These findings show that microbubbles existing of different constituents do not 
have equal capacities for drug and gene delivery, which suggest that it could be useful to develop 
a gene-delivery-specific microbubble. 
Designing “smart” microbubbles: targeted microbubbles 
A recent and intriguing issue in contrast agents is the development of targeted microbubbles. In 
combination with ultrasound, microbubbles have shown to be capable of delivering genes to 
specific tissue. As described earlier, microbubbles can be loaded with genes and injected into a 
vein, followed by localized ultrasound. In this way, microbubbles are aspecific and local delivery 
is controlled by the local application of ultrasound. However, as currently used microbubbles are 
relatively stable and circulate through the whole body, delivery of material could partly result in 
deposition of the contents of the microbubble in tissue that is not the target tissue, e.g. in the chest 
wall, or in the lungs, in which microbubbles with higher diameters are filtered. Therefore, it 
would be greatly desirable to have a microbubble which can be targeted to a specific tissue by 
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using ligands and receptors that are incorporated in the bubble shell (Fig 4). This would enable 
active attachment of microbubbles to target tissue and create further possibilities for diagnostic 
imaging and therapy like local drug delivery to target lesions. Targeted microbubbles have been 
developed to various types of tissue and processes, e.g., endothelial cells, thrombi, inflamed tissue 
and angiogenesis (44). Villanueva et al. tested a new perfluorocarbon gas-filled microbubble 
prepared with a monoclonal antibody on the shell as a ligand for endothelial cell binding (28) 
(Table 2). It was demonstrated that these microbubbles with intercellular adhesion molecule-Ι 
(ICAM-Ι) antibodies, in contrast to control bubbles, bind to endothelial cells expressing ICAM-Ι. 
As expression of ICAM-Ι by endothelial cells is associated with early atherosclerosis, this could 
have major concequences for diagnosis of preclinical atherosclerosis. Another important 
application of this technique in vivo was the non-invasive identification of acute cardiac 
transplant rejection in mice (45). 
 
 
Figure 4: Targeted microbubble, connected by ligand and receptor. 
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Figure 5. Thrombus specific targeted microbubble. 
 
Schumann et al. explored a method to visualize vascular clots, known to be associated with 
cardiovascular diseases as stroke and myocardial infarction (27). As the GPIIb IIIa  receptors play 
a key role in the formation of vascular clots, a lipid-coated perfluorocarbon gas containing 
microbubble with bioconjugated ligands inserted into the membrane, was developed (Fig 5). In 
contrast to untargeted control bubbles, targeted bubbles showed improved binding to vascular 
thrombi in vitro and in vivo (mouse cremasteric muscle). This finding creates great opportunities 
for identification and treatment of vascular clots in humans. Clot lysis is known to be improved 
by ultrasound, and the presence of microbubbles further stimulate this effect by cavitation. The 
finding of microbubbles targeted to vascular clot creates the possibility of clot lysis by ultrasound 
in combination with targeted microbubbles loaded with thrombolytics. Another way to target 
microbubbles has been investigated by Lindner et al. Lipid microbubbles are retained within 
inflamed tissue because of complement-mediated attachment to leukocytes (26;46;47). 
Incorporation of phosphatidylserine into the bubble shell enhances this process by amplifying 
complement activation and creates the possibility of ultrasound imaging of inflammation. The 
extent of inflammation determined by microbubble ultrasound imaging correlated closely with 
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tissue myeloperoxidase activity, indicating inflammation. Using this technique, postischemic 
myocardial inflammation was also characterized (48). Klibanov et al. studied an avidin-biotine 
model to study the possiblity of targeting (49). Biotin was attached to the microbubble whereas 
avidin was adsorbed on the surface of culture plates. In contrast to the control surfaces, 
microbubbles with biotin attached firmly to avidin surfaces. A higher content of biotin in the 
bubble shell was more efficient than lower concentrations, which suggest that binding is regulated 
by a number of attachment points. Flow along the target surface was not able to dislocate the 
bubble from its target. This is an important finding for in vivo applications whereby a targeted 
microbubble is attached to an endothelial cell, which is thereby continuously exposed to capillary 
blood flow. Stability despite shear stress on the bubble would probably favor uptake of entrapped 
material in the cell.  
These studies have described the first results in the assessment of targeted microbubbles. 
Identification of inflammation, preclinical atherosclerosis, angiogenesis and vascular clots or 
thrombi is promising and creates options for diagnosis and treatment of cardiovascular diseases 
(25). 
Microbubbles and thrombolysis: a test case 
Several serious cardiovascular diseases like myocardial infarction and non-hemorrhagic stroke 
result from thromboembolic processes. Although rapid thrombolysis improves morbidity and 
mortality from these diseases by degrading fibrinogen and fibrin in blood clots, recanalization of 
the occluded vessel is not reached in a substantial part of patients and systemic administration of 
thrombolysis can be complicated, especially by bleeding (50). However, in most hospitals 
invasive revascularization therapies are limited. In the last decade, several studies have 
investigated the influence of ultrasound on thrombolysis. A wide range of ultrasound frequencies, 
from 26 kHz to 1.03 MHz was assessed in absence or presence of fibrinolytic therapy in vitro and 
in vivo (51-58). Although not all studies showed a positive correlation between the use of 
ultrasound and thrombolysis (53), the presence of ultrasound was found to increase clot lysis in 
most studies both in vitro and in vivo. Enhancement of thrombolysis was seen particularly in low-
frequency ultrasound with high power. Ultrasound, existing from positive and negative pressure 
waves, causes cavitation and motion of fluid. These mechanisms are thought to induce 
penetrating forces and shear-stress on the surface of the vascular clot and could play a role in 
microfragmentation which makes the clot more susceptible for fibrinolytic agents (59). The 
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studies mentioned above did not assess the influence of microbubbles on thrombolysis. As 
described before, microbubbles lower the energy needed for cavitation. Whereas lineair 
oscillations in a low acoustic field may cause microstreams around the bubble, destruction by 
high power ultrasound can create powerful microjets that accelerate the thrombus-dissolving 
effect of ultrasound alone. Tachibana et al. were one of the first to descibe the effect of an echo-
contrast agent on fibrinolysis in vitro (60). The combination of urokinase, microbubbles 
(Albunex) and ultrasound (170 kHz) resulted in significant increase in fibrinolysis after 60 
minutes of incubation, in contrast to ultrasound and urokinase or urokinase alone. This result was 
confirmed by another study (61) (Table 3). Birnbaum et al. were one of the first to describe the 
effect of microbubbles in combinaton with ultrasound without the use of fibrinolytics on 
thrombolysis in vivo. In a rabbit-study it was shown that in contrast to ultrasound or contrast 
agent alone, dissolution of a vascular clot in the iliofemoral artery could be achieved by 
intravenous administration of perfluorocarbon-exposed sonicated dextrose albumin (PESDA) 
microbubbles and transcutaneous ultrasound (37 kHz) (62). This result was confirmed in other 
studies also using rabbit iliofemoral arteries and dodecafluoropentane microbubbles (63). A 
number of factors may influence clot lysis by microbubbles and ultrasound. First, the stability of 
the contrast agent. Room air containing microbubbles are less stable in blood and cavitation may 
be enhanced more by PESDA bubbles (64). Mizushige et al. showed that thrombolysis using a 
dodecofluoropentane emulsion was significantly enhanced compared with a control group, air-
filled albumin microbubbles or galactose coated air filled microbubbles, which indicates that 
stability of the bubble plays an important role (65). Another explanation for this effect is possibly 
the microbubble concentration, which is significantly higher in PESDA-bubbles. The observation 
that thrombolysis by microbubbles was accompanied by characteristic increase in echo intensity 
of the surface layer of the thrombus and the histological presence of numerous microcavities, 
specific for microbubble treated thrombi, suggests that the echo contrast agent directly harms the 
clot surface (61). Therefore, a higher concentration of microbubbles could give rise to a higher 
concentration of cavitation nuclei.  
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Although improvement of clot lysis with the use of ultrasound, thrombolytics or microbubbles 
was seen in many in vitro and in vivo models, it is uncertain whether the same effects can be 
reached in humans. Earlier studies reported endothelial cell injury of microvessels (66), which 
could be a potential danger in clinical applications. Diagnostic imaging uses frequencies of 
around 1.5 MHz. Possibly, thrombolysis by ultrasound would require lower frequencies with 
higher acoustic pressure. Enhancement of thrombolysis by ultrasound is a promising technique 
and microbubbles would be an interesting option in treatment of cardiovascular disease, however, 
the bioeffects of low frequency ultrasound with high power and the safety of these techniques in 
humans need further investigation. 
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Conclusion 
In this article we described the most important issues in the development of contrast agents. 
Firstly, specific acoustic and biological properties make microbubbles a promising tool as a 
vehicle for drug and gene delivery. In vivo studies have been performed and showed the 
expression of genes delivered by microbubbles in combination with ultrasound. Although results 
were positive, more in vivo animal studies are needed to investigate possible future applications 
in humans. An interesting problem is the precise interaction of microbubbles with living cells. 
Although several options, like transient cell membrane holes, endocytosis, phagocytosis and 
fusion of microbubble shell components with the cell membrane have been proposed, the exact 
mechanism remains to be elucidated. Recent advances in live-cell imaging techniques (e.g. 
multidimensional digital imaging microscopy) offer excellent opportunities to study this process 
at the (sub)cellular level in real-time, thereby creating the possibility to visualize the interaction 
of fluorescent labeled microbubbles and myocardial or endothelial cells under high ultrasound 
pressure (Fig 2). Secondly, the use of targeted microbubbles has been a great step forward. 
Microbubbles have been targeted to receptors of leukocytes and blood clots, and may in the future 
probably be used in diagnostic imaging of thrombo-embolic or inflammatory processes. Targeted 
microbubbles create various challenging therapeutic options, not only in cardiovascular disease 
but also in treatment of inflammatory and malignant diseases. These microbubbles can be used as 
a vehicle for drugs or genes and local delivery can be achieved by destruction of microbubbles 
with ultrasound. The same mechanism could be used in treatment of thrombo-embolic processes. 
Enhancement of thrombolysis with the use of microbubbles and ultrasound looks promising in 
vitro and in vivo. The development of microbubbles targeted to GP IIbIIIa receptors could be a 
step forward in treatment of vascular thrombi. Attachment of microbubbles loaded with 
thrombolytic agents and administration of ultrasound may in the future well be a therapeutic 
option.  
In summary, over the past years, contrast agents in echocardiography have rapidly evolved from a 
diagnostic adjuvant to a possible therapeutic agent. In the coming years, this promising technique 
needs further development to make it available for clinical applications. 
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Chapter 2:  Quantification of myocardial perfusion 
 
2.1 Quantification of myocardial perfusion using intravenous myocardial contrast 
echocardiography in healthy volunteers: comparison with positron emission tomography 
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Abstract 
Background Intravenous myocardial contrast echocardiography (ivMCE) has the potential to 
evaluate myocardial contraction and perfusion simultaneously. The purpose of this study was to 
assess quantification of myocardial blood flow (MBF) using ivMCE and to compare this with 
MBF as measured with positron emission tomography (PET). 
Methods 16 Healthy volunteers underwent ivMCE using power pulse inversion and Sonovue® 
microbubbles at rest and during pharmacologically induced vasodilation. Microbubble destruction 
was achieved with a burst of high energy ultrasound, followed by imaging of contrast 
replenishment with low energy ultrasound. Regions of interest were drawn and time intensity 
curves were calculated that were fitted to a mono-exponential function. An estimate of MBF (PE) 
was calculated as the product of the plateau value A and the exponential ß describing the 
replenishment curve. MBF was measured with PET using oxygen-15-labeled water (H215O) at 
rest and during adenosine stress.  
Results Significant correlations were found between MBF as measured with PET and PE as 
measured with ivMCE in the left anterior descending artery (r=0.87, p<0.01), right coronary 
artery (r=0.66, p<0.01), and left circumflex artery (r=0.75, p<0.01) territories. Heterogeneity, 
however, was significantly larger for ivMCE (coefficient of variation 32±15%) than for PET 
(9±6%) measurements (P<0.01).   
Conclusion Perfusion parameters as measured with ivMCE correlated with PET derived MBF, 
but associated heterogeneity was significantly larger. At present, this heterogeneity precludes true 
quantification of MBF using ivMCE. 
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Background 
Evaluation of myocardial perfusion is the cornerstone of diagnosis, management, and risk-
stratification in patients with ischemic heart disease. Positron emission tomography (PET) using a 
perfusion tracer is the gold standard for assessment and quantification of myocardial perfusion 
(1;2). As a result of recent developments in ultrasound methodology, intravenous myocardial 
contrast echocardiography (ivMCE) is emerging as a relativey new technique that has the 
potential of evaluating myocardial contraction and perfusion simultaneously (3-5). Wei et al 
demonstrated that ivMCE using intermittent triggered imaging and a relatively high emission 
power could be used for quantification of myocardial blood flow (MBF) in dogs (6). 
Progressively prolonged intervals were applied between ECG-gated imaging pulses and it was 
demonstrated that signal intensity increased over time until a plateau value was reached at which 
refilling of the imaging field between pulses was complete. The time-intensity curve was fitted to 
an exponential equation (y=A (1-e-βt)), of which A was peak plateau intensity and β was the rate 
of signal increase. It was shown that both β and the product of A and β correlated with MBF. New 
techniques provide the possibility to quantify MBF by myocardial contrast echocardiography 
using continuous infusion of contrast and low emission power (3;4;6-8). Several studies using 
triggered or real-time ivMCE compared myocardial perfusion imaging qualitatively with nuclear 
stress testing, showing good correlations (9-15). Although various studies have addressed 
quantification of MBF by ivMCE (8;16-21), quantitative analysis of myocardial perfusion is still 
a relatively unknown territory. During real-time perfusion imaging, wall motion analysis can be 
performed instantaneously, whereas quantitative information on segmental myocardial perfusion 
can be obtained by multiplying the exponential constant β and plateau value A of the time-
intensity curve after ultrasound induced destruction of the continuously infused contrast agent. 
However, the true clinical value of ivMCE still remains to be determined. Studies assessing the 
validity of this technique for quantitative evaluation in humans are scarce and normal database 
profiles of contrast replenishment curves are absent altogether. The purpose of the present study 
was to assess ivMCE for real-time quantitative perfusion imaging in healthy volunteers both at 
rest and during vasodilator stress by comparing it with PET. 
Study population 
Sixteen healthy volunteers (mean age 29±4, 11 males) with a normal physical examination, 
electrocardiogram, laboratory investigation and transthoracic echocardiogram were studied. 
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Participants were selected for having a good acoustic window (2 volunteers were excluded 
because of an inadequate window). Exclusion criteria were history of cardiac disease, smoking, 
diabetes, hypercholesterolemia, a positive family history of cardiac disease, hypertension, chronic 
obstructive pulmonary disease, pulmonary hypertension, pregnancy, protein allergy, conduction 
abnormalities, and structural heart disease. All participants underwent both ivMCE and PET at 
rest and during adenosine stress within three weeks (patients refrained from xanthine and caffeine 
derivatives at least 12 hours before the study). 
All participants gave written informed consent to participate in the study. The study protocol was 
approved by the VU University Medical Center Ethics Committee. 
Myocardial contrast echocardiography 
Image acquisition  
Sonovue® (Bracco Diagnostic Inc, Geneva, Switzerland), a sulphur hexafluoride filled, 
phospholipid coated second generation ultrasound contrast agent with a mean microbubble 
diameter of 2.5 µm was used to perform ivMCE. Sonovue was intravenously injected with a 
continuous infusion rate of 0.7-1.5 ml per minute using a mechanical pump (Vueject, Bracco, 
Geneva, Switzerland). The infusion rate was adjusted to obtain maximal opacification of the 
myocardium without basal attenuation due to intracavitary contrast, and was kept constant 
throughout the experiment. To reach a steady state of microbubbles in the blood, image 
acquisition was started 4 minutes after the start of contrast infusion.  
Imaging was performed with a Philips ATL 5000 with a broadband 2 to 4 MHz transducer. Real-
time ivMCE was performed by color-coded power pulse inversion imaging, at rest and during 
vasodilator stress. Presets were a pulse repetition frequency of 2500 Hz and line density low. 
Baseline settings, like mechanical index (0.11-0.15), depth (<13.5 cm), and color gain, were 
determined prior to the start of the procedure and were kept constant thereafter. Color gain was 
adjusted before infusion of contrast, so that no colorizing of the left ventricular cavity or 
myocardium was seen, with acceptance of near field- and mitral valve motion artifacts. Before the 
start of contrast infusion, baseline images were captured (4-, 2- and 3-chamber views). A burst of 
high acoustic energy (flash, mechanical index 0.9) was used for destruction of the microbubbles, 
followed by imaging with low acoustic pressure ultrasound with a frame rate of 18-20 Hz during 
 41
ten seconds, allowing contrast replenishment in the myocardium. During acquisition of the 
images, patients were asked to hold their breath to prevent movement of the scanning plane. 
Stress images were obtained two minutes after the start of infusion of adenosine (0.140 mgkg-
1min-1). During the study, heart rate and blood pressure were measured every three minutes. 
Analysis 
Images were analyzed using the HDI lab (ATL-Ultrasound, Bothell, Washington, USA). End 
systolic images were selected and regions (ROI) of interest were drawn according to segments 
defined by a 16 segment model(22). Also, ROI were placed in the left ventricular cavity, adjacent 
to each ROI in the myocardium. Subsequently, time intensity curves were calculated from 
segmental contrast replenishment following microbubble destruction by a flash of high acoustic 
pressure ultrasound (Fig 1a). Time-intensity curves of each segment were fit to a mono-
exponential function (y=A (1-e-βt)) (6) (Fig 1b), were y represents signal intensity at any given 
time (t), A is the plateau signal intensity (intensity units (IU)) that reflects microvascular cross-
sectional area or myocardial blood volume, β is the rate of signal intensity rise (s-1) (exponential 
“slope” of the curve) that reflects myocardial microbubble velocity, and t is time (s) after flash. 
The product of A and β provides a perfusion estimate (PE) (IU s-1) in each myocardial segment, 
which ideally corresponds to MBF. Signal intensity of each segment in the left ventricular cavity 
(ALV) was also determined. The estimate of global myocardial perfusion was calculated by 
averaging over all myocardial segment. PE in different vascular territories was calculated by 
averaging over constituent myocardial segments. Vascular territories were defined as follows: left 
anterior descending artery (LAD): anteroseptal, anterior, apex, inferoseptal distal; right coronary 
artery (RCA): inferior, inferoseptal basal; circumflex coronary artery (Cx): posterolateral, lateral. 
As resting MBF is related to the rate-pressure-product (RPP, systolic blood pressure * heart rate), 
corrected resting PE (PE/RPP)*10.000 was also determined. Additionally, besides calculation of a 
perfusion estimate, true MBF was calculated with ivMCE using the model as described by Vogel 
et al (8). In short, in this model MBFMCE is calculated from the blood volume pool relative to the 
surrounding tissue (rBV), the exchange frequency of this blood volume, and tissue density: 
MBFMCE=rBV*β/ρT=(A/ALV)*β/ρT. According to this model, the blood volume exchange 
frequency equals β (min-1), the rBV can be estimated quantitatively by the division of myocardial 
plateau intensity A and the adjacent left ventricular intensity (ALV), and ρT is 1.05 gr ml-1. 
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Positron emission tomography 
Data acquisition 
All scans were performed in 2D mode, using an ECAT EXACT HR+ (Siemens/CTI, Knoxville, 
Tenn., USA). This scanner acquires 63 planes of data over an axial field of view of 15 cm. A ten 
minute transmission scan, using 3 rotating 68Ge line sources together with sinogram windowing, 
was performed after a short transmission scan for patient positioning. Subjects were constantly 
monitored with single lead electrocardiography, and blood pressure was measured every 3 min. 
After the transmission scan, 1100 MBq of H215O dissolved in 5 ml saline was injected 
intravenously, followed by a 40 ml saline flush at a rate of 4 ml/s (bolus injection). A dynamic 
scan was acquired consisting of 40 frames with variable frame length for a total duration of 10 
minutes (12x5”, 12x10”, 6x20”, 10x30”). Following the rest study, a hyperemia study was 
performed during infusion of adenosine at a rate of 140 µg/kg/min. Subsequently, blood pool 
imaging was performed. For this latter scan, the patient inhaled at least 2000 MBq of C15O over a 
period of 2 minutes and a single frame was acquired for a duration of 6 minutes, starting 1 minute 
after the end of inhalation to allow for equilibrium in the blood pool. Emission data were 
corrected for physical decay of 15O, dead time, scatter, randoms and photon attenuation. 
Reconstruction of the H215O emission sinograms was performed using filtered back projection 
with a Hanning filter at 0.5 of the Nyquist frequency, resulting in a transaxial spatial resolution of 
~7 mm full width at half-maximum.  
Data analysis 
Anatomical tissue images were generated by subtracting the blood pool image from the 
transmission image. Subsequently, images were resliced into short-axis images according to the 
anatomical axis of the heart. The same reslicing parameters were automatically applied to the 
dynamic H215O images. Regions of interest (ROI) were defined on the short-axis anatomical 
tissue images. At the basal and midventricular level, these ROI divided each short axis in six 
equidistant sectors angulated 60º apart, starting from the posterior insertion of the right 
ventricular free wall into the left ventricular myocardium. At the apical level, one ROI was 
defined. For each patient, corresponding ROI from a variable number of slices were grouped to 
compose thirteen volumes of interest (6 basal, 6 midventricular and 1 apical). Additional ROI 
were defined in the left and right ventricular chamber for image derived input functions. The 
complete set of ROI was projected onto the dynamic H215O images in order to generate time-
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activity curves (TAC). Using the standard single compartment model, MBF (ml·min-1·ml-1 
perfusable tissue) was determined from these TAC. Corrections were made for left and right 
ventricular spillover effects using the method described by Hermansen et al. (23). Global MBF 
was calculated by grouping all volumes of interest. MBF reserve was calculated as the ratio of 
hyperemic to resting MBF. As resting MBF is related to the RPP, corrected resting MBF 
(MBF/RPP)* 10.000 was also determined.  
Comparison of ivMCE and PET 
For comparison of ivMCE and PET, a 13-segment model was used. To compare apical MBF as 
measured with PET with the corresponding ivMCE PE, the mean value of PE of four apical 
segments (septal, lateral, inferior, and anterior) was calculated. For each patient, both mean MBF 
and MBF of the three vascular territories were compared with the corresponding PE values. 
Statistical analysis 
All data were analyzed using a commercially available statistical package (SPSS 9.0). Data were 
expressed as mean values ± standard deviation  (SD). For comparison of 2 datasets, the unpaired 
Student t test was used. Comparison of multiple datasets was performed using ANOVA. 
Correlations between ivMCE and PET were calculated using lineair regression analysis. 
Heterogeneity was expressed as the coefficient of variation (100*SD/mean). For graphical 
presentation of intrasubject heterogeneity, both ivMCE and PET measurements were corrected for 
intersubject variation by dividing the values of each vascular territory at rest by the respective 
mean values for that patient, yielding normalized ivMCE and PET data. A p-value of <0.05 was 
considered to be statistically significant. 
Results 
In all 16 volunteers, ivMCE and PET were successfully completed. Baseline characteristics are 
summarized in table 1.  
Hemodynamic data 
Hemodynamic data during ivMCE and PET are summarized in table 2. During both ivMCE and 
PET, resting heart rate and RPP increased significantly during hyperemia, whilst no significant 
differences were seen in either systolic or diastolic blood pressures. Except from a slightly higher 
resting heart rate during ivMCE as compared with PET (p<0.05), no significant differences 
existed between hemodynamic parameters during ivMCE and PET.  
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IvMCE 
Of a total of 416 segments, 79 (19%) segments were not used in the quantitative analysis because 
of attenuation artifacts. Of these 79 segments, 50 (63%) were basal lateral and basal anterior 
segments. The average values per volunteer of both A (3.68±0.87 vs 8.02+1.93 IU) and β 
(0.33±0.07 vs 0.73±0.19 s-1) significantly increased (P<0.01) from rest to hyperemia. PEcorr 
significantly increased from 1.43±0.35 IU s-1 at rest to 5.70±2.44 IU s-1 at stress (P<0.01), 
resulting in a mean flow reserve of 3.94±1.31. The distribution of PEcorr in the different vascular 
territories at rest and during hyperemia is shown in table 3. At rest, a significantly higher 
perfusion estimate was seen in the RCA-territory (1.84±0.57 IU s-1) vs. the LAD- (1.39±0.48 IU 
s-1) (P<0.05) and Cx-territory (1.21±0.43 IU s-1)(P<0.01). During stress, PE was significantly 
lower in the Cx-territory (3.57±1.59 IU s-1) (P<0.01) as compared with the LAD-territory 
(6.61±3.28 IU s-1). However, the RCA-territory (5.76±2.31 IU s-1) did not significantly differ 
from the Cx and LAD. Intrasubject coefficient of variation of PEcorr was 32±15%. 
MBFMCE, calculated according to the model of Vogel et al, increased from 1.72±0.57 mLmin-1gr-1 
at rest to 4.62±1.69 mLmin-1gr-1 during hyperemia. 
 
Figure 1A: example of ivMCE. Three-chamber view during hyperemia. a: pre-contrast image, b: 
flash, c-h: subsequent replenishment of contrast. 
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PET 
The average MBFcorr per volunteer significantly increased from 1.31±0.24 mlmin-1ml-1 at rest 
(corrected for rate-pressure product) to 4.37±0.84 mlmin-1ml-1 during hyperemia, with a mean 
flow reserve of 3.39±0.63. No differences were found between vascular territories (table 3). 
Intrasubject coefficient of variation of MBF was 9±6%. 
Comparison of ivMCE estimates with PET  
At rest, no significant correlation between global PEcorr as measured with ivMCE and global 
MBFcorr as measured with PET was found (r=0.18, P=NS). No significant correlation within each 
of the vascular territories of the LAD (r=0.27, P=NS), the RCA (r=-0.01, P=NS) and Cx (r=-0.24, 
P=NS) was established. During hyperemia, global PE was significantly correlated with global 
MBF (r=0.54, P=0.03). This correlation was also seen in the LAD-territory (r=0.67, P<0.01), but 
not in either RCA- (r=0.29, P=NS) or Cx- (r=0.29, P=NS) territories. 
 
Figure 1B: example of a mono-exponential time-video intensity curve (y=A (1-e-βt)). A: maximum value 
(IU); ß: slope of the time-intensity curve(s-1). 
 
ß 
A 
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PEcorr correlated significantly with MBFcorr (Fig 2). This correlation was found in all territories 
(LAD: r=0.87, P<0.01 (Fig 2b; RCA: r=0.66, P<0.01 (Fig 2b); Cx: r=0.75, P<0.01 (Fig 2c)). In 
addition, plateau value A and exponential β demonstrated a significant correlation (r=0.90, 
P<0.01 and r=0.69, P<0.01, respectively) with MBF. Calculation 
of MBFMCE using the model of Vogel et al, did not improve the correlation between PET and 
ivMCE (r=0.78, P<0.01). MBFMCE correlated significantly with MBFPET in the LAD-territory 
(r=0.83, P<0.01) (Fig 2d), the RCA-territory (r=0.45, P<0.01), and the Cx-territory (r=0.47, 
P<0.01). The intrasubject coefficient of variation of PET (9±6%) was significantly (P<0.01) 
lower than that of ivMCE (32±15%), as illustrated in Fig 3. 
 
Figure 2. A: relation between the absolute MBF in the LAD-territory per patient as measured with PET 
(mL min-1 mL-1) and the estimate of myocardial perfusion PE as measured with ivMCE (IU s-1); B: relation 
between the absolute MBF in the RCA-territory per patient as measured with PET (mL min-1 mL-1) and the 
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estimate of myocardial perfusion PE as measured with ivMCE (IU s-1); C: relation between the absolute 
MBF in the Cx-territory per patient as measured with PET (mL min-1 mL-1) and the estimate of myocardial 
perfusion PE as measured with ivMCE (IU s-1); D: relation between the absolute MBF in the LAD-
territory per patient as measured with PET (mL min-1 mL-1) and the MBF as measured with MCE in the 
LAD-territory (ml min-1gr-1). 
 
 
 
 
 
Figure 3: frequency of distribution of normalized MBF (dashed line) and ivMCE (solid line). The 
coefficient of variation was increased for ivMCE compared with PET, indicating increased heterogeneity 
(P<0.01). 
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Discussion  
Myocardial perfusion is an important prognostic factor for morbidity and mortality in patients 
with cardiovascular disease. Consequently, quantitative assessment of myocardial perfusion has 
become increasingly important. Currently, PET is the clinical standard for true quantification of 
MBF. Drawbacks of PET, however, are its limited availability and its relatively high costs. 
Previous studies assessed the potential of ivMCE to quantify MBF by comparing it with MBF as 
measured with microspheres in open chest models in dogs or with Doppler flow measurements in 
human beings (17;20;21). Recently, quantification of MBF by ivMCE using coherent contrast and 
imaging and Optison was compared to MBF as measured PET using 13N-Ammonia(8). These 
studies showed good results, however, data regarding quantification of MBF with ivMCE is still 
scarce. 
In the present study the feasibility of ivMCE to quantify myocardial perfusion in a clinical 
situation was investigated using power pulse inversion imaging. To this end, the perfusion 
estimate PE was compared with MBF obtained using PET. The data show that: 1; plateau value 
A, “slope” β of the mono-exponential contrast replenishment curve, and PE were significantly 
increased from rest to stress, 2; plateau value A, exponential constant β, and perfusion estimate 
PE correlated with MBF as measured with PET, 3; true quantification of MBF did not improve 
correlation between ivMCE and PET, and 4; intrasubject heterogeneity of PE was substantially 
higher than that of MBF obtained with PET. 
ivMCE  
The results of the present study indicate that not only β and PE significantly increased from rest to 
stress, but also the plateau value A of the replenishment curve, reflecting myocardial blood 
volume. This is known from previous studies. In contrast to intracoronary injection of adenosine, 
intravenous infusion of adenosine causes a higher rate pressure product, a higher oxygen demand, 
and an increase in myocardial blood volume (6;8;18;24). This increase in myocardial blood 
volume correlates with the increase in myocardial blood flow. It should be noticed, however, that 
in a few subjects, especially those with extremely low resting heart rate and/or low systolic blood 
pressure, the plateau phase could not be reached completely at rest. This implies that the 
myocardial blood volume at stress is not twice as high compared to rest, as is suggested by our 
data. 
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The present study demonstrates that significant correlations exist between ivMCE parameters and 
MBF as measured with PET. Quantification of MBF by ivMCE was characterized by a larger 
degree of heterogeneity than PET, which has been previously demonstrated for intermittent 
ivMCE. In this study, one end-systolic frame per cardiac cycle was used for generation of the 
replenishment curve. Analysis of three frames per cycle did nor change the coefficient of 
variation, or the correlation with PET. The finding of a larger heterogeneity is caused by the fact 
that the homogeneity of the contrast enchancement is affected by attenuating factors like ribs, 
lungs or intracavitary contrast. The presence of the lowest contrast intensities in the vascular 
territories that include the (postero)lateral and anterior walls, support this conclusion. At rest, 
significantly higher values of PE were seen in the RCA vascular territory in comparison with the 
LAD and Cx vascular territories. At stress, attenuation occurs as a result of increased contrast 
intensity in apex and distal segments, which is reflected in a relatively lower contrast intensity at 
the basal segments.   
In spite of a higher heterogeneity, ivMCE has some important advantages in comparison with 
PET. IvMCE has the potential of simultaneous assessment of contraction and perfusion, whereas 
wall motion can not be assessed with PET. The high spatial resolution of ivMCE, which is circa 2 
mm, makes it suitable for detection of small perfusion defects. Although no patients with 
coronary artery disease were included in this study, ivMCE may have strong additional value in 
detecting coronary stenosis that are non-flow limiting at rest, and cause subendocardial perfusion 
defects during adenosine stress.      
Correlation between ivMCE and PET 
At rest, no correlations between A, β and PE, and MBF as measured with PET could be seen. The 
most likely explanation for this fact is that, in contrast to stress and especially overall correlations, 
the flow range at rest is limited, which hinders identification of a correlation with a relatively low 
number of subject. Due to storage capacity, only a maximum of ten seconds could be acquired 
after destruction of the microbubbles. Therefore, in a few subjects, the plateau phase could not be 
reached completely, probably resulting in a lower perfusion estimate PE. To improve reliability of 
the replenishment curve, a second analysis was performed, in which three end-systolic frames per 
beat in stead of one were used (data not shown). However, this did not improve correlations with 
PET. Alternatively, for assessment of perfusion with PET we used 15-O-labeled water. Uncertain 
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is whether the use of another PET-tracer, e.g. 13N-Ammonia could have improved the correlation 
with ivMCE (2).  
The results of the present study are roughly in agreement with the findings of Vogel et al, who 
quantified MBF with PET and 13N-Ammonia, and with ivMCE using Optison and coherent 
contrast imaging (8). In the latter study, significant correlations were also found between ivMCE 
and PET, although correlation coefficients in the present study are slightly different. As both 
techniques used real-time perfusion imaging techniques, and patient populations and design of 
both studies were equal, the differences between this study and the present study can only be 
explained by the use of a different PET-tracer. Furthermore, it should noted that in the present 
study, true quantification of MBF with the algorithm that was used in the study of Vogel et al, did 
not improve the correlation between PET and ivMCE.  
Limitations 
Although ivMCE has several advantages over PET with respect to availibility and costs, some 
disadvantages need to be mentioned. IvMCE is based on reflection of ultrasound by ultrasound 
contrast agents, which implies that lung- or tissue artifacts, and displacement of the heart during 
image acquisition influence assessment of myocardial perfusion. In the present study, 19% of all 
segments could not be used in quantitative analysis. However, more than 60% of these segments 
that could not be analyzed were basal lateral and anterior segments that are known to be prone to 
attenuation artifacts. These problems can likely be solved by using other imaging techniques, 
such as high power intermittent imaging, which decreases the number of segments with 
attenuation artifacts. New developments of ultrasound techniques, especially three-dimensional 
echocardiography which use a more homogenous ultrasound field, are promising tools that have 
the potential to further improve assessment of myocardial perfusion. 
In this study, ivMCE was compared with the current clinical standard for assessment of 
myocardial perfusion. PET was analyzed using a 13-segment model, with segments consisting of 
a three-dimensional volume. As presently, no real-time three-dimensional ivMCE can be 
performed, two-dimensional ivMCE was compared with PET. Although the scanning plane used 
with ivMCE had a 3-4 mm thickness, and segmental analysis was in fact performed on 3-
dimensional volumes, matching of segments might not have been perfect. However, as this study 
was performed in healthy volunteers, myocardial perfusion was distributed homogeneously, and it 
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was assumed that two-dimensional ivMCE would provide reliable perfusion estimates that could 
be compared with PET. 
Conclusion 
In conclusion, the estimate of myocardial perfusion as measured with ivMCE using real-time 
perfusion imaging correlates with PET measurements of MBF with PET in healthy volunteers. 
However, heterogeneity of perfusion measurements with ivMCE is large compared with PET, and 
true quantification of MBF with ivMCE is still challenging. 
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Chapter 3:  Myocardial contrast echocardiography in routine clinical care 
 
3.1 Myocardial contrast echocardiography evolving as a clinically feasible technique for 
accurate, rapid, and safe assessment of myocardial perfusion: the evidence so far 
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Abstract 
Intravenous myocardial contrast echocardiography (MCE) is a recently developed technique for 
assessment of myocardial perfusion. Up to now, many studies have demonstrated that the 
sensitivity and specificity of qualitative assessment of myocardial perfusion by MCE in patients 
with acute and chronic ischemic heart disease are comparable to contemporary techniques like 
cardiac scintigraphy and dobutamine stress echocardiography. Furthermore, quantitative 
parameters of myocardial perfusion derived from MCE correlate well with the current clinical 
standard for this purpose, positron emission tomography. Altogether, MCE provides a promising, 
valuable tool for assessment of myocardial perfusion. Although MCE has been primarily 
performed for medical research, its implementation in routine clinical care is evolving. This 
manuscript is intended to give an overview of the current status of MCE. 
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Introduction 
The use of ultrasound contrast agents for left ventricular opacification and myocardial perfusion 
in echocardiography has significantly improved the diagnostic accuracy of stress 
echocardiography. In the last decade, the clinical value of intravenous myocardial contrast 
echocardiography (MCE) in patients with both acute and chronic ischemic heart diseases has been 
demonstrated. At the same time, experimental and clinical studies have demonstrated the 
physiologic basis for quantification of myocardial perfusion with MCE. In comparison to other 
imaging techniques, MCE is a rapid, easy-to-perform, and safe bed-side technique for the 
assessment of myocardial perfusion. This manuscript provides a review of the current status of 
MCE with respect to clinical value, practical issues, and conditions that need to be fulfilled for 
clinical implementation. 
MCE protocols 
Ultrasound contrast agents 
Since 1968, when the existence of ultrasound contrast was established, the development of 
ultrasound contrast agents has undergone significant advances. Initially, contrast agents were air-
filled microbubbles, that were relatively unstable in the blood, and could not pass the pulmonary 
capillary bed, rendering them unsuitable for the assessment of the left side of the heart during 
intravenous injection. Second generation contrast agents were developed for this reason, 
containing a gas with low solubility and diffusibility, and a shell of lipids, albumin, or galactose 
to prolong their life span. The microbubbles have a diameter less than that of a red blood cell, 
resist arterial pressure, and remain intravascular in the intact circulation. These properties allow 
passage of the pulmonary vasculature, opacification of the left ventricular cavity, and imaging of 
myocardial perfusion. Currently, the most used second generation contrast agents are Sonovue®, 
Optison®, and Definity®. These agents are licensed for left ventricular opacification only. These 
agents differ in terms of their shell constituents and gas content, that influence shell-stiffness and 
stability of the microbubble, and determine physical properties. All are suitable for MCE. 
Physical principles 
The mechanism by which microbubbles enhance echocardiographic images, depends on their 
behavior under acoustic pressure. Low energy ultrasound causes microbubbles to oscillate 
linearly, reflecting ultrasound at the insonation (fundamental or f0) frequency. Ultrasound with an 
intermediate energy level, induces non-linear oscillations of microbubbles, resulting in generation 
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of frequencies other than the fundamental frequency (multiples of the fundamental frequency), 
that are called harmonic frequencies (for example 2f0). Finally, high intensity ultrasound (within 
the energy levels used for diagnostic imaging) destroys microbubbles. In contrast to 
microbubbles, cardiac tissue produces much less harmonic frequencies, so selective reception of 
harmonic echoes will preferentially detect signals emanating from contrast agent rather than the 
myocardium. 
Imaging modalities 
Initial contrast imaging modalities relied mainly on harmonic imaging techniques, where 
fundamental frequencies were eliminated, and harmonic frequencies were selectively detected. 
Although these methods improved the ‘signal-to-noise ratio’, off-line image processing was 
frequently required to evaluate myocardial perfusion, as tissue signals were still present. 
Harmonic imaging also used high acoustic powers that destroyed microbubbles - consequently, 
the imaging frame rate had to be reduced substantially with electrocardiographic triggering in 
order to allow microbubbles to replenish the myocardial microcirculation between pulses. 
Recently, several novel approaches to imaging microbubbles were developed: these include high 
power modalities with superior tissue noise suppression that allow on-line assessment of 
myocardial perfusion, and low power modalities that permit imaging with high frame rates. These 
modalities specifically take advantage of the non-linear behavior of microbubbles in an acoustic 
field. Many techniques use multiple transmitted pulses that are, e.g. full and half amplitude 
(power modulation (figure 1), to distinguish non-linear microbubble signals from tissue (1). 
Reflected echoes are scaled and subtracted. As tissue responds linearly (especially at low acoustic 
powers), subtraction and scaling results in zero signal. Microbubbles reflect non-linearly, so 
received echoes will not be cancelled out, enabling selective microbubble detection. Most of these 
multipulse techniques additionally use power Doppler, and the resulting signal is color coded and 
displayed (2). 
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Figure 1A 
 
 
Figure 1B 
 
Figure 1 Pulse cancellation techniques: principles of power modulation. A:resulting signal of tissue 
reflection. B: resulting signal of contrast reflection. 
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As high power imaging destroys microbubbles, imaging of myocardial perfusion cannot be 
performed in real-time. Low power imaging (mechanical index<0.2) increases signal-to-noise 
ratio, and because of minimal bubble destruction continuous imaging may be performed. Both 
high and low power MCE have their advantages and disadvantages. High power imaging 
precludes continuous imaging due to destruction of contrast and hence wall motion cannot be 
assessed simultaneously. On the other hand signal-to-noise ratio is good. Low power imaging 
allows simultaneous assessment of perfusion and contraction, but has a lower sensitivity for the 
detection of microbubbles. 
Stress agent 
The most commonly used stress agents are adenosine, dipyridamole and dobutamine. All three 
agents have been used widely for pharmacologic stress during MCE. Although the working 
mechanism of these agents differ, all agents have a high diagnostic value for detection of 
coronary artery disease (CAD) (table 1, 2). 
Assessment of myocardial perfusion 
Qualitative assessment 
During continuous infusion of microbubbles in a patient with intact coronary microvasculature 
and normal myocardial blood flow (MBF), destruction of microbubbles in the microcirculation by 
ultrasound is followed by relatively uniform contrast appearance in the coronary microcirculation, 
and homogenous opacification of the myocardium. In case of diminished epicardial flow, e.g. in 
significant CAD during stress, or after AMI, when microvascular integrity is affected, the speed 
and amount of contrast replenishment will be decreased. Earliest studies assessing MCE mainly 
used qualitative analysis in which contrast replenishment after microbubble destruction was 
scored as normal, reduced, or severely reduced. With such a scoring system, irreversible and 
reversible contrast defects in patients with flow-limiting CAD could be detected. Also, in patients 
with acute coronary syndrome (ACS), these scoring systems have proven their value in 
determining infarct size, viability, and prediction of functional recovery. 
Quantitative assessment 
As the microvascular rheology of microbubbles is similar to that of red blood cells, assessment of 
the transit of microbubbles through the coronary microcirculation with MCE should allow 
quantification of myocardial blood flow (MBF) (3). The first in vivo studies assessing 
quantification of MBF with MCE used bolus injections of microbubbles (4-6). The ratio of video 
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intensity (VI) in diseased/non-diseased vascular territories correlated well with radiolabeled 
microsphere derived blood flow ratios. The use of bolus injections of microbubbles, however, 
only allows assessment of relative differences in MBF, and not assessment of absolute MBF. This 
limitation was overcome with continuous microbubble infusions, which allows a steady state 
microbubble concentration to be reached in the blood. At this time, after microbubbles are 
destroyed by ultrasound, the subsequent replenishment of microbubbles into the ultrasound beam 
elevation will reflect MBF. The replenishment of contrast can be characterized by a time-intensity 
curve (figure 2, 3), which can be fitted to a mono-exponential function: y=A(1-eβt).  
 
 
Figure 2 Example of adenosine stress-MCE (subsequent end-systolic frames) with region of interest for 
quantification: apical 3-chamber view; a: baseline; b: contrast destruction; c-h: contrast replenishment. 
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Figure 3: Example of (A) replenishment curve with slope (β) and plateau value (A) of the replenishment 
curve fitted to a mono-exponential function (B). 
 
The reappearance rate of microbubbles, reflected by the slope of the replenishment curve (β) 
provides a measure of mean myocardial microbubble velocity, whereas the plateau value (A) of 
the replenishment curve reflects the microvascular cross-sectional area (7). The product of A and 
β therefore represents MBF. Animal studies using a coronary stenosis model demonstrated that 
the MCE-estimate of MBF correlates very well with absolute MBF, as measured with 
radiolabeled fluorescent microspheres (8-10). During pharmacologic stress, impaired hyperemic 
flow in the presence of coronary stenosis was associated with decreases in both A and β. Thus 
abnormalities in either MBF velocity or MBV during stress can be used to detect and quantify 
stenosis severity. In a canine model, quantification by triggered MCE appeared to be accurate 
enough to make a distinction between endo- and epicardial flow (11). In humans, similar results 
were found (12). MBF-reserve decreased in a step-wise manner in mild, moderate and severe 
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stenosis. Quantitative measures of MCE can not only be used to estimate stenosis severity, also, 
they can be used to assess perfusion defect after AMI, or predict recovery of hibernating 
myocardium (13;14). 
Absolute MBF in mL per minute per gram of tissue can be derived using MCE (14). Vogel et al. 
have shown that myocardial blood volume (MBV) fraction can be derived from the ratio of 
myocardial VI and that of the adjacent left ventricular cavity (15). This method adjusts for 
inhomogeneous contrast-enhancement of the myocardium due to technical factors such as 
attenuation. MBV fraction can then be used to derive absolute MBF (MBF=relative blood 
volume* β/tissue density, where the relative blood volume is A myocardium/A cavity). In this 
study, MCE derived absolute MBF was compared to PET, showing excellent correlations. 
A new application of quantitative MCE is generation of parametric images derived from contrast-
enhanced images (16). These images contain information about the quality of acquisition, the 
maximal intensity of contrast in the myocardium, and the speed of contrast replenishment (figure 
4), and allows fast, visual interpretation of myocardial perfusion. 
MCE in detecting stable coronary artery disease 
In normally perfused myocardium, the rate of capillary blood flow is 1 mm/second. Saturation of 
the coronary microvasculature by microbubbles therefore takes about 5 seconds (since the 
thickness of the ultrasound beam is approximately 5 mm). When there is no flow limiting 
stenosis, MBF increases 5 times during hyperemia (stress testing), thus the myocardium 
replenishes in 1 second. In addition, a flow limiting stenosis leads to a reduction in capillary 
blood volume in the distal microvasculature, with an accompanying decrease in signal intensity 
during MCE. These two features (slowed contrast appearance and decreased capillary blood 
volume) form the basis for detecting CAD using MCE. 
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Figure 4: Parametric image of apical 4-chamber view, containing information about A: peak intensity; B: 
slope of replenishment curve; C: estimate of MBF; D: quality of data. 
 
One of the first studies assessing MCE with triggered imaging in stable CAD patients showed that 
MCE can define the presence of abnormal perfusion at rest and during pharmacologic stress, with 
a high concordance between MCE and 99mTc-sestamibi-SPECT (17). Also, comparison of 
accelerated intermittent imaging at rest and with exercise to 99mTc-sestamibi-SPECT 
demonstrated a concordance of 76-92% (18). Several other studies assessed the accuracy of MCE 
and SPECT/dobutamine stress echocardiography (DSE) for detection of stable CAD, comparing 
the concordance of both techniques. In general, agreements are high, ranging from 65-92% (table 
1) (19-27). 
 
 
 
 
 
 
 
 
 
 
Table 1. Concordance of MCE and SPECT for detection of significant coronary artery stenosis in patients
with suspected coronary artery disease.
Concordance, % (kappa)
Patients (n) Imaging mode Patient basis Territory basis Segment basis
Kaul et al, [17] 30 THI 86% (0.71) 90% (0.77) 92% (0.99)
Heinle et al, [26] 123 HPD 81% (0.60) 76% (UN) 70% (0.32)
Shimoni et al, [18] 101 AII 76% (0.50) 76-89% (UN) 92% (0.32)
Wei et al, [23] 54 HPD 84% (0.63) 65% (0.41) UN
Rocchi et al, [21] 25 HPD 84% (0.67) 92% (0.81) UN
Olszow ska et al, [19] 44 HPD UN 73-91% (0.4-0.8) 89% (0.81)
Senior et al, [22] 55 IPI UN 70% (0.37) UN
Xie et al, [31] 36 RTI 75% (0.50) 85% (0.61) UN
Korosoglou et al, [27] 120 PPI UN 83 (0.65) 86 (0.65)
Data are expressed as concordance and agreement (kappa). CAD, coronary artery disease; THI, triggered harmonic imaging; UN, un-
know n; HPD, harmonic pow er Doppler; AII, Accelerated intermittent imaging; PCI, pow er contrast imaging; RTI, real-time imaging; IPI, inter-
mittent pulse inversion; PPI, pow er pulse inversion.
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A number of these studies have employed angiography as the gold standard (table 2). Most report 
a sensitivity of MCE for CAD-detection that is similar to or higher than SPECT/DSE, ranging 
from 64-97%, compared to 33-100% for the latter (18;19;21;22;24;27-31). Furthermore, the 
addition of MCE may improve sensitivity for detection of CAD over wall motion analysis during 
DSE (18;29;31;32). We performed a meta-analysis of these studies and showed that the 
sensitivity and specificity of MCE for detection of CAD are at least not inferior to SPECT/DSE 
(table 2, figure 5). 
MCE also provides prognostic value in patients with stable CAD (33). Patients with normal 
perfusion have a better outcome than patients with normal wall motion. This underscores the 
value of incorporating MCE in stress echocardiography. An example of a perfusion defect with 
real time perfusion during DSE is shown in figure 6. 
 
 
Figure 5 We conducted a meta-analysis on 8 studies (Pubmed, reference lists; restricted to English 
language literature) assessing the sensitivity and specificity of MCE and SPECT/dobutamine stress 
echocardiography (DSE) for detection of significant CAD, that were published until january 2006. The 
employed text words were ‘myocardial contrast echocardiography (MCE), single photon emission 
computed tomography (SPECT), dobutamine stress echocardiography, and stress echocardiography’. 
Studies were included when coronary angiography was used as gold standard, and if results were analyzed 
on a patient-based analysis. RevMan 4.2 of the Cochrane Collaboration group was used to calculate 
variance weighted pooled difference of proportions for the differences in sensitivity and specificity 
between MCE and SPECT/DSE according to a random effect meta-analysis. The pooled estimates of the 
differences in sensitivity and specificity were 0.14 [CI: 0.09-0.20] and 0.03 [CI: -0.14-0.21], respectively, 
indicating a higher sensitivity for MCE than for SPECT/DSE. No difference was found for the specificity. 
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“n/N” indicates the number of patients with CAD that were detected by MCE or SPECT/DSE, divided by 
the total number of patients with CAD; Sens, sensitivity; RD, risk difference; *indicates DSE. 
 
MCE in acute coronary syndromes 
Currently, the diagnosis of ACS is based on the triad of clinical history, ECG, and laboratory 
investigation. These methods, although useful, can often be non-diagnostic in this setting. As 
MCE is the only technique that permits immediate assessment of wall motion and perfusion, it 
has a unique role in the diagnosis of ACS. MCE allows quick evaluation of myocardial perfusion 
in the emergency department and may be used to triage patients into a low- and high-risk 
category. The value of MCE in acute coronary syndromes has been studied experimentally using 
coronary balloon occlusions in pigs. MCE accurately reflects the decrease in myocardial 
perfusion during balloon occlusion,  
 
 
Figure 6 Example of dobutamine stress contrast echocardiography. Reversible posterior/apical (apical 3-
cv, A3C) and inferior/apical (apical 2-cv, A2C) perfusion defect during peak stress (arrows). Coronary 
angiography demonstrates corresponding significant stenoses in both the left anterior descending, left 
circumflex (postero-apical defect), and right coronary arteries (infero-apical defect). 
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compared to microsphere derived MBF (1). Studies have also shown that during coronary 
occlusion, the area at risk correlates closely with the contrast defect early after contrast flash 
destruction, whereas the plateau contrast defect identifies infarct size (34). Kamp et al. were the 
first to report the sensitivity of MCE to detect perfusion defects in patients suspected of having 
AMI. With 1:1 end-systolic triggered imaging, MCE perfusion defects were detected in 19 of 32 
patients (59%) with TIMI 0 flow before PTCA (35). The sensitivity of MCE tended to decrease 
when patients had better TIMI-flow and inferior infarctions (20%), whereas the sensitivity of 
MCE in patients with an anterior coronary artery occlusion was high (88%). Other studies 
assessing the potential of MCE to acute coronary syndromes also report high sensitivities, 
comparable to that of standard echocardiography and SPECT (35-37;42;43) (table 3). In addition, 
MCE appears to have important prognostic value in patients presenting to the emergency 
department with acute chest pain (39-43). Besides detection of acute ischemic heart disease, MCE 
may play a pivotal role in prediction of functional recovery in patients post ST-elevation MI. The 
severity of myocardial damage is currently mainly estimated by enzymatic damage and wall 
motion score, whereas recovery of myocardial function is importantly dependent on reflow of 
blood to the risk area. The presence of reflow after coronary angioplasty is suggested by 
resolution of chest pain, and the degree of resolution of ST-elevation, but can be visualized by 
MCE (figure 7). Kloner was the first to demonstrate the deleterious effect of no-reflow on clinical 
outcome (44). Later, it was shown that the presence of no-reflow on MCE after AMI related to 
absence of pre-infarction angina, number of Q-waves, wall motion score at presentation, TIMI-
flow 0, the size of the area at risk, and the occlusion status of the culprit artery (45). Conversely, 
Table 2. Sensitivity and specificity of MCE and SPECT/DSE to detect stable coronary artery disease: gold
standard angiography.
                       MCE                    SPECT/DSE
Patients (n) Definition stenosis Imaging mode Sensitivity Specif icity Sensitivity Specif icity
Shimoni et al, [18] 44 >50% AII 75% 100% 75% 81%
Olszow ska et al, [19]1 44 >60% RTHI 97% 93% 93% 84%
Rocchi et al, [21]1 25 >70% HPD 89% 100% 100% 88%
Elhendy et al, [29]* 169 >50% RTPI 91% 51% 70% 74%
Senior et al, [22] 55 >50% IPI 83% 58% 49% 92%
Peltier et al, [24] 35 >70% PM 86% 69% 82% 85%
Tsutsui et al, [28]1 16 >50% RTI 64% 92% 68% 61%
Xie et al, [31]* 27 >50% PPI 66% 65% 33% 72%
Jeetley et al, [30] 123 >50% TRI 84% 56% 82% 52%
Korosoglou et al, [27] 89 >75% PPI 84% 93% 77% 52%
Karavidas et al, [in press] 47 >50% TPD 91% 92% 73% 72%
Pooled estimate 85% [81.5-88.5] 74%[67.7-80.3] 71% [66-76] 71% [64-78]
DSE, dobutamine stress echocardiography; AII, accelerated intermittent imaging; RTHI, real-time harmonic imaging; HPD, harmonic pow er Doppler;
RTPI, real-time perfusion imaging; IPI, intermittent pulse inversion; PM, pow er modulation; RTI, real-time imaging; PPI, pow er pulse inversion; TRI, 
triggered replenishment imaging; TPD, triggered pow er Doppler; *Compared to DSE; 1Analysis by territory, excluded f rom meta-analysis.
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intact microvasculature after AMI (reflow), is a positive predictor of functional recovery (46). 
Patients without microvascular dysfunction on MCE have less enzymatic elevation, better 
functional performance, better recovery of global and regional wall motion, less remodeling, and 
better survival, independent of other predictors (47-49). The ability of MCE to predict functional 
recovery has been summarized in table 4 (50-63), and is comparable to that of cardiovascular 
magnetic resonance imaging (64;65) (figure 8). Altogether, the existing literature suggests that 
MCE has important additional value for diagnosis and risk stratification in patients with acute 
ischemic heart disease. 
 
Targeted imaging with ultrasound contrast 
Recently, ‘targeted microbubbles’ have been developed by incorporating ligands in the 
microbubble shell. Experimental studies demonstrated that specific ligands to intercellular 
adhesion molecule-1 (ICAM-1) and GPIIbIIIa enabled these targeted agents to bind selectively to 
ICAM-1 expressing tissue, and thrombus respectively (66;67). As expression of ICAM-1 is 
associated with early atherosclerosis, targeted imaging could possibly play a role in diagnosis of 
preclinical atherosclerosis. Imaging of thrombus enables us to localize vascular clots in humans 
non-invasively. Furthermore, lipid microbubbles with phosphatidylserine in the microbubble shell 
appear to attach to inflamed tissue (68). Localized attachment of targeted ultrasound contrast to 
specific tissue creates great opportunities for development of new diagnostic tools, and also 
treatment modalities (targeted drug delivery). 
 
Table 3. Sensitivity and specificity of MCE for detection of impaired perfusion in patients with
suspected acute coronary syndrome.
Patients (n) Type ACS Sensitivity Specificity Gold standard
Kamp et al, [35] 59 STEMI 59% NA Angiography
Rocchi et al, [43] 30 AMI 84% 94% Angiography
Moir et al, [36] 34 STEMI 79% 50% Angiography
Hagendorf et al, [42] 100 ACS 84% 93% Guidelines ACC/AHA
Winter et al, [37] 35 ACS 81% 67% Angiography
Pooled estimate 258 82% 63%
ACS, acute coronary syndrome; STEMI, ST-elevation myocardial infarction; NA, not applicable; AMI, acute myocardial infarc-
tion; ACC, American College of Cardiology; AHA, American Heart Association.  
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Figure 7: No-reflow after primary PTCA for acute myocardial infarction (real-time MCE). 
 
 
Figure 8: Fixed septal/apical perfusion defect (arrows) with MCE (left), SPECT (middle), and delayed 
enhancement with MRI (right) after myocardial infarction. 
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Safety 
The most important study assessing the safety of MCE was performed by Tsutsui et al. (69). More 
than 1500 patients underwent dobutamine stress MCE with low mechanical index real time 
perfusion, during which no major adverse events were seen. MCE has a similar safety profile as 
dobutamine stress echocardiography. In patients with heart failure, intravenous contrast did not 
show any deleterious hemodynamic effects compared to placebo (70). The occurrence of 
premature ventricular contractions, especially during end-systolic high mechanical index imaging, 
has been a matter of concern. However, data regarding this aspect are conflicting, and as 
significant arrhythmias during MCE are observed rarely, the clinical significance is doubtful (71). 
Practical issues 
MCE is a relatively simple technique for imaging of myocardial perfusion. However, there is a 
learning curve like all non-invasive techniques. As perfusion of the myocardium is assessed in 
one specific region, it is important to keep the transducer still, to minimize movement of the 
heart. In contrast to real-time imaging, triggered imaging does not allow continuous visualization 
of the heart (unless the system is equipped with monitoring mode). Especially with this technique, 
the quality of the images improves with more experience. Training is also required for 
interpretation. 
When performing MCE, infusion pump, blood pressure, and heart rate monitoring must be 
available. Stress testing with the formerly mentioned stressors is safe, and the excellent safety 
profile is not expected to change when used in contrast echocardiography. However, a physician 
needs to be present to monitor the well-being of the patient (72). Emergency medication and 
facilities should be present in case of adverse events, that, however, occur rarely. 
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Future perspectives 
Real-time three dimensional myocardial perfusion echocardiography 
A promising tool within MCE is the development of real-time three dimensional perfusion 
echocardiography (73). The current matrix transducers use a more homogeneous ultrasound field, 
which improves image quality, and acquire a full volume in stead of one scanning plane. Image 
interpretation is favored by slicing the myocardium in the appropriate view, by which perfusion 
defects can be visualized in any chosen myocardial region. 
Conclusion 
In the past 10 years, MCE has developed from a research tool to a clinically valuable technique in 
patients with known or suspected CAD. It is a rapid, safe and accurate method for imaging of 
myocardial perfusion, and can be used for qualitative, and quantitative assessment of MBF. Large 
prospective, multicenter trials would probably facilitate formal approval and more widespread 
acceptance of MCE. 
 
 
 
 
 
Table 4. Prediction of recovery of regional and global function, and prediction of events by MCE in 
patients after acute myocardial infarction.
Regional function
Patients (n) FU (month) Sensitivity Specif icity PPV NPV Accuracy
Bolognese et al, [53] 30 1 96% 18% 41% 89% 47%
Agati et al, [59]* 23 2 100% 90% 81% 100% 93%
Sw inburn et al, [58]* 96 3-6 59% 76% 47% 84% UN
Main et al, [60] 34 2 77% 83% 90% 63% 79%
Hillis et al, [55] 37 2 80% 67% 66% 81% 73%
Janardhanan et al, [56] 50 3 87% 78% 65% 93% 81%
Korosoglou et al, [57] 32 1 81% 88% 95% 61% 83%
Huang et al, [63] 34 4 83% 82% 92% 66% 83%
Nunes Sbano et al, [61] 50 6 95% 52% 55% 94% 68%
Abe et al, [41] 21 6 98% 32% 43% 96% 55%
Pooled estimate 407 81% 69% 64% 83% 74%
Global function and events Reflow-group No-reflow-group
Patients (n) EF baseline EF FU FU(% cardiac death) EF baseline EF FU FU(% cardiac death)
Ito et al, [51] 39 42±11 56±13 35±9 43±9
Porter et al, [52] 45 59±10 63±9 55±13 46±5
Sakuma et al, [48] 50 44±9 56±12 4% 35±18 45±14 12%
Bolognese et al, [47] 124 40±7 51±11 3% 33±8 NA 25%
Data are presented as percentage. FU, follow  up; PPV, positive predictive value; NPV, negative predictive value; UN, unknow n; EF, 
ejection fraction; *patients partly revascularized.
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Abstract 
We hypothesized that in patients with recent acute myocardial infarction (AMI) and residual wall 
motion abnormalities, real-time adenosine stress myocardial contrast echocardiography (MCE) 
provides additional value for assessment of the extent of myocardial damage and prediction of 
recovery of left ventricular (LV) function compared to rest MCE. 
Methods 
Twenty-five patients with acute myocardial infarction (AMI) underwent baseline 
echocardiography and real-time MCE at rest and adenosine stress, 3±2 days after AMI. ECGs for 
assessment of ST-elevation, and laboratory investigation (CK-MB) for assessment of enzymatic 
myocardial damage were performed serially. Myocardial perfusion was graded and a perfusion 
score index (PSI) per segment was calculated. Follow-up echocardiography was performed at 6 
months for assessment of segmental LV recovery.  
Results 
Both the PSI at rest and adenosine stress correlated significantly with peak CK-MB (r=0.76, 
p<0.01 and r=0.85, p<0.01). The residual ST-elevation immediately after PCI, showed a clear 
correlation with the PSI at rest (r=0.86, p<0.001), and adenosine stress (r=0.66, p<0.01). 
Compared to rest, the sensitivity of adenosine stress for the prediction of segmental recovery was 
higher (97% versus 88%), but the specificity was lower (42% versus 67% respectively).  
Conclusion 
Both rest and adenosine stress MCE are safe, and accurately reflect the magnitude of myocardial 
damage. Adenosine stress MCE has a higher sensitivity for assessment of functional recovery 
than rest MCE. 
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Introduction 
Acute myocardial infarction (AMI) results in regional left ventricular (LV) dysfunction that is 
caused by myocardial stunning or necrosis. As residual LV function is a major determinant of 
long-term survival, differentiation between necrosis and stunning is of importance for risk 
stratification and prognosis. Major determinants for recovery of function are adequate 
reperfusion, and an intact microvasculature, which is closely associated with myocardial viability 
after AMI in humans. Several studies have demonstrated that lack of myocardial reperfusion is a 
predictor of poor recovery of LV function in AMI patients (1-3). Up to now, clinical methods to 
predict LV functional recovery after reperfused AMI have mainly focused on clinical parameters, 
contractile reserve, and myocardial perfusion (4-10).  
During the last years, myocardial contrast echocardiography (MCE) has been established as a 
validated, bed-side technique for assessment of microvascular perfusion (11). Recent studies, 
mainly using triggered MCE, demonstrated that MCE accurately predicts functional recovery in 
the subacute phase of AMI (12-19). Until now, these studies only used MCE at rest for this 
purpose. As vasodilator stress is the ultimate test for assessment of vasodilator reserve and the 
presence of microvascular perfusion, adenosine MCE may have additional value for prediction of 
functional recovery, and may be a more accurate reflector of the magnitude of myocardial 
infarction.  
We hypothesized that in patients in the subacute phase after AMI, with and residual wall motion 
abnormalities, real-time adenosine MCE provides additional value for prediction of the extent of 
myocardial damage, and recovery of segmental LV function.  
Methods 
Study population 
Twenty-five consecutive patients presenting with a first AMI within 12 hours of the onset of 
symptoms were included. The diagnosis of AMI was based on the guidelines for management of 
AMI of the ESC (20). Patients were included if they had at least a two-fold rise in serum creatine 
kinase (CK)-MB level or a rise in troponin T above the reference value. Exclusion criteria were 
previous myocardial infarction, chronic obstructive pulmonary disease, pulmonary hypertension, 
pregnancy, protein allergy, or known allergy to the ultrasound contrast agent 
(Sonovue®/Optison®).  
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Protocol 
Electrocardiograms were made before, immediately after, and 24 hrs after percutaneous coronary 
intervention (PCI). Protocol-specified blood sampling for cardiac biochemical markers (CK-MB, 
troponin T) was performed at baseline and at 8 hrs, 12 hrs, 24 hrs, and 48 hrs after PCI. All 
patients underwent baseline echocardiography and MCE between 2-7 days after AMI. Follow-up 
echocardiography was performed at 6 months for assessment of LV functional recovery. All 
participants gave written informed consent. The study protocol was approved by the VU 
University Medical Center Ethics Committee. 
Myocardial contrast echocardiography 
Second generation contrast agents (Sonovue®, Bracco, Milan, Italy; Optison®, Amersham Health 
AS, Oslo, Norway) were used for MCE. The contrast agent was intravenously injected with a 
continuous infusion rate of 0.5-1.5 ml per minute using a mechanical pump (Vueject, Bracco, 
Geneva, Switzerland). The infusion rate was adjusted to obtain maximal opacification of the 
myocardium without basal attenuation due to intracavitary contrast, and was kept constant 
throughout the experiment. To reach a steady state of microbubbles in the blood, image 
acquisition was started 2 (Sonovue) to 4 (Optison) minutes after the start of contrast infusion. 
Imaging was performed with a Sonos 7500 (Philips Medical Systems, Best, The Netherlands) 
with a broadband 1.3 to 2.6 MHz transducer. Real-time MCE was performed with color-coded 
power modulation imaging, at rest and during vasodilator stress (adenosine: 0.140 mg kg-1min-1). 
Baseline settings, such as mechanical index (0.11-0.18), depth (<13.5 cm), and color gain, were 
determined prior to the start of the procedure and were kept constant thereafter. Imaging was 
performed to obtain apical 4-, 2-, and 3-chamber views. A burst of high acoustic energy (i.e. a 
flash, mechanical index 1.0, 12 frames) was used for destruction of the microbubbles, followed by 
imaging of contrast replenishment with low acoustic pressure ultrasound with a frame rate of 18-
20 Hz during ten seconds. Similarly, stress images were obtained two minutes after the start of 
infusion of adenosine.  
Analysis of electrocardiogram 
The ECG was used for assessment of maximal ST-elevation before, immediately following PCI, 
and 24 hours after PCI. The total ST-segment elevation was calculated as the sum of ST-elevation 
in all leads, which was measured 20 ms after the end of the QRS-complex. No-reflow was defined 
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as residual ST-elevation of 50% or more compared to the first ECG. For interobserver variability, 
a second blinded, independent observer analysed ST-elevation of 20 ECGs.   
Analysis of 2D echo / MCE 
Two experienced echocardiographers blinded to the patients’ data analyzed the echocardiographic 
images. LV volumes were calculated using the biplane Simpsons method. Wall motion was 
scored as normal (0), hypokinetic (1), akinetic (2) or dyskinetic (3) based on a 16-segment model 
(21). Recovery of segmental function was defined as improvement of segmental wall motion from 
baseline to follow-up. For all segments, perfusion at rest and adenosine was scored as normal (1), 
reduced (2), or absent (3). For assessment of prediction of recovery of function, segmental 
perfusion was estimated as the presence of any segmental perfusion (1 and 2) versus absent 
perfusion (3). For both wall motion and perfusion an index was calculated, defined as the total 
sum of segmental scores divided by the total number of segments, resulting in the wall motion 
score index (WMSI) and the perfusion score index (PSI) respectively.   
Statistical analysis 
SPSS 9.0 (SPSS Inc, Chicago, US) was used for analysis of data. Categorical variables are shown 
as percentages. Continuous variables are shown as mean ± standard deviation. Student’s T-test 
was used for comparison of continuous variables. Correlation were calculated using linear 
regression analysis. The sensitivity (95% confidence interval (C.I.)), specificity, positive 
predictive value (PPV), and negative predictivey value (NPV) for prediction of recovery of 
function on a segmental basis were determined for both rest and adenosine MCE. Differences 
were considered statistically significant at p<0.05.  
Results 
Clinical characteristics 
Twenty-five patients (mean age 56±13, 78% males), were recruited into the study. Two patients 
were excluded due to previous myocardial infarction. One patient was excluded from follow-up 
due to re-infarction. One patient was lost-to-follow-up. In 1 patient rest PSI was not calculated 
due to 4 infarct-related segments that could not be analysed. Of all patients, 92% suffered from 
ST-elevation infarction, which was treated with PCI. The culprit laesion was localized in the left 
anterior descending artery in 9 (39%), in the right coronary artery in 9 (39%), and in the left 
circumflexal artery in 5 (22%). The mean time from the onset of symptoms to coronary 
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reperfusion was 3.9±2.9 hrs. Baseline echocardiography and MCE were performed 3.0±2.0 days 
after AMI. Demographic and clinical characteristics are shown in table 1.  
 
Table 1. Clinical characteristics.
Demographics N=23 
 Age (yrs) 56±13 
 Sex (% males) 78 
 BMI (kg/m2) 26.0±3.1 
  
Medical history  
 History of IHD (%) 17 
 Prior PTCA (%) 0 
 Prior CABG (%) 4 
  
Risk factors  
 Hypertension (%) 43 
 Hypercholesterolemia (%) 35 
 Diabetes (%) 13 
 Smoking (%) 70 
 Family history (%) 48 
  
Hemodynamics  
 Heart rate 78±15 
 Systolic blood pressure 144±32 
 Diastolic blood pressure 82±18 
  
Acute MI  
 Time symptom onset-PCI (hrs) 3.9±2.9 
 ST-elevation (%) 92 
 PTCA (%) 96 
 Mean number of stents 1.3±0.9 
 Anterior infarction (%) 38 
  
 
 
Electrocardiography and laboratory values 
In patients with ST-elevation AMI, the mean total amount of ST-elevation was 10.3±9.1 mm in 
12 leads at presentation, which decreased to 4.5±4.4 mm immediately after PCI (p<0.01), and to 
3.1±3.2 mm 24 hours after PCI (p<0.01). The mean percentage of ST-segment reduction 
immediately after PCI was 54±40%. Interobservervariability for assessment of ST-elevation was 
excellent (r=0.97, p<0.0001). Peak-CK level was 2485±3214 IU/L, with a peak-CK-MB iso-
enzyme of 198±177 IU/L (table 2). 
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Wall motion and perfusion 
Wall motion could not be analyzed in 3/336 segments (1%). MCE was well tolerated in all 
patients, without important adverse events. Myocardial perfusion at rest was inadequately 
visualized in 15/336 segments (4%). In one patient, adenosine imaging was not performed. In 7 of 
the remaining 320 segments (2%) at stress, perfusion was not adequately visualized. At baseline, 
21 patients had a total of 131 dysfunctional segments, which is a mean of 6.2 segments per 
patient, resulting in a mean WMSI of 0.57±0.32. The end-diastolic- and end-systolic volumes 
were 91±27 mL and 42±17 mL respectively, with a mean EF of 56±7%. At rest, 32 (24%) of the 
131 dysfunctional segments had no-reflow, 46 (35%) had reduced perfusion, and 53 (40%) had 
normal perfusion (figure 1). 
Table 2. Echocardiography, electrocardiography, laboratory values
Baseline (23) Follow-up (21)
Echocardiograpy
 EDV (mL) 91 92
 ESV (mL) 42 35
 EF (%) 56 62
 Wall motion score index 0.57±0.32 0.35±0.34
 PSI rest (unitless) 1.36±0.31 NA
 PSI stress (unitless) 1.28±0.30 NA
Electrocardiography
 Sum ST-elevation presentation 10.3±9.1 NA
 Residual ST-elevation post PCI 4.5±4.4 NA
 Residual ST-elevation at 24 hrs 3.1±3.2 NA
 ST reduction post PCI (%) 54±40 NA
Laboratory values
 Peak CK (IU/L) 2485±3214 NA
 Peak CK-MB (IU/L) 198±177 NA
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Figure 1. Example of adequate reflow (A) and no-reflow (B) in two different patients with anterior wall 
myocardial infarction. 
 
The mean PSI at rest was 1.36±0.31. At stress, the number of segments without any perfusion 
decreased to 23/123 (19%), whereas the number of segments with normal perfusion increased to 
55 (45%). The PSI at stress (1.28±0.30) was significantly lower compared to rest (p=0.02). 
Assessment of extent of MI 
Cardiac markers of enzymatic myocardial damage, such as peak-CK-MB, showed strong 
correlations with the WMSI at baseline (r=0.84, p<0.01) and at follow-up (r=0.77, p<0.01). The 
PSI at rest, which is an accurate reflector of myocardial (no-)reflow and thus myocardial damage, 
also significantly correlated with peak CK-MB (r=0.76, p<0.01, figure 2a), with a similar 
correlation for PSI at stress (r=0.85, p<0.01, figure 2b). With increasing WMSI, a linear increase 
in PSI at rest was found (r=0.90, p<0.01).  
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Figure 2. A: Relation between the perfusion score index at rest and the peak enzymatic release (CK-
MB).,B: Relation between the perfusion score at stress and the peak  enzymatic release (CK-MB). 
 
Interestingly, the electrocardiographic marker for no-reflow, residual ST-elevation immediately 
after PCI, showed a clear correlation with the PSI at rest (r=0.86, p<0.001, figure 3a), and at 
stress (r=0.66, p<0.01, figure 3b). A similar correlation was also demonstrated between rest PCI 
and the residual ST-elevation 24 hours after PCI (r=0.78, p<0.001). The PSI at rest and the 
amount of initial ST-elevation before PCI correlated weakly (r=0.49, p=0.02). The residual ST-
elevation immediately after PCI not only correlated with the PSI, but also with the WMS at 
baseline (r=0.78, p<0.001) and follow-up (r=0.69, p<0.001). Correlation coeffictients of the PSI 
at rest compared to adenosine are shown in table 3. 
 
Figure 3. A: Relation between the residual ST-elevation after PCI and the perfusion score index (unitless) 
at rest. B: Relation between the residual ST-elevation after PCI and the perfusion score index (unitless) at 
adenosine stress. 
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Reflow versus no-reflow 
Of the 21 patients that underwent PCI for STEMI, 10 were classified as having no-reflow. The 
mean sum of ST-elevation was 12.1±11.5 mm before PTCA, and 2.0±2.7 mm immediately after 
in the reflow-group, corresponding with a mean reduction of ST-elevation of 86%. In the no-
reflow group, the ST-segment changed from 10.6±5.6 mm to 7.9±3.7 mm before and after PTCA 
respectively, with a mean reduction of almost 19%, which was statistically different from the 
reflow group (P<0.01). At baseline, peak CK-MB and baseline WMSI did not differ between the 
two groups, with values of 250±207 IU/L versus 179±151 IU/L (p=0.38) and 0.74±0.35 versus 
0.49±0.26 (p=0.08) respectively. The PSI at rest, however, was higher in the no-reflow group 
(1.52±0.36) compared to the reflow-group (1.23±0.19, p=0.04). At stress, the PSI showed a trend 
towards a decrease in the reflow group (1.42±0.36 versus 1.18±0.17, p<0.08). Also, the WMSI at 
follow-up was significantly higher in the no-reflow group, compared to the patients with reflow 
(0.54±0.43 versus 0.21±0.18, p<0.05). 
  
6 Month follow-up 
In contrast to the EF (62% at follow-up, p<0.01 compared to baseline), the end-diastolic (92 mL) 
and end-systolic (35 mL, p=0.05) left ventricular volumes did not change compared to baseline 
volumes (figure 4). Also, the WMSI significantly improved from baseline (0.57±0.32) to follow-
up (0.35±0.34, p<0.01).  
Prediction of recovery with MCE 
In 21 patients, 131 segments were hypo- or akinetic at baseline. Contractile function improved in 
76 of these segments, of which 67 (88%;95% confidence interval(C.I.) 83-93%) had normal or 
reduced perfusion, and 46 (61%; 95% C.I. 53-69%) had normal perfusion at rest. In 55 segments 
without recovery of function, 48 (87%; 95% C.I. 83-93) had reduced or absent perfusion at rest. 
Furthermore, segments that recovered function had any form of perfusion at stress in 97% (95% 
Table 3. Correlation of myocardial perfusion with enzymatic damage, ECG, and echo.
PSI rest p PSI stress p
r (p) r (p)
Peak CK-MB 0.76 <0.001 0.85 <0.001
Wall motion score baseline 0.90 <0.001 0.78 <0.001
Residual ST-elevation after PCI 0.86 <0.001 0.66 <0.01
Ejection fraction -0.52 0.02 -0.50 0.02
∆ Ejection fraction baseline-FU 0.00 NS 0.16 NS
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C.I. 94-100%) of the cases. The prediction of recovery of segmental function by rest and stress 
MCE is depicted in table 4.  
 
 
 
Figure 4. LV volumes and ejection fraction of the AMI population at baseline and 6 month follow-up. 
 
 
 
 
 
 
 
 
For assessment of prediction of recovery of function, segmental perfusion was estimated according to the 
presence of any segmental perfusion (1 and 2) versus absent perfusion (3). 
 
 
 
 
 
 
Table 4. Prediction of recovery of segmental dysfunction after AMI using MCE
     
 Sensitivity Specificity PPV NPV 
MCE rest (n=131)     
A 88%(82-93) 42%(34-52) 68%(60-76) 72%(65-80) 
MCE stress (n=123)     
A 97%(94-100) 39%(30-48) 67%(59-75) 91%(86-96) 
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Discussion 
In patients after AMI, residual LV function is an important determinant of morbidity and 
mortality. Severe depression of segmental LV function leads to deterioration of global LV 
function, which is a predictor of a worse prognosis. In the subacute phase after AMI, impairment 
of regional wall motion may be a consequence of myocardial necrosis, or myocardial stunning. 
With stunning, despite the presence of intact myocardial blood flow, contractile function is 
diminished. MCE is a valuable tool for assessment of microvascular integrity, which enables 
classification of patients into reflow or no-reflow. The presence of no-reflow with MCE relates to 
the coronary flow velocity, and predicts the occurrence of arrhythmias, remodeling, heart failure, 
and death (14;22-24).  
The present study demonstrates that 1. The PSI derived from MCE accurately reflects the 
magnitude of myocardial damage; 2: MCE has a high sensitivity for prediction of segmental 
recovery after AMI, and a relatively low specificity; 3: adenosine stress MCE has additional 
predictive value for segmental recovery after AMI. 
Extent of myocardial infarction 
In agreement with the findings of others, we demonstrate that the enzymatic estimate of infarct 
size correlates with functional myocardial damage (25). Besides, the PSI, which is an accurate 
marker of reflow in AMI-patients, also correlated strongly with biochemical damage in this 
patient category, with a similar correlation coefficient and level of significance. Interestingly, the 
residual ST-elevation immediately after PCI, being a predictor of poor functional recovery, 
showed a clear correlation with both rest and stress PSI (8-10). This relation was also 
demonstrated at 24 hrs after PCI, whereas the relation between ST-elevation before PCI and the 
PSI was much less strong. In the present study, we demonstrated that no-reflow defined by 
residual ST-elevation on the electrocardiogram, is accompanied by less perfusion, and a higher 
WMSI at follow-up. These findings confirm that MCE accurately reflects the extent of (no-) 
reflow. 
Comparison of proportions with previous studies 
The predictive value of MCE has been investigated in previous studies, mainly using triggered 
imaging. A meta-analysis shows that the predictive value of rest MCE for recovery of segmental 
function is high, with a sensitivity of circa 81%, and a specificity of 69% (Dijkmans et al, JACC 
2006, in press). The positive and negative predictive value are approximately 64% and 83% 
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respectively. The results of the present study demonstrate that the presence of any form of 
perfusion seems to be a prerequisite of recovery of segmental function, although the presence of 
perfusion does not per se lead to recovery. Apparently, post AMI segmental perfusion does not 
garantee an intact contractile apparatus. This is in agreement with the findings of Kloner et al., 
who demonstrated that morphological damage to a myocyte histologically occurs before 
endothelial cell necrosis is seen. This explains the presence of segments with perfusion without 
recovery of function. 
With the addition of adenosine stress MCE, the sensitivity of MCE for detection of functional 
recovery increases, toghether with the negative predictive value. We can only speculate on the 
working mechanism. Previous studies showed that immediately and several days following PCI 
for AMI, the infarcted territory still has vasodilator reserve (26). Some studies show, that during 
intravenous adenosine stress, capillary recruitment occurs, which is the opening of capillaries that 
are not used at rest, due to increased metabolic demand (11;27). Similarly, in a myocardial 
infarction model, these capillaries that are not visualized at rest, may enable the myocardium to 
recover function on the long term. A second explanation for the higher sensitivity of adenosine 
MCE is the visualization of coronary collaterals. The infarcted area can be divided into at least 
two zones: the central necrotic zone, which is dependent on the blood flow through the infarct 
related artery only, and the ischemic border zone, which is supplied with blood from the infarct-
related artery, and an adjacent coronary artery. The occlusion during AMI leads to hypoperfusion 
of the latter area. The collateral flow prevents this area from becoming necrotic, however, blood 
flow is insufficient for maintaining full contractile function. The presence of vasodilator reserve 
in this area could enable recovery of function, and can be visualized with adenosine MCE.   
The results of the present study suggest additional value of stress MCE after AMI for the 
prediction of recovery. In our study, 24 patients underwent adenosine MCE, which was tolerated 
well, without the occurrence of important adverse events. It can thus be stated that adenosine 
stress is safe in the early phase after AMI. 
Study limitations 
Several limitations should be acknowledged. In this study, we used two types of ultrasound 
contrast agent, Sonovue and Optison. This was caused by a temporary withdrawal of Sonovue, 
and later restrictions in its use. As the working mechanisms of both Sonovue and Optison are 
essentially the same, and the imaging method was not changed, we do not expect important 
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differences in the results by the use of these two contrast agents. A second limitation is the 
relatively low number of included patients. However, as our analysis for calculations of 
proportions was based on an analysis of sixteen segments per patient, the influence on the results 
is probably limited. 
Conclusion 
MCE can be used for accurate assessment of the magnitude of myocardial damage, and is an 
accurate predictor of recovery of function after AMI. The use of adenosine stress MCE has 
additional value for this purpose and seems safe in this patient category in an early phase after 
AMI.  
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Abstract 
The introduction of ultrasound contrast agents has led to a markable improvement of diagnostic 
capabilities in echocardiography. As no serious adverse events were seen during the preclinical 
development phase, ultrasound contrast agents were thought to be safe. Recently, three fatal and 
nineteen severe, non-fatal adverse reactions were reported in a post marketing analysis of more 
than 150,000 studies of Sonovue®, which has led to the addition of several contra-indications for 
the use of this ultrasound contrast agent. Although a strong relationship was established between 
the non-fatal cases and administration of Sonovue®, a causal relationship between the fatal cases 
and the use of Sonovue® is debatable. Therefore, the risk associated with the use of this 
ultrasound contrast agent should be judged carefully, taking into consideration the prevalence of 
adverse effects of other contrast media and diagnostic procedures used in cardiology.  
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The widespread introduction of ultrasound contrast agents (UCAs) a few years ago has led to a 
markable improvement of diagnostic capabilities in echocardiography. As only minor adverse 
events (AEs) were seen during the preclinical development phase of several currently registrated 
second generations contrast agents, the general belief is that UCAs were safe. Recently, post 
marketing analysis of 157,838 studies of Sonovue® brought to light nineteen cases of severe, 
non-fatal (0.012%) and three cases of fatal AEs (0.002%) after the use of this UCA [1]. This has 
led to a restriction for the indication of the use of Sonovue®. Although it’s generally assumed that 
there was a strong relationship between administration of Sonovue and the non-fatal cases, a 
causal relationship between these fatal AEs and the use of this UCA is uncertain. Therefore, the 
risk which arises from the use of UCAs should be judged carefully, taking into consideration the 
additive value of UCAs, and the risks and prevalence of adverse effects of other contrast agents 
and diagnostic tests used in cardiology. The use of contrast agents is widely spread in nuclear 
medicine, radiology, and cardiology. Intravenous administration of contrast agents in general is, 
although relatively safe, known to cause side effects. Several studies investigating the prevalence 
of adverse reactions to nuclear radiopharmaceuticals, magnetic resonance agents, and ionic/non-
ionic radiological contrast media have shown that adverse drug reactions are, although present in 
only a few percent of the population, inevitable and can be serious. The prevalence of AEs after 
the use of Gd-GTPA, a magnetic resonance imaging (MRI) contrast agent, was studied by 
Niendorf et al. in a phase IIIb-IVa study in 13,439 patients [2]. Serious or fatal AEs were not 
reported (table 1). In this study, postmarketing surveillance data included over 2,000,000 
applications, in which 39 (0.002%) serious AEs occurred. Seven deaths were seen following 
administration of Gd-GTPA, however, no causal relationship could be established in the fatal 
cases that occurred in temporal coincidence of administration of this contrast agent. Similar 
results were shown by Katayama et al. in a large comparitive study of ionic and non-ionic 
contrast agents used in urography, contrast enhanced computed tomography, and digital 
subtraction angiography [3]. Although the prevalence of serious AEs was relatively high, i.e. 
0.22% in ionics and 0.04% in non-ionics, the number of fatal AEs was limited to 2 in 352,187 
(0.0006%). These fatal events could also not be causally related to the administration of the 
contrast media. This adverse event rate was lower than that was found by Shehadi et al., who 
reported 18 deaths (0.006%) in a prospective study of 302,083 applications of intravascular 
contrast media [4]. Adverse reactions in a third large group, namely radiopharmaceuticals used in 
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nuclear medicin were investigated by Silberstein et al. In a prospective study, the prevalence of 
adverse reactions to 783,524 radiopharmaceuticals and 67,835 nonradioactive drug 
administrations was studied [5]. In this registration, no serious AEs for radiopharmaceuticals 
(99mTc-derivatives most commonly linked to adverse reactions) and 1 for non-radioactive drugs 
were reported, while no deaths occurred.  
In the case of Sonovue, preclinical safety studies did not show the occurrence of related serious 
adverse events. Post-marketing analysis, however, revealed 3 fatal AEs that occurred in temporal 
coincidence with the use of this agent (0.002%) [1]. All three patients appeared to have advanced 
coronary artery disease and were probably in an unstable condition at the time of receiving 
Sonovue. Although a causal relationship between administration of Sonovue and these events 
could be established in none of these cases, the close temporal relationship between Sonovue 
administration and these fatal AEs clearly suggests that Sonovue might be a triggering factor in 
this high risk population. Besides the three fatal cases, 19 other serious non-fatal AEs have been 
reported (0.012%), 18 of which were anaphylactoid or vasovagal reactions. Of these 19 serious 
AEs, 9 were cardiac events (4 bradycardia, 2 tachycardia, 3 myocardial ischemia). 11 of these 19 
patients received Sonovue for the echocardiography indication. The rate of fatal AEs of Sonovue 
appears to be higher than the AE rate ofOptison, another second generation UCA (table 1). Ten or 
less cases of serious (<0.002%) and no fatal adverse events were reported after the use of this 
contrast agent until so far, although more than 500,000 studdies have been performed in a similar 
patient population (Personal communication Amersham Health AS/GE Healthcare, 2005).The AE 
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rate of Sonovue® also seems to be relatively high when compared with contrast agents used in 
MRI, radiology, and nuclear radiopharmaceuticals. However, differences exist between the 
population in which these contrast media are used. As reported by Katayama et al., the prevalence 
of (serious) AEs is about twice as high in patients suffering from cardiovascular disease. As 
UCAs are used for left ventricular opacification or myocardial perfusion in patients with known 
or suspected cardiovascular disease on a large scale[6], the AE rate is expected to be higher in this 
patient group. The analysis of the European Medicines Agency (EMEA) shows that a higher AE 
rate is reported when Sonovue® is used for cardiac imaging than for non-cardiac imaging, 
however, to date, no studies on the safety of UCAs have been published with a solid subgroup 
analysis to estimate the specific risk of AEs in patients with cardiovascular disease. UCAs have 
been used in patients suffering from severe cardiovascular disease, unstable coronary syndromes, 
or heart failure, which increases the risk of a worse outcome of a serious AE. As contrast agents 
like Gd-GTPA, contrast media used in radiology, and radiopharmaceuticals are probably used less 
in such a patient population, this can possibly give an explanation for the relatively low rate of 
fatal AEs of these contrast agents. The lower adverse event rate of Optison compared with 
Sonovue® is remarkable. Shell constituents and shell characteristics (e.g. charge) may account for 
the difference between these UCAs. As the shell of Sonovue contains polyethylene glycol 
(macrogol 4000), which is known to be associated with the occurence allergic reactions, this 
chemical may have played a role in the adverse reactions after use of Sonovue.[7]  
For a global evaluation of the risks and benefits of the use of Sonovue, the risks and yield of other 
diagnostic tests used in cardiology should be considered and compared with the AE rate of this 
contrast agent. Especially exercise testing and dobutamine stress echocardiography are widely 
used and the threshold for performing such a study is relatively low. The safety of these tests has 
been studied extensively for the occurrence of AEs [8,9] In a survey including 518,448 exercise 
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tests of Stuart et al., a death rate of 0.5 per 10,000 cases (0.005%) was found (table 2). Although 
studies with such large numbers are not available for dobutamine stress echocardiography, no 
deaths have been reported in several cohorts with a total of more than 10,000 studies.[10-14] In 
these studies, other serious side effects like myocardial infarction or major arrhythmias, are 
estimated to occur in ~1 of 230 studies (0.43%). These exercise tests are regarded as relatively 
safe and are performed on a much larger scale than contrast echocardiography, whereas the AE 
rate seems to be much higher. However, a comparison of the AE rate of on the one side stress 
testing and on the other side administration of Sonovue cannot be made without recognizing the 
different profits of different tests. Whereas stress testing is used for detection of ischemic heart 
disease, UCAs are used as a adjuvans in echocardiography. Only in a minority of cases it is used 
in stress echocardiography, and as no license for myocardial contrast echocardiography has been 
obtained, a simple comparison of AE event rates is not valid. The risk profile of a contrast-
enhanced stress echocardiogram, however, seems to be similar as a conventional stress 
echocardiogram, and serious AEs have not been reported yet.[1] This raises the question whether 
the diagnostic value of exercise tests is more important than the diagnostic value of a contrast-
enhanced echocardiogram using Sonovue. Another diagnostic procedure which plays an 
important role in cardiology and should be considered is cardiac catheterization. Although this 
examination is much more invasive than contrast echocardiography, the risk profile of the patient 
population undergoing these examinations is similar with respect to underlying disease. In a 
multicenter study, Noto et al. estimated the mortality associated with cardiac catheterization to be 
0.11 %, which is high compared to the use of any contrast agent or diagnostic test [15]. Also with 
respect to catheterization, it must be emphasized that a comparison between the AE rate cannot be 
made directly, but only when considering the difference in diagnostic value of each procedure. 
Another important aspect is the circumstance under which a contrast echocardiogram is 
performed. Intravenous injection of medical products always must be considered as 
administration of medication. This means that attention should be paid to the possible occurrence 
of known side effects, and the possibility of severe side effects like an anaphylactic reaction must 
be kept in mind. As a contrast echocardiogram is relatively simple to perform, negligence of the 
risk of a contrast injection frequently occurs. Therefore, such a procedure must be carried out 
under supervision of an experienced doctor and in an environment where facilities for emergency 
care are immediately available. 
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After a thorough investigation on the relationship between the nineteen non-fatal- and three fatal 
cases and the use of Sonovue®, the EMEA has decided to reinstate the echocardiography 
indication, albeit with addition of several contra-indications. Assuming that the three fatal adverse 
reactions are indeed related to the administration of Sonovue®, the fatal AE rate of this UCA of 
0.002% is in between the safe Gd-GTPA, and the fatal AE rate of 0.11% found by Noto et al. of a 
diagnostic cardiac catheterization. Including serious AEs in this comparison, the AE rate of 
Sonovue® increases to a level which is in between that of Gd-GTPA and non-ionic contrast 
media. When compared with exercise testing and dobutamine stress echocardiography, 
administration of UCAs seems to be relatively safe. This comparison stimulates the discussion 
about which risk is clinically acceptable for the diagnostic value of a specific test. Within this 
discussion, a central issue is what the clinical importance is of other contrast examinations and 
diagnostic (exercise) tests, and whether the diagnostic value of these procedures is higher than 
that of contrast echocardiography. This ethical topic should be discussed not only estimating the 
risks and the diagnostic values of UCAs, but also the clinical benefit and risks of other contrast 
agents and diagnostic tests used in cardiology. 
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Chapter 4:  Safety of the use of ultrasound contrast agents 
 
4.2 Safety and feasibility of Real-time adenosine myocardial contrast echocardiography 
with emphasis on induction of arrhythmias: a study in healthy volunteers and patients with 
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Introduction  
Some studies have reported an increased incidence of premature ventricular complexes (PVCs) 
during triggered myocardial contrast echocardiography (MCE) using high-intensity ultrasound 
destruction. Whether PVCs are also induced by real-time MCE using low emission power, is 
unknown. The aim of the study was to assess the occurrence of arrhythmias during real-time 
adenosine MCE in healthy volunteers and patients with stable coronary artery disease (CAD). 
Methods  
In a single-center study, fifty healthy volunteers and twenty-six patients with stable CAD 
underwent real-time MCE using Sonovue® and power pulse inversion (ATL 5000) at rest and 
during adenosine stress. The occurrence of premature atrial complexes (PAC) and PVCs was 
analyzed before and during MCE using ECG-tracings from video-tapes. 
Results  
In healthy subjects, the occurrence of PVCs at baseline (0.04±0.23 PVCs/min) was similar at rest 
(0.04±0.23 PVCs/min, P=NS), and adenosine stress (0.03±0.14, P=NS). In CAD patients, the 
occurrence of PVCs at baseline was 0.30±0.76 PVC/min, compared to 0.29±0.74 at rest (P=NS), 
and 0.34±0.74 during adenosine stress (P=NS). The number of subjects demonstrating PVCs did 
not increase during MCE. The occurrence of PACs during MCE was not increased compared to 
baseline in any of the study groups. 
Conclusion  
Our data demonstrate that real-time adenosine MCE using low-emission power does not increase 
the occurrence of premature complexes in healthy volunteers or stable CAD patients, and is a safe 
and feasible imaging technique for evaluation of coronary artery disease. 
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Introduction 
Myocardial contrast echocardiography (MCE) is becoming an increasingly important imaging 
technique for assessment of myocardial perfusion.(1-5) MCE makes use of ultrasound contrast 
agents, that are small, gas-filled microbubbles, sufficiently stable in the blood to pass the 
pulmonary capillary bed, thus reaching the myocardium. Specific acoustic properties of 
microbubbles, i.e. stable oscillation under influence of low-intensity ultrasound and high-energy 
ultrasound-induced destruction, allow visualization and quantification of the myocardial capillary 
blood flow. These processes are known as stable and inertial cavitation respectively, which is the 
creation, vibration, and collapse of gas-filled bubbles in a liquid environment. Ultrasound is 
known to induce cavitation, which leads to bioeffects on insonated tissue, such as heating, and 
induction of chemical processes.(6-10) Microbubbles exaggerate ultrasound-induced bioeffects 
by enhancement of the cavitation-process. Additionally, forceful collapse of insonated 
microbubbles causes local shear stress on cell the surface.(11-13) As assessed in vitro and in 
animal models, this enhanced cavitation process may harm microvascular integrity, and increase 
myocardial excitability, leading to occurrence of premature ventricular complexes (PVCs).(14-
21)  
Recently, several studies showed the induction of PVCs by MCE in humans.(22-24) These 
studies concerned triggered MCE, which uses intermittent ultrasound pulses with high acoustic 
energy, triggered to end-systole or end-diastole. Whereas an increase in PVCs was reported when 
using a relatively high mechanical index of 1.6, triggered at end-systole, this effect was not 
confirmed with lower acoustic energy, nor with end-diastolic triggering. Real-time MCE differs 
from triggered MCE as it uses continuous imaging with low emission power, with an intermittent 
high-energy acoustic flash to destroy ultrasound contrast. Microbubbles are continuously 
oscillating during real-time MCE, which possibly causes continuous cavitation effects on the 
surrounding tissue. Until so far, no studies assessed whether real-time MCE increases the 
occurrence of premature complexes (PVCs of premature atrial complexes (PACs)). 
Therefore, the aim of the present study was to determine whether real-time adenosine MCE 
induces PCs in healthy volunteers and patients with stable coronary artery disease (CAD). 
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Methods 
Study population 
Fifty-six healthy volunteers (mean age 30 years old, 54% males) with a normal physical 
examination, electrocardiogram, laboratory investigation and transthoracic echocardiogram were 
studied retrospectively. Exclusion criteria were history of cardiac disease, smoking, diabetes, 
hypercholesterolemia, a positive family history of cardiac disease, hypertension, chronic 
obstructive pulmonary disease, pulmonary hypertension, pregnancy, protein allergy, known 
allergy to Sonovue®, conduction abnormalities, and structural heart disease.  
Additionally, thirty patients with known or suspected stable CAD were also included in the study. 
Eighteen patients had at least one angiographically documented significant coronary artery 
stenosis of at least 70%, and had a positive exercise test for ischemia. Exclusion criteria were 
chronic obstructive pulmonary disease, pregnancy, known allergy to Sonovue®, and pulmonary 
hypertension.  
All participants underwent real-time MCE at rest and during adenosine stress (patients were 
refrained from xanthine and caffeine derivatives at least 12 hours before the study). All 
participants gave written informed consent. The study protocol was approved by the VU 
University Medical Center Ethics Committee. 
Ultrasound contrast agent 
A commercially available, second generation contrast agent, Sonovue® (Bracco, Milan, Italy) 
was used. Sonovue® consists of microbubbles filled with sulphur hexafluoride gas, with a 
phospolipid-monolayer shell, with a mean diameter of 2.5 µm.    
Protocol 
The time lines of the imaging scheme are outlined in figure 1. All subjects received a continuous 
infusion of ultrasound contrast. Before contrast infusion, ECG-monitoring was performed for at 
least three minutes. After reaching a steady state in the blood, at least 1.5 minutes after start of 
contrast infusion, imaging was started. Adenosine infusion was started after acquisition of the rest 
images. Two minutes after start of adenosine, stress images were acquired. Before contrast 
infusion, during rest and stress imaging, heart rate and blood pressure were measured. 
Myocardial contrast echocardiography 
The contrast agent was intravenously injected with a continuous infusion rate of 0.5-1.5 ml per 
minute using a mechanical pump (Vueject, Bracco, Geneva, Switzerland). The infusion rate was 
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adjusted to obtain maximal opacification of the myocardium without basal attenuation due to 
intracavitary contrast, and was kept constant throughout the experiment. To reach a steady state of 
microbubbles in the blood, image acquisition was started 1.5-4 minutes after the start of contrast 
infusion. Imaging was performed with a Philips ATL 5000 with a broadband 2 to 4 MHz 
transducer. Real-time MCE was performed with color-coded power pulse inversion imaging, at 
rest and during vasodilator stress. Baseline settings, such as mechanical index (0.11-0.18), depth 
(<13.5 cm), and color gain, were determined prior to the start of the procedure and were kept 
constant thereafter. Imaging was performed to obtain apical 4-, 2-, and 3-chamber views. A burst 
of high acoustic energy (i.e. a flash, mechanical index 1.0, 12 frames) was used for destruction of 
the microbubbles, followed by imaging of contrast replenishment with low acoustic pressure 
ultrasound with a frame rate of 18-20 Hz during ten seconds. Stress images were obtained two 
minutes after the start of infusion of adenosine (0.140 mg kg-1min-1).  
ECG monitoring 
The ECG was monitored in a single-lead configuration and continuously recorded on videotape 
throughout the protocol. The number of PVCs and PACs were derived by review of the videotape 
ECG trace. Data were obtained during three time-periods: pre-infusion (baseline), during rest-
imaging, during stress-imaging. The occurrence of PCs during each period was calculated as the 
number of PCs divided by the duration of that corresponding period (PACs/minute, PVCs/minute, 
or PCs/minute), and also the number of subjects demonstrating PCs was calculated as a 
percentage of the total number of subjects. 
PVCs were defined as an early QRS complex of wide morphology without a preceding P-wave. A 
flash-related PVC was defined as a PVC being the first beat after the start of the flash. PACs were 
defined as an early QRS complex of narrow morphology with a preceding P-wave. Flash-related 
PACs were defined as a PAC being the first beat after the start of the flash. PCs were defined as 
occurrence of PVCs or PACs. 
Statistical analysis 
SPSS 9.0 (SPSS Inc, Chicago, US) was used for analysis of data. Data existing from continuous 
variables are expressed as mean ± standard deviation. Student’s T-test was used for comparison 
of continuous variables. A non-parametric test (Wilcoxon signed rank test) was used for 
comparison the mean number of PCs per minute. McNemar test was used for analysis of  
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Figure 1: time-lines of real-time adenosine MCE protocol. 
 
binominal variables. Interobserver variability was expressed as agreement (Kappa). Differences 
were considered significant at p<0.05.  
Results 
Real-time MCE was performed successfully in all healthy subjects without complications. ECG-
tracings of stress-studies in six healthy subjects were of insufficient quality due to respiratory 
artifacts. These subjects were excluded from further analysis. In twenty-nine stable CAD patients, 
MCE was successfully completed. In one patient, occurrence of a second degree AV-block 
prompted to interrupt adenosine infusion, hindering completion of the stress study. This patient 
was excluded from further analysis. Three other studies were excluded because of insufficient 
quality of ECG-tracings. Clinical characteristics and baseline laboratory values of healthy 
subjects are shown in table 1. 
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The mean duration of all studies was 16.5±3 minutes. The mean duration of each separate time 
period was 2.7±1.2 minutes, 6.6±1.9 minutes, 2.0±0.3 minutes, and 5.3±1.6 minutes for 
establishment of a steady contrast state, rest imaging, establishment of adenosine stress, and stress 
imaging respectively. None of the patients experienced major adverse events. Only 2.6% minor 
adverse events (table 2).  
 
 
 
 
 
 
 
 
 
Data on the time periods of assessment for both healthy subjects and CAD patients are depicted in 
table 3. The mean infusion rate of Sonovue was 0.85±0.3 ml min-1(n=49). The mean mechanical 
index that was used for imaging was 0.14±0.02. 
 
 
Table 1. Clinical characteristics 
Controls CAD patients
n=50 n=26
Age, y 30±9 64±11
Length, m 1.78±0.09 1.74±0.08
Male (%) 54 67
Weight, kg 70±11 83±15
BMI, kg/m² 22.0±2.2 27.3±4.2
SBP, mmHg 122±11 133±16
DBP, mmHg 71±9 77±11
HR, min־¹ 63±11 66±11
Glucose, mmol/l 4.7±0.6 5.5±1.2
Cholesterol, mmol/l 4.4±0.8 4.6±1.4
Creatinine (ug/l) 91±10 91±20
Values are mean and standard deviation. CAD,
coronary artery disease; BMI, body mass index; 
SBP, systolic blood pressure; DBP, diastolic blood 
pressure;HR, heart rate.
Table 2. Adverse events
n=76
Major adverse events 0.0%
Minor adverse events 2.6%
Headache 0.0%
Warmth 0.0%
Local sensation at injection site 1.3%
Nausea 0.0%
Taste 1.3%
Percentage of all subjects w ith most com-
mon adverse events to contrast agent.
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Healthy subjects 
Compared to baseline, heart rate in healthy subjects was significantly lower at rest (P<0.01), and 
significantly higher at stress (P<0.01). The time period before contrast infusion was longer than at 
rest (P<0.01) and stress (P<0.01). A total number of 4, 5, and 6 PACs was counted at baseline, 
rest and stress respectively. The sum of PVCs was 15, 14, and 7 at baseline, rest, and stress 
respectively. The mean frequency of PACs per minute at baseline was 0.01±0.07 PAC/min and 
remained equal at rest (0.02±0.07 PACs/min, P=NS versus baseline), and at stress (0.03±0.13 
PACs/min, P=0.11 versus baseline). The number of PVCs per minute at baseline (0.04±0.23 
PVCs/min) did not differ from the number of PVCs/min at rest (0.04±0.23, P=NS), and stress 
(0.03±0.14, P=NS).  
Although the occurrence of PVCs remained equal from baseline to rest and stress, the percentage 
of subjects demonstrating any PC tended to increase (figure 3a). Whereas 6% of subjects showed 
any kind of PC at baseline, 16% showed PCs during the total period of contrast infusion (P=NS).   
Table 3. Data on assessment of PCs in study population
Baseline Rest Stress
Healthy subjects (n=50)
  HR, bmp 65±11 63±10 88±13*
  Duration of  period (minute) 8±4 7±2* 5±2*
  Total duration of  investigated period (minute) 406 330 270
  Sum of PACs all subjects 4 5 6
  Sum of PVCs all subjects 15 14 7
Sum of triggered PACs all subjects NA 0 0
Sum of triggered PVCs all subjects NA 1 3
CAD patients (n=26)
  HR, bmp 63±8 61±8 75±11*
  Duration of  period (minute) 10±4 7±2* 5±2*
  Total duration of  investigated period (minute) 254 171 135
  Sum of PACs all subjects 5 0 24
  Sum of PVCs all subjects 52 25 28
Sum of triggered PACs all subjects NA 0 0
Sum of triggered PVCs all subjects NA 1 0
Values are mean and standard deviation. PC, premature contraction; PAC, premature atrial 
contraction; PVC, premature ventricular contraction; CAD, coronary arterydisease; HR, heart rate;
*P<0.01 versus baseline.
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Figure 2: example of flash-induced PVC. A: frame before flash; B: first frame during flash 
and immediately occurring PVC. 
 
At rest, a total of 380 flashes were applied in the healthy subjects (7.6±1.3 flashes per subject). At 
stress, 324 flashes were applied, which corresponds to 6.8 flashes per subject. One flash-related 
PVC occurred in one case at rest. In this case, the flash-related PVC was demonstrated in a 
subject that also had frequent premature contractions at baseline. 
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Figure 3 a-c: frequency of subjects demonstrating premature contractions. A: healthy subject; B: CAD 
patients; C: all subjects pooled 
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At stress, three subjects demonstrated flash-related PVCs (figure 2). Two of three subjects did not 
show PVCs at baseline or at rest, and no statistically significant difference could be established. 
The number of subjects showing PCs did not increase significantly from baseline to rest or stress 
(figure 3a). 
Patients with CAD 
Mean age was 64±11 years, 67% was male. Significant stenosis (>70%) had been demonstrated in 
18 patients, in the left anterior descending artery in 75%, the right coronary artery in 33%, and the 
circumflexal artery in 25%. The occurrence of PACs/minute was 0.03±0.06 at baseline, 0% at rest 
(P=NS compared to baseline), and 0.15±0.51 at stress (P=NS). The occurrence of PVCs/minute at 
baseline was 0.15±0.53, compared to 0.13±0.51 at rest (P=NS), and 0.18±0.55 at stress (P=NS). 
PCs of any kind did not occur more often during the total period of contrast infusion than before 
(0.24±0.59 PCs/min compared to 0.18±0.54 PCs/min (P=NS)). Although more patients tended to 
show PACs at stress compared to baseline (3.8% versus 11.5%), no statistical significance was 
found (figure 3b). The occurrence of PVCs was not higher during contrast infusion compared to 
baseline. At rest, 177 flashes were applied, which is 6.8±1.1 flashes per subject. At stress, 160 
flashes were used, meaning 6.2 ±1.4 flashes per subject. At rest, 1 trigger-related PVC occurred, 
whereas no stress related PVCs were demonstrated. In 8 patients, flashes were applied as a 
control before contrast infusion. A total of 48 flashes did not provoke PCs.  
All subjects 
The pooled number of PCs per minute for both healthy volunteers and CAD patients did not differ 
between any of the time periods. The mean number of PACs was 0.02±0.11 at baseline, compared 
to 0.01±0.05 at rest (P=NS), and 0.07±0.32 at stress (P=NS). The mean number of PVCs at rest 
was 0.07±0.04, and 0.08±0.03 at stress, compared to 0.08±0.04 at baseline (P=NS). The 
occurrence of PCs in the total population is depicted in figure 3c. The infusion rate of Sonovue 
was not higher in subjects in which PCs occurred at rest or stress compared to subjects that did 
not demonstrate PCs (0.85±0.3 versus 0.83±0.3, P=NS). No doublets, non-sustained or sustained 
ventricular tachycardias were seen during MCE in any of the patients. 
Interobserver variability 
Twenty randomly selected subjects were assessed for the occurrence of PVCs in each time period 
by an independent reviewer. Agreement was 98% (Kappa 0.86).    
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Discussion 
The present study assessed the occurrence of cardiac arrhythmias during real-time adenosine 
MCE in healthy volunteers and stable CAD patients. Our data indicate that 1: real-time MCE with 
continuous infusion of contrast agent using low emission power and bursts of high acoustic 
energy for contrast destruction is safe with respect to occurrence of arrhythmias, and a feasible 
imaging technique for evaluation of coronary artery disease, and 2: although no significantly 
higher amount of PCs was demonstrated, flash-related PCs seem to occur incidentally. Our data 
are in agreement with the different findings of other studies assessing the occurrence of 
arrhythmias during triggered MCE. 
The present study demonstrates that PCs do not significantly occur more frequently, or in a higher 
number of subjects during MCE. The most important finding that supports this conclusion is the 
comparison between the baseline period and rest MCE, as possible confounding by vasodilator 
stress is absent. Apart from a non-significant trend to an increased number of healthy subjects 
demonstrating PACs, no significant differences were established. Despite the absence of a 
significant effect of MCE on induction of arrhythmias, isolated flash-related PVCs and PACs 
incidentally occurred in both healthy volunteers and CAD patients. In some subjects in which 
flash-related PVCs occurred, PVCs were also present at baseline, suggesting the presence of a 
pre-existing focus generating ectopic beats. In two cases, however, flash-related PVCs occurred 
despite the absence of PVCs during the baseline period. During MCE, no specific triggering 
moment was used, as the destruction flash could only be applied manually, which hinders 
identification of a time-dependent interrelationship between flashes and flash-related PCs. Also, 
the concentration of microbubble infusion did not differ between patients with and without 
extrasystole. Therefore, it remains unclear, why flash-related PCs do occur in individual subjects.   
Our study used real-time MCE, in which continuous imaging with low emission power (MI 0.10-
0.15) is interrupted by a flash of high acoustic intensity (MI 1.0), destroying ultrasound contrast 
in the myocardium. A marked difference with triggered imaging is that, besides a superposed 
recurrent flash, continuous imaging with low emission power causes ongoing stable cavitation. In 
theory, the process of continuous cavitation during real-time MCE could have additional effects 
on myocardial irritability. In our study, this has not led to increased atrial or ventricular ectopy. 
The question rises, whether real-time MCE may induce arrhythmias in individual subjects that are 
more susceptible to cavitation effects. As the prevalence of flash-related arrhythmias is low, and 
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the number of investigated subjects is limited, it remains uncertain whether the occurrence of 
flash-related arrhythmias would gain significance when investigating more subjects. 
The results of the present study are in line with that of previous studies that investigated the 
prevalence of arrhythmias in humans undergoing triggered MCE using high MI (1.0-1.5).(22-24) 
End-systolic triggered second harmonic imaging with continuous infusion of AIP101 and imaging 
at high MI (1.5) significantly increased the incidence of PVCs, however, end-diastolic triggering, 
or imaging with lower MI (1.1) did not significantly induce arrhythmias. The contrast agent used 
in this study, AIP101, consisting of air-filled, heat stabilized albumin microcapsules with a 
relatively thick shell, required higher MI’s to produce contrast effect, possibly provoking the 
occurrence of PVCs. This theory is supported by another study, that assessed the prevalence of 
PVCs during end-diastolic imaging with triggered harmonic power Doppler and lower ultrasound 
energy (MI<1.0) in 135 individuals.(23) No increased number of PVCs was found in this study. 
The findings of these studies may be explained by the differences in the moment of triggering, the 
used contrast agent, and the amount of ultrasound energy, being lower in the latter study. A third 
important study demonstrated that the number of PVCs increases with higher ultrasound energy, 
microbubble concentration, and with continuous wave imaging.(24) The results of these three 
studies suggest that PVCs are induced solely when ultrasound energy is high, the trigger is set at 
end-systole, and a high concentration of ultrasound contrast is used. 
An explanation for the occurrence of PCs during application of ultrasound with higher intensity 
may be found in the physiology of cardiac contraction. In vitro studies have demonstrated that in 
biological tissue, cavitation occurs under influence of ultrasound.(25;26) This process causes 
thermal, chemical and mechanical effects, such as heating, the induction of reactive oxygen 
species, and shear stress along cell membranes. The possible induction of arrhythmias by 
ultrasound is thought to be caused by these effects, the magnitude of which is dependent on the 
amount of ultrasound energy used.(6) In the presence of ultrasound contrast agents, cavitation is 
enhanced, which has an incremental effect on cavitation processes.  
According to the excitation-contraction coupling theory, for a contraction to occur, an increase in 
intracellular Ca2+ concentration is needed. Under normal physiological conditions, this influx is 
mainly caused by voltage-dependent L-type-Ca2+-channels, T-type-Ca2+-channels, and gradient 
dependent Ca2+ influx.(27) The results of previous studies indicate that acoustic cavitation leads 
to Ca2+ influx from outside the cell, for which the L-type Ca2+-channel is probably not 
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responsible.(26) As the presence of T-type-Ca2+-channel in ventricular myocytes is negligible, it 
is possible that the Ca2+-influx is caused by a passive, gradient-mediated influx.(27) Tachibana et 
al demonstrated that ultrasound with high-intensity causes micropores in the cell 
membrane.(25;26;28) As the Ca2+ gradient over the cell membrane is extremely high, a gradient-
mediated influx through these micropores, leading to Ca2+-induced Ca2+-release from the 
sarcoplasmatic reticulum, may lead to consequent cell contraction. It is probable that, in vivo, the 
bio-effects of cavitation that occur on cellular level at relatively low ultrasound intensity are 
tolerated well. Nevertheless, administration of ultrasound contrast agents with application of 
ultrasound with a an intensity above a certain level, may result in a higher amount of cavitation 
effects, leading to more pronounced bioeffects, more mechanical stress and formation of 
micropores, and increased ventricular ectopy. 
Limitations 
A limitation of our study is the duration of the period in which PCs were monitored. As the 
duration of the baseline period is significantly longer than that of rest and stress analysis, the 
frequency of subjects experiencing at least one PC at baseline is slightly overestimated compared 
to rest and stress. By expressing the incidence of PCs as number per minute, this confounding 
factor was eliminated. Furthermore, a limited number of CAD patients was assessed. As the 
prevalence of PCs in this patient population is higher than in healthy subjects, an eventual 
increase during real-time MCE may be more difficult to prove.    
Conclusion 
Our study demonstrates that real-time adenosine MCE using low emission power and relatively 
low-intensity flashes is safe with respect to induction of arrhythmias and well tolerated, in both 
healthy subjects, and CAD patients. However, incidentally, flash-related PCs seem to occur. The 
present study confirms the current view that real-time MCE is a safe and feasible imaging 
technique for evaluation of coronary artery disease. 
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Chapter 5:  Therapeutic applications of ultrasound contrast agents 
 
5.1 Transient permeabilization of cell membranes by ultrasound-exposed microbubbles is 
related to formation of hydrogen peroxide. 
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Abstract 
In the present study, we addressed the interactions between ultrasound, microbubbles and living 
cells as well as consequent arising bioeffects. We specifically investigated whether hydrogen 
peroxide (H2O2) is involved in transient permeabilization of cell membranes in vitro after 
ultrasound exposure at low diagnostic power, in the presence of stable oscillating microbubbles, 
by measuring the generation of H2O2 and Ca2+ influx. 
Ultrasound, in the absence or presence of SonoVueTM microbubbles, was applied to H9c2 cells at 
1.8 MHz with a mechanical index (MI) of 0.1 or MI 0.5 during ten seconds. This was repeated 
every minute for five times. The production of H2O2 was measured intracellular with CM-
H2DCFDA. Cell membrane permeability was assessed by measuring real-time changes in 
intracellular Ca2+ with Fluo-4 using live-cell fluorescence microscopy.  
Ultrasound, in the presence of microbubbles, caused a significant increase in intracellular H2O2 at 
MI 0.1 of 50% and at MI 0.5 of 110% compared to control (p<0.001). Furthermore, we found 
increases in intracellular Ca2+ at both MI 0.1 and 0.5 in the presence of microbubbles, which was 
not detected in the absence of extracellular Ca2+. In addition, in the presence of catalase Ca2+ 
influx immediately after ultrasound exposure was completely blocked at MI 0.1 (p<0.01) and 
reduced by 50% at MI 0.5 (p<0.001). Finally, cell viability was not significantly affected, not 
even 24 hours later. These results implicate a role for H2O2 in transient permeabilization of cell 
membranes induced by ultrasound-exposed microbubbles. 
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Introduction  
Several years ago contrast-enhanced echocardiography was introduced in the clinic. Ultrasound 
contrast agents consist of microbubbles that reflect ultrasound more effectively than the 
surrounding tissue, and are used for contrast enhancement of ultrasound images and improvement 
of diagnosis (7,8). However, interactions between ultrasound, microbubbles and living cells as 
well as consequent arising bioeffects have not yet been fully explored. Additionally, in light of 
the fact that it has recently been shown that ultrasound and microbubbles enhance transgene 
uptake (16,17,19,23), it is especially important to understand the different bioeffects caused by 
ultrasound and microbubbles. 
Different experimental studies have indicated several subtle bioeffects as a consequence of the 
interaction between ultrasound, microbubbles and cell membranes (3,15,20,22,25). These 
bioeffects can be divided into three groups: 1) Thermal effect: there is a local rise in temperature 
due to the absorption and dissipation of ultrasound energy (25); 2) Chemical effect: the generation 
of reactive oxygen species (ROS) (2,3,15); and 3) Mechanical effect: due to the oscillations of the 
microbubble, the surrounding fluid is set in motion, causing microstreaming along the cell 
membrane (22). These effects together may result in permeability changes of the cell membrane, 
or even in the formation of physical pores in the cell membrane (20) and in an increased uptake of 
transgenes (2). Deng et al. showed a Ca2+ influx to demonstrate these permeability changes in the 
presence of microbubbles exposed to continuous wave ultrasound (6). Being an important second 
messenger, Ca2+ influx is not only an indicator for membrane permeability changes, but may have 
several consequences for intracellular Ca2+ homeostasis and signal transduction. For instance, it 
has been shown that patients can have extrasystoles during contrast-echocardiography (5,21), 
which might be explained by triggered Ca2+ influxes.  
However, it remains to be elucidated whether extracellular ROS production, in particular H2O2, 
by ultrasound exposure in the presence of microbubbles provokes Ca2+ influx. In the present 
study, we therefore focused on the possible role of H2O2 in transient permeabilization of cell 
membranes. We are specifically interested in these effects at low diagnostic ultrasound power in 
the presence of stable oscillating microbubbles. We investigated i) whether more H2O2 is 
generated in the presence of microbubbles than when ultrasound alone is applied; ii) whether 
H2O2 affects cell membrane permeability for Ca2+ by measuring Ca2+ influx; and iii) whether cell 
viability is affected. 
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Materials and Methods 
Ultrasound exposure  
Ultrasound was applied using two different settings: a diagnostic apparatus for off-line 
measurements and a single-element transducer for on-line measurements. In the first setting, 
ultrasound was applied in the second harmonic mode with the Sonos 5500 (Philips, Eindhoven, 
The Netherlands) equipped with a S4 transducer emitting at 1.8 MHz and receiving at 3.6 MHz, 
with a mechanical index (MI) of 0.1 or 0.5 during 10 seconds. This was repeated every minute for 
five times. The tip of the transducer was positioned in a 37˚C water bath at 3 cm distance from 
cell surface. In the second ultrasound setting, a 1 MHz unfocused single-element transducer 
(Panametrics, Waltham, USA) was mounted in a 37ºC water bath on the microscope (figure 1a). 
The ultrasonic wave was generated by an arbitrary waveform generator (Agilent 33220A, Agilent 
Technology, California, USA) and amplified (150A100B, EMV Benelux, Nieuwkoop, The 
Netherlands). Peak-to-peak acoustic pressure generated at the region of interest (ROI) was MI 0.1 
or MI 0.5, with a duty cycle of 0.2% and pulse repetition frequency of 20 Hz.  
Ultrasound contrast agent 
Sonovue (Bracco Research SA) is a second-generation contrast agent. It contains sulfur 
hexafluoride gas and has a phospholipid monolayer shell. The suspension contains 2*108 
microbubbles/mL with a mean diameter of 2.5 µm (18). 
Cell culture 
H9c2 rat cardiomyoblast cells (LGC Prochem, Teddington, UK) were grown in cell culture flasks 
(Micronic, Lelystad, The Netherlands) in 12 mL Dulbecco’s Modified Eagles Medium (Gibco, 
Breda, The Netherlands) supplemented with 10% foetal bovine serum (Gibco) and 1% 
penicillin/streptomycin (Gibco) in a humidified incubator at 37˚C with 5% CO2. Two days prior 
to the day of the experiment, the cells were plated in an OptiCell growth chamber (50 cm2 
growth surface) (Sanyo Gallenkamp, Etten-Leur, The Netherlands), reaching about 70% 
confluence on the day of the experiment. 
Generation of H2O2 
The generation of H2O2 was measured intracellular with 5-(and-6)-chloromethyl-2',7'-
dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA) (Molecular Probes, Leiden, 
The Netherlands), which is a carboxy derivative of DCF-DA that exhibits much better retention in 
living cells than DCF-DA. CM-H2DCFDA, being non-polar, diffuses passively into cells, where 
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its acetate groups are cleaved by intracellular esterases, and is trapped within the cell. In this 
status it provides a substrate for oxidation by H2O2, resulting in the production of a highly 
fluorescent intracellular product emitting fluorescence with intensity proportional to the level of 
intracellular H2O2 (1). H9c2 cells were grown in an OptiCell growth chamber and loaded with 
CM-H2DCFDA (5 µM) in ADS buffer (in mM: NaCl 116, KCl 5.3, MgSO4.7H2O 1.2, 
NaH2PO4.H2O 1.13, HEPES 20, CaCl 1, pH 7.4), and incubated 15 minutes at 37˚C (Fig. 1b). 
After this, 0.1 mL Sonovue microbubbles or 0.1 mL ADS buffer (control) was added followed 
by ultrasound exposure with the Sonos 5500. After ultrasound exposure, cells were incubated 60 
minutes at 37˚C, allowing the oxidized CM-H2DCFDA to accumulate in the cells (figure 1b). 
Fluorescence microscopy was performed to qualitatively and quantitatively assess the generation 
of H2O2, using a widefield digital imaging fluorescence microscope (MarianasTM, I.I.I., Denver 
CO, USA) with a 10x objective. All images were digitally processed using custom made software 
(SlideBook version 4.0.8.3, I.I.I., Denver CO, USA) to quantify the intensity of fluorescence. 
Fluorescence was corrected for background and expressed in arbitrary units; mean intensity of 
fluorescence (MIF). Necrotic cells were not included in the evaluation. Changes in CM-
H2DCFDA were also measured in the presence of the H2O2 scavenger catalase (1250 U/mL) 
(Sigma). Finally, to quantify the increase in MIF induced by ultrasound and microbubbles, cells 
were loaded with CM-H2DCFDA as described above. After 15 minutes different concentrations 
of exogenous H2O2 (0, 1, 2.5, 5, 7.5 and 10 µM) were added to the cells.  
Ca2+ permeability  
Changes in intracellular Ca2+ were measured with the fluorescent probe Fluo-4 (C51H50F2N2O23), 
a cell-permeant acetoxymethyl (AM) ester sensitive for free cytosolic Ca2+ (Molecular Probes). 
Cells were grown in the OptiCell growth chamber and loaded with Fluo-4 (3 µM) in ADS 
buffer and incubated 30 minutes at 37˚C, the cells were washed in ADS, incubated another 30 
minutes at 37˚C to allow the fluorescence to stabilize (figure 1c). 0.1 mL Sonovue 
microbubbles was added, followed by ultrasound exposure. Intensity of fluorescence was 
measured in real-time, i.e. during ultrasound exposure, using live-cell fluorescence microscopy. 
Changes in intracellular Ca2+ were also measured in the presence of the H2O2 scavenger catalase 
(1250 U/mL) and L-type Ca2+ channel blocker verapamil (10 µM) (Sigma). To quantify the 
increase in MIF induced by ultrasound and microbubbles, cells were loaded with Fluo-4 as 
described above. After incubation with Fluo-4 different concentrations of exogenous H2O2 (0, 1, 
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2.5, 5, 7.5 and 10 µM) were added to the cells.Cell viability Cell viability was assessed by flow 
cytometry (FACS Calibur). After ultrasound exposure cells were harvested from the OptiCell 
membrane using trypsin (0.25%, Gibco). The cell suspension (200 µL) was placed in 5 mL 
polystyrene round-bottom tubes. In order to assess viability, 10 µL annexin-V (Molecular Probes) 
was added. Annexin-V has a high affinity for phosphatidyliserine (PS), which is translocated 
from the internal to the external surface of early apoptotic cells. Necrotic cells also stain for 
annexin-V due to loss of membrane integrity, they are discriminated from apoptotic cells by 
propidium iodide (PI) (Molecular Probes), which is excluded from viable and apoptotic cells. 
Terminal deoxynucleotide transferase dUTP nick end labeling (TUNEL) assay (Promega, Leiden, 
The Netherlands) was performed to detect DNA fragmentation by endonucleases in late apoptosis 
using luorescence microscopy. Furthermore, cells were observed by differential  
interferencecontrast (DIC) microscopy to detect possible morphological changes after ultrasound 
and microbubble exposure.  
Statistical analysis 
Data were expressed as mean ± standard error of the mean (SEM). Differences between different 
groups were evaluated by one-way ANOVA followed by Bonferroni’s post-test if values passed 
normality test. If values did not pass normality test (p<0.05), the one-way ANOVA was replaced 
by a non-parametric Kruskal-Wallis test followed by Dunn’s post-test. Results were considered 
significant when p<0.05. 
Results 
Generation of H2O2 
Ultrasound at low diagnostic power caused a significant increase in intracellular H2O2 in the 
presence of stable oscillating microbubbles, i.e., 50% increase at MI 0.1 and 110% increase at MI 
0.5, respectively (p<0.001 compared to control cells) (see figure 2). Ultrasound applied in the 
absence of microbubbles at both MI 0.1 and 0.5, however did not increase H2O2 production 
compared to control cells. Representative images of cells displaying the oxidized fluorescent 
product of CM-H2DCFDA are shown in figure 3. To quantify the amount of H2O2 generated by 
ultrasound exposure and microbubbles, different concentrations of exogenous H2O2 were added to 
the cells. The increase in intensity of fluorescence induced by ultrasound and microbubbles 
corresponded to adding ~2.5 µM H2O2 for MI 0.1 and ~7.5 µM H2O2 for MI 0.5, respectively (see 
figure 2c).  
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Figure 1. Experimental design. Panel A: Schematic drawing of the ultrasound (US) setting on the 
microscope used for online measurements. Panel B: Schematic overview of experiments with 
CM-H2DCFDA. Panel C: Schematic overview of experiments with Fluo-4.  
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Figure 2, A. Generation of H2O2 measured 60 minutes after ultrasound (US) exposure is shown as mean 
intensity of fluorescence (MIF) expressed as percentage of control cells. Panel A: Cells exposed to 
ultrasound at mechanical index (MI) 0.1, demonstrating a 50% increase in H2O2 in the presence of 
microbubbles, ξp<0.001 compared with control cells. Catalase completely blocked the increase in cells 
exposed to ultrasound and microbubbles at MI 0.1 (p<0.001). (Control: 398 cells; ultrasound: 283 cells; 
ultrasound + microbubbles: 378 cells; ultrasound + microbubbles + catalase: 884 cells). 
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Figure 2, B. Panel B: Cells exposed to ultrasound at MI 0.5, demonstrating a 110% increase in the 
presence of microbubbles, ξp<0.001 compared with control cells. Catalase significantly reduced the H2O2 
by approximately 80% (p<0.001) in cells exposed to ultrasound and microbubbles at MI 0.5. (Control: 365 
cells; ultrasound: 268 cells; ultrasound + microbubbles: 217 cells; ultrasound + microbubbles + catalase: 
548 cells). 
 
 
 
 
Figure 2, C. Cells exposed to exogenous H2O2 (Control: 688 cells, 1 µM: 308 cells, 2.5 µM: 387 cells, 5 
µM: 725 cells, 7.5 µM: 317 cells, 10 µM: 305 cells.  Data shown as mean ± SEM. 
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Ca2+ permeability 
Ultrasound, in the presence of microbubbles, caused a transient increase in the permeability of the 
cell membrane for Ca2+ at both MI 0.1 and MI 0.5 (figure 4a+c). There was no detectable Ca2+ 
influx in the absence of microbubbles. Furthermore, it was shown that in the presence of 
microbubbles, more Ca2+ entered the cells at MI 0.5 compared to MI 0.1. This is in line with the 
levels of H2O2 production: no increase in H2O2 production in the absence of microbubbles, and in 
the presence of microbubbles, significantly more H2O2 was detected at MI 0.5 compared to MI 
0.1. Control cells not exposed to ultrasound or microbubbles showed a minor decrease in 
intracellular Ca2+ in time (figure 4a), probably due to bleaching of Fluo-4. In addition, cells 
exposed to ultrasound and microbubbles with only 1 µM Ca2+ in the buffer showed an even more 
pronounced decrease in intracellular Ca2+ compared to control cells (p<0.001, from t = 60s 
onwards), indicating that there is a net loss of intracellular Ca2+ from the cell. However, under this 
condition the increase in intracellular H2O2 was still observed (data not shown). The increase in 
intracellular Ca2+ corresponded with the addition of ~2.5 µM exogenous H2O2 for MI 0.1 and 
~7.5 µM for MI 0.5, respectively, as can be seen in figure 4e. This was also in line with the levels 
of H2O2 measured with CM-H2DCFDA. 
In the presence of catalase the Ca2+ influx following ultrasound exposure was completely blocked 
at MI 0.1 (p<0.01) and reduced by 50% at MI 0.5 (p<0.001) (figure 4b+d). In contrast, L-type 
Ca2+ channel blocker verapamil was not able to prevent Ca2+ influx (figure 4b). Representative 
images of cells loaded with Fluo-4 before and during ultrasound exposure in the presence of 
microbubbles are shown in figure 5.  
Cell viability 
Ultrasound exposure at both MI 0.1 and MI 0.5 in the absence or presence of microbubbles did 
not cause any alterations in overall cell morphology or excessive detachment of cells. In addition, 
24 hours later all cells were still viable. This was confirmed by flow cytometry: there was only a 
small, insignificant increase in the percentage annexin-V (+ 6.4%, p>0.05.) and annexin-V/PI (+ 
1.4%, p>0.05) positive cells exposed to ultrasound and microbubbles compared to controls (figure 
6). Likewise, apoptosis could not be detected with the TUNEL assay. 
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Figure 3. 
Representative images of H9c2 cells displaying the oxidized fluorescent product of CM-H2DCFDA. Panel 
A: Control cells. Panel B: Cells exposed to ultrasound at MI 0.1 in the presence of microbubbles. Panel C: 
Cells exposed to ultrasound at MI 0.5 in the presence of microbubbles. Bar represents 10 µm. 
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Figure 4.  
Changes in intracellular Ca2+ in time in H9c2 cells loaded with Fluo-4. Data shown as mean intensity of 
fluorescence (MIF) ± SEM, expressed as percentage of MIF on t = 0s. Dotted lines represent moments of 
ultrasound (US) on and off switch, respectively. 
 
 
Figure 4, A. Cells exposed to ultrasound at mechanical index (MI) 0.1, control cells received no US. Cells 
exposed to ultrasound alone did not display an increase in intracellular Ca2+. Cells exposed to ultrasound in 
the presence of microbubbles displayed a significant increase in intracellular Ca2+ directly after ultrasound 
exposure (#p<0.01 and *p<0.05). 
 
 
Figure 4, B. Cells exposed to MI 0.1 and microbubbles compared to cells exposed to MI 0.1 and 
microbubbles in the presence of catalase. Catalase completely blocked the increase in intracellular Ca2+ 
(*p<0.05 at t = 56s, #p<0.01 at t = 64s and ξp<0.001 from t = 72s, indicated by arrow). 
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Figure 4, C. Cells exposed to ultrasound at MI 0.5, control cells received no ultrasound. Cells exposed to 
ultrasound alone did not display increases in intracellular Ca2+, whereas cells exposed to ultrasound in the 
presence of microbubbles show a pronounced increase in intracellular Ca2+ (ξp<0.001 from t = 56s). Cells 
exposed to MI 0.5 and microbubbles in the presence of only 1 µM Ca2+ in the buffer did not show 
increases in intracellular Ca2+. 
 
 
 
 
Figure 4, D. Cells exposed to MI 0.5 and microbubbles compared to cells exposed to MI 0.5 and 
microbubbles in the presence of catalase. Catalase significantly reduced the increase in intracellular Ca2+ 
(ξp<0.001 from t = 56s). Note the different y-axis scales at MI 0.1 and MI 0.5. 
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Figure 4, E. Peak fluorescent intensities of cells exposed to exogenous H2O2 (Control: 147 cells, 1 µM: 
118 cells, 2.5 µM: 104 cells, 5 µM: 136 cells, 7.5 µM: 103 cells, 10 µM: 111 cells). 
 
 
Figure 5. H9c2 cells loaded with the fluorescent Ca2+ indicator Fluo-4, in the presence of microbubbles. 
Panel A: prior to the onset of ultrasound exposure. Panel B: during ultrasound exposure (MI 0.1): increases 
in intracellular Ca2+. Images are an overlay of fluorescence (dark field) with bright field. Bar represents 10 
µm. 
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Figure 6. Prodium Iodide (PI) and Annexin-V positivity in control cells and in cells exposed to MI 0.5 in 
the presence of microbubbles. It is shown that there is no significant increase in necrosis (PI positivity) or 
early-apoptosis (Annexin-V positivity) following exposure to ultrasound and microbubbles. 
 
Discussion 
In the present study, we demonstrated that ultrasound at low diagnostic power, causing stable 
oscillations of the microbubbles, results in a transient increase in membrane permeability for 
Ca2+, as reflected by a Ca2+ influx, which is partially caused by generation of H2O2. In the 
presence of microbubbles, we detected a significant increase in H2O2 production at both MI 0.1 
and MI 0.5 (50% and 110%, respectively; p<0.001 compared to controls) (figure 2). Basta et al. 
previously reported a 50% increase after ultrasound exposure at MI 1.3 after 30 minutes exposure 
time in the absence of microbubbles. Interestingly, we detected a similar increase already after 
five times 10 seconds of ultrasound exposure at MI 0.1 in the presence of microbubbles, 
indicating that the presence of stable oscillating microbubbles has significant effects on 
surrounding cells (3). Furthermore, our findings are supported by a recent study by Marmottant et 
al., who demonstrated that gentle (linear) microbubble oscillations induce pronounced effects on 
phospholipid bilayers (11). 
Role of H2O2 in Ca2+ permeability 
The presence of ultrasound-exposed microbubbles in close proximity to cells has an effect on the 
permeability of cells. This permeability change is a result of a number of as yet undefined 
physical, chemical and mechanical forces acting on microdomains of the cell membrane. Due to 
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the difficulty of investigating ultra-rapid alterations in cell membrane phospholipid bilayer 
organization, specific mechanisms of pore formation have not yet been definitely proven. 
Microbubble oscillation, cavitation, collapse and the resulting shear forces are all suggested to 
play a role in the increase in permeability of the cell (15,22).  We demonstrated increased 
permeability of the cell membrane by revealing Ca2+ influxes at both MI 0.1 and MI 0.5 in the 
presence of microbubbles, already with pulsed ultrasound with a duty cycle of 0.2% and pulse 
repetition frequency of 20 Hz. This is ultrasound with low energy compared to ultrasound used by 
other groups (6,13,20). This is an important finding as it underlines that ultrasound exposed 
microbubbles can indeed provoke alterations in cell membrane permeability, which may have 
several consequences for intracellular ion homeostasis. Especially relevant to this, it has been 
shown that patients can have extrasystoles during contrast-echocardiography (5,21), which might 
be explained by triggered Ca2+ influxes. Furthermore, our findings are in correspondence with a 
voltage-clamp study performed by Deng et al (6). In the presence of microbubbles, an inward 
Ca2+ current was demonstrated, already after one second of continuous wave ultrasound exposure. 
They suggested that the increased ion permeability resulted from pore formation in the cell 
membrane, rather than increased opening of endogenous voltage or ligand-gated ion channels. 
During ultrasound exposure, the membrane potential was clamped at a constant voltage and the 
solution bathing the cells contained no ligand known to activate endogenous ion channels. By 
comparing the amplitude of the current step increase (~0.1 µA) with the maximum current 
amplitude through a single K+ channel (~100 pA), and assuming that the current amplitude is 
only dependent on pore size, the ultrasound induced pore can be as large as 0.1 µm (6). This 
corresponds with our results from the experiments with verapamil, an L-type Ca2+-channel 
blocker, where we still measured a Ca2+ influx. In addition, it is also in agreement with the results 
from a study from Honda et al (9), who showed that the Ca2+ influx does not occur via the L-type 
Ca2+ channels. Furthermore, Tachibana et al. showed such pores by electron microscopy in 
leukemia cells after insonation with continuous wave ultrasound (20).  
In order to detect whether Ca2+ enters the cytoplasmic region via the cell membrane or by a 
release from intracellular Ca2+ stores, cells were exposed to ultrasound in buffer with only 1 µM 
Ca2+. In the absence of extracellular Ca2+ we measured a decrease in cytosolic Ca2+ after 
ultrasound exposure, which is also in agreement with Deng et al; they demonstrated that there was 
no resealing of the cell membrane in the absence of extracellular Ca2+ and Ca2+ could leak out of 
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the cells (6). Most importantly, in the presence of catalase – a H2O2 scavenger – the Ca2+ influx 
was completely blocked at MI 0.1 (p<0.01) and significantly reduced by approximately 50% at 
MI 0.5 (p<0.001), as can be seen in figure 4. It is now recognized that Ca2+ signalling and H2O2 
production are two closely related aspects of cell functioning (4). We show an effect of H2O2 on 
the influx of Ca2+ in ultrasound-exposed cells in the presence of microbubbles. Our present 
findings – i.e. no increase in intracellular Ca2+ in the presence of only 1 µM extracellular Ca2+ and 
a reduced increase in cytosolic Ca2+ when H2O2 is scavenged – implicate a role for H2O2 in 
transient permeabilization of cell membranes during ultrasound exposure in the presence of 
microbubbles. In addition, Marumo et al. have reported a VEGF-elicited, ROS-dependent 
increase in the macromolecule permeability of bovine microvascular endothelial cells (12). In 
contrast with these findings are the results of an earlier study by Lawrie et al, which indicated that 
ultrasound enhanced transgene expression is not dependent upon ROS. However, they used high 
intensity ultrasound (MI 2.0), which causes inertial cavitation with high mechanical forces acting 
on cell membranes (10).  
Transient permeabilization and implications for cell viability 
There are several reports on ultrasound exposed microbubbles induced apoptosis and necrosis 
(9,14). Importantly, using our ultrasound parameters, we found that cell viability was not 
significantly affected, despite the transient permeabilization with concomitant Ca2+ influx. Only a 
small, non-significant increase in early-apoptotic and necrotic cells was detected by flow 
cytometry. In addition, no increase in late-apoptotic cells could be detected by TUNEL, and DIC 
microscopic observation of exposed cells showed no alteration in overall cell morphology or 
excessive cell detachment. Also after 24 hours these cells were still viable. Thus, H2O2-induced 
Ca2+ influxes are not necessarily a precursor for cell death. This is in agreement with a study of 
Volk et al. in which low levels of H2O2 triggered subtoxic Ca2+ oscillations (24). The majority of 
cells recover fast from the primary wave of Ca2+ influx: directly after ultrasound exposure Fluo-4 
fluorescence peaks and then rapidly falls back to baseline. Transient permeabilization of cell 
membranes during and following ultrasound exposure in the presence of microbubbles is of great 
interest in relation to local gene delivery and enhanced transgene uptake. Increased cell 
membrane permeability has been demonstrated by several groups by an increase in ion fluxes (6) 
as well as enhanced uptake of different macromolecules (13) or transgenes (17,19,23). Although 
the present findings are in support of a role for H2O2 in transient permeabilization of cell 
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membranes by ultrasound-exposed microbubbles, this is probably not the sole effect involved in 
permeabilization of cell membranes. Most likely it is a combination of the production of H2O2 
and the bioeffects mentioned in the introduction, i.e. a local rise in temperature and 
microstreaming along the cell membrane that will finally lead to physical pores in the membrane 
causing increased uptake of macromolecules and transgenes. At different intensities and energy 
levels of ultrasound, one bioeffect may play a greater role than the others. Further studies have to 
be directed towards investigating the combination of these effects of ultrasound-exposed 
microbubbles at different intensities and energy levels on cell membrane permeability and 
transgene uptake. Although enhanced transgene uptake is often accomplished by microbubble 
destruction with high-intensity ultrasound, studying bioeffects at lower intensity ultrasound is 
important for our understanding of increased permeability. If effects like H2O2 production and 
Ca2+ influx are already present at these low intensities in vitro, they are also likely to occur in vivo 
during contrast echocardiography where imaging takes place for a longer period of time. 
 
In conclusion, we observed a significant increase in the production of H2O2 after ultrasound-
exposed microbubbles compared to ultrasound alone. This is a novel observation in the setting of 
low power ultrasound in the presence of stable oscillating microbubbles. Furthermore, increased 
H2O2 production was associated with increased cell membrane permeability, reflected by Ca2+ 
influxes, as scavenging H2O2 reduced this influx. 
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Chapter 5:  Therapeutic applications of ultrasound contrast agents 
 
5.2 Local drug and gene delivery through microbubbles and ultrasound:  
a safe and efficient alternative for viral vectors? 
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Abstract 
Although gene therapy has great potential as treatment for diseases, clinical trials are slowed 
down by the development of a safe and efficient gene delivery system. In this review, we will 
give an overview of the viral and non-viral vehicles used for drug and gene delivery, and the 
different non-viral delivery techniques, thereby focusing on the delivery through ultrasound 
contrast agents. 
The development of ultrasound contrast agents, containing encapsulated microbubbles, has 
increased the possibilities not only for diagnostic imaging, but for therapy as well. Microbubbles 
have been shown to be able to carry drugs and genes, and destruction of the bubbles by ultrasound 
will result in local release of their contents. Furthermore, ligands can be attached so that they can 
be targeted to a specific target tissue. The recent advances of microbubbles as vehicles for 
delivery of drugs and genes will be highlighted. 
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As a consequence of the identification of thousands of genetic factors, gene therapy has great 
potential as treatment of several (cardiovascular) diseases in the near future. However, clinical 
trials are slowed down by the development of safe and efficient systems for local gene delivery. 
At present two categories of delivery vehicles are available; viral and non-viral. Up till now, the 
use of viruses is the most efficient gene transfer method because of the specific viral machinery 
that has evolved to introduce viral DNA into their host cells (1). However, there are many 
problems regarding the safety of viral vectors. The ideal delivery system should be safe, i.e. elicit 
no immune response, and efficient, i.e. able to transfect the majority of cells. There should be no 
breakdown of DNA before it reaches target, the system should be able to bypass the endosomal 
degradation route and there should be sustained transgene expression. Besides this, the amount of 
DNA or drugs delivered to be effective should be minimal regarding possible side effects and it is 
convenient if it can be commercially produced on a large scale (2-4). 
Viral vehicles  
Enveloped viruses accomplish the delivery of their genome into the host cell by fusing their 
envelopes with the host cell membrane, mediated by proteins incorporated in the viral envelope. 
Conversely, viruses that enter via endocytosis have specific proteins to destabilize the endosomal 
membrane in order to be able to escape the lysosomal degradation route (5-6). As viral DNA 
often contains several nuclear localization sequences it will be imported into the nucleus, 
followed by integration into the host’s genome via integration sites on the viral DNA (7). 
Particularly retroviruses, lentiviruses and adeno (-associated) viruses have been extensively used 
as vehicles (2). 
Retroviral vectors were the first to be designed, and a breakthrough in generating a safe and 
transcriptionally adjustable vectors was the development of self-inactivating vectors, in which the 
viral regulatory elements have been deleted. The main limitation of retroviral vectors is their 
inability to infect non-dividing cells, meaning that tissues such as brain, eye and lung are not 
amenable for direct in vivo gene delivery. Furthermore, on transplantation of transduced cells in 
the host, transcription of the transgene is often ‘switched off’ and the transgene is no longer 
expressed (2). 
Lentiviral vectors, derived from the human immuno-defiency virus, belong to the retrovirus 
family, but have acquired the, for retroviruses unusual, property of infecting non-dividing cells. 
Although the first-generation lentiviral vectors were promising, the possibility remained that they 
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could recombine and generate the dangerous immuno-defiency virus. To minimize this chance as 
many viral accessory genes as possible were deleted, while maintaining the capacity of infecting 
non-dividing cells. This technique is also applied to the e.g. adenoviral vectors to create a safe 
‘gutless’ virus. However, there are still no reports of clinical trials using lentiviral vectors as they 
have the disadvantage of non-specific integration in the host’s genome, which could theoretically 
lead to activation of pro-oncogenes (2). 
Adeno-associated viral vectors are the most promising viral vectors. The adeno-associated virus 
is non-pathogenic and is a member of the dependoviruses, meaning that it needs extra genes to 
replicate. These genes are provided by the adenovirus or herpesvirus. The broad host range, 
relatively low level of immune response, longevity of gene expression, and the ability to integrate 
site-specifically have enabled the initiation of a number of clinical trials. The main disadvantage 
using adeno-associated viral vectors is that the gene that enables the site-specific integration is 
cytostatic or even cytotoxic to the host cells. Another drawback for using this vector for gene 
therapy is that it can only code for a transgene of maximal 4.5 kb (2,8). 
Adenoviruses belong to a family of DNA tumor viruses. Advantages of adenoviral vectors are that 
they retain the ability to transduce dividing and non-dividing cells efficiently and the relative 
easiness to generate high-titre commercial-grade recombinant vectors. The problem with 
adenoviral vectors is that the expression of the trangene in adult animals only lasts for a short 
period of time (5-20 days post-infection), which is now generally recognized as a consequence of 
the immune response. The immune response of the host is the biggest challenge facing all viral 
vectors. Even inactivated adenoviral vectors can elicit a strong immune response: a few years ago 
an 18-year old patient died as a direct consequence of the severe immune response to the 
adenoviral vector used in a phase I gene therapy clinical trial (2,8). 
Non-viral delivery techniques 
As viral vectors bring along many problems associated with immunity, a non-viral but yet 
efficient gene delivery method is desirable. Currently, the following non-viral gene delivery 
systems available.  
Micro-injection, where DNA transfer is performed by direct injection of naked DNA into a cell 
nucleus. This is a very effective method but as only one cell at the time can be transfected, its use 
is limited (2,4). 
Gene gun, non-viral gene delivery can also be performed with the so-called ‘gene gun’, where 
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DNA coated gold particles are accelerated to a high velocity and shot under a helium pressure 
into the skin (4). Originally, this method was developed by Sanford and colleagues in 1987 to 
deliver genes to plant cells. The gene gun is a convenient device that provides rapid and direct 
gene transfer into a range of targets in vitro as well as in vivo (9). However, this procedure is not 
yet widely used because the DNA entry pathway is difficult to control (4). 
Electroporation is another relatively effective method. Electrical pulses are used to transiently 
permeabilize the cell membrane, thus permitting cellular uptake of macromolecules. This process 
was first used to deliver DNA in vitro to mammalian cells already in 1982. It is one of the most 
efficient methods to transfect skeletal muscle cells, but its use is limited because of the high 
mortality of cells after high-voltage exposure and the difficulty to apply in vivo. Also, the efficacy 
in human is yet to be tested (10).  
Magnetofection, a novel delivery technique under development uses the magnetic force acting on 
gene vectors that are associated with magnetic particles. Magnetofection does not necessarily 
improve overall performance of any given standard gene transfer method in vitro, its major 
potential lies in the very rapid and efficient transfection at low vector doses and the possibility to 
remotely control vector targeting in vivo. Although this technique is still in its infancy, it has great 
potential (11,12). 
 
Figure 1. Alignment of the different particles according to their size, starting with an erythrocyte for size 
comparison. 
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Ultrasound contrast agents, another recent new technique that is characterized by the local 
delivery of genes and/or drugs through microbubbles and ultrasound to specific target tissues, 
including the heart (13-16). 
Non-viral vehicles 
During the last decade much attention has been focused on the use of various (phospho)lipid 
complexes and formulations as vehicles for drug and gene delivery (11-20).  
Micelles are mostly used as carriers to deliver drugs in anti-cancer therapy; they are phospholipid 
particles and about 10-100 nm in diameter, approximately ten times bigger than a virus, as can be 
seen in figure 1 (17). 
Liposomes have a phospholipid bilayer and are on average only 100 nm in diameter. Liposomes 
were a promising tool in gene and drug delivery and although in vitro studies do show good 
results, in vivo studies are disappointing (18,19). 
Microbubbles create new options. Gramiak and Shah were the first to notice an elevated signal 
after they injected saline intracardiac, although it was later that they attributed this to the 
reflection of ultrasound by minibubbles in the saline (20). Since then, microbubbles have evolved 
rapidly, not only in diagnostic imaging, but as possible therapeutic agents as well (14). 
Microbubbles are on average about 2-5 µm in diameter, which is relatively large compared to 
other carriers used in gene and drug delivery, e.g. the mentioned particles for magnetofection, are 
only 10-20 nm (11,12). The very first microbubbles manufactured were room air microspheres. 
Albunex was the first contrast agent to be approved for clinical use in the United States and 
Japan; it consists of air stabilized with a thin shell of human albumin (21). However, air bubbles 
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disappear in a few seconds after intravenous administration as the solubility of air in blood is 
high and the bubbles are filtered by the lungs (22-24). Improved stability and survival was 
reached by stabilizing the microbubbles with a high molecular-weight gas, e.g. sulphur-
hexafluoride, which decreases solubility, and thus improves survival and stability under high 
pressure. At this moment different ultrasound contrast agents are commercially available with 
different gas and different types of shells, a few well-known microbubbles and their 
characteristics are shown in table 1, and figure 2 shows fluorescent labelled microbubbles.  
Microbubble properties: an ideal vehicle  
An interesting feature of microbubbles is the specific acoustic properties they show in the 
presence of ultrasound, due to the encapsulated gas. This provides various possible methods of 
increased cell permeability by these ultrasound microbubbles (25,26).  
Firstly, an important mechanism in permeabilizing cell membrane is cavitation; the interaction 
between the ultrasound and the surrounding fluid (26,27). In body tissue or blood, cavitation sets 
fluid in motion and creates small shock waves that give rise to microstreaming and shear stress 
along the endothelial cells (26,28). It is hypothesized that microbubbles acting as cavitation nuclei 
lower the threshold for cavitation, potentiating the formation of transient holes in the plasma 
membrane and possibly the nuclear membrane, which would facilitate macromolecule uptake 
(10,27).  
Figure 2. Fluorescently labeled Sonovue® microbubbles. 
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Ultrasound applied at low or intermediate acoustic power (MI <0.5) results in linear and non-
linear oscillations of microbubbles respectively, inducing stable cavitation (27). When 
microbubbles are exposed to ultrasound with high acoustic power, i.e. MI >1.0, it will lead to 
non-linear expansion and compression of the microbubbles with high oscillation amplitude, 
eventually leading to bubble destruction (29). When microbubbles are destroyed they may act as 
“fragmentation bombs” (figure 3), shooting the genes into the cells. Price and colleagues showed 
that microbubble destruction is able to create microvessel ruptures large enough to permit the 
extravasation of microbubbles, yet cell and tissue damage are minimal and limited to the rupture 
site itself. This study shows that microbubbles in the presence of ultrasound can be used to deliver 
genes across the endothelial lining of the blood vessel to the underlying tissue (13). Local release 
of the bubble’s cargo by destruction can be well used for the local delivery of a high 
concentration of drugs to target tissue. All forms of drug therapy in which drugs are administered, 
systemically require plasma concentrations within the therapeutic range. Although many diseases 
like cancer, inflammatory diseases or thromboembolic processes may require higher 
concentrations of certain drugs, plasma concentrations are limited by the occurrence of potentially 
dangerous side effects. After systemic administration microbubbles loaded with drugs can rupture 
under influence of localized ultrasound and drug release will result in higher local concentrations 
in comparison with systemic administration (30). 
 
 
Figure 3. Microbubble collapse under influence of ultrasound, thereby perforating the cell membrane. 
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Secondly, changes in the plasma membrane fluidity may facilitate microbubble and/or DNA 
uptake. When diagnostic cardiac ultrasound is applied oxygen radicals are produced in the 
endothelial cells (31). This could lead to an increased permeability of the plasma membrane, 
however, a dramatic increase in oxygen radicals may also have toxic effects. Thirdly, ultrasound 
in the presence of microbubbles causes a local, transient rise in temperature (32). This could also 
contribute to an increased fluidity and permeability of the cell membrane. A fourth cell entry 
mechanism is the fusion of the phospholipid-shelled microbubble or exchange of bubble 
fragments with the plasma membrane, delivering the bubble’s cargo direct into the cytoplasm of 
the cell. Or finally, microbubbles may be actively taken up via phagocytosis or endocytosis. This 
is most likely to happen when the microbubbles are targeted; when a microbubble binds to, e.g. 
the transferrin receptor, endocytosis is triggered. Also non-targeted microbubbles, as they often 
have a net positive charge, may bind to the negatively charged cell surface molecules and 
triggering endocytosis (33). 
Targeting the microbubbles 
As mentioned briefly, microbubbles are ideal delivery vehicles as they can be loaded with genes 
or drugs, but besides that they can be targeted to specific tissue by the incorporation of ligands 
into the shell. There are several ways of attachment of drug, genes or ligands to a microbubble 
(figure 4). Especially negatively charged DNA can rather easily be attached to a positively 
charged bubble shell (figure 4a). Another way to load a bubble with drugs is to incorporate a 
lipophilic drug in the lipid membrane (figure 4b), or to enclose the drug within the microbubble 
itself (figure 4c). Furthermore, drugs can be bound by ligands that are embedded in the membrane 
(figure 4d). Whether a bubble can be loaded with a certain drug depends on important factors like 
molecular weight, lipophilicity and charge (34). 
Recent experiments show that it is possible to create targeted microbubbles by incorporating 
monoclonal antibodies into the membrane (35-38). Villanueva and colleagues demonstrated that 
microbubbles with intercellular adhesion molecule-Ι (ICAM-Ι) antibodies bind to endothelial cells 
expressing ICAM-Ι. As the expression of ICAM-Ι by endothelial cells is associated with early 
atherosclerosis, this has major consequences for diagnosis of pre-clinical atherosclerosis (35). 
Schumann and colleagues demonstrated that vascular clots, known to be associated with 
cardiovascular diseases such as stroke and myocardial infarction could be visualized by 
microbubbles targeted to the GPIIbIIIa receptors, which play a key role in the formation of 
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vascular clots. Clot lysis is known to be improved by ultrasound, this creates the possibility of 
enhanced clot lysis by ultrasound in combination with targeted microbubbles loaded with 
thrombolytics (37-39). 
 
 
 
Figure 4. Different ways to bind drugs, genes, and ligands to microbubbles. 
 
Although many studies implicate that microbubbles can be used as vehicles for targeted drug and 
gene delivery, it is important to know how exactly cell entry occurs under different circumstances 
and what the bioeffects are that microbubbles and ultrasound can cause, before this technique can 
be used as a safe and efficient tool to deliver genes or drugs in humans. Adverse bioeffects, like a 
rise in blood temperature or hemolysis when using ultrasound and microbubbles, have been 
causes of concern for several investigators. Microbubbles exposed to ultrasound can cause 
mechanical stress and damage upon cells and consequently even permanent cell injury (40). The 
extent of the bioeffects in which therapeutic ultrasound microbubbles can result, depends on 
ultrasound parameters like frequency and amplitude, which are lower for diagnostic ultrasound 
compared to therapeutic ultrasound (26,32,41,42). Implications for side effects in humans and 
their clinical importance need further investigation. 
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Perspectives 
Different approaches for non-viral gene and drug delivery are being explored, and much is 
learned from viruses that have evolved extremely efficient infection mechanisms. Recent in vivo 
studies have shown that enhanced expression of genes delivered by microbubbles in combination 
with ultrasound is feasible. The most interesting is the precise interaction of microbubbles with 
living cells. Although several options, like transient cell membrane holes, phagocytosis, 
endocytosis and fusion of microbubble shell components with the cell membrane have been 
proposed, the exact mechanism(s) remain(s) to be unravelled. Recent advances in live-cell 
imaging techniques, e.g. multidimensional digital imaging microscopy, offer excellent 
opportunities to study in vitro this process at the (sub)cellular level in real-time, thereby creating 
the possibility to visualize the interaction of fluorescent labelled microbubbles and myocardial or 
endothelial cells under ultrasound pressure.  
Over the past few years, contrast agents have rapidly evolved from a diagnostic to a possible 
therapeutic application. In the coming years, this promising technique needs further development 
to make it available for safe and efficient local gene therapy and drug delivery as this technique 
creates various challenging therapeutic options, not only in cardiovascular disease but also in the 
treatment of different types of cancer.  
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Chapter 6:  Summary 
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The present thesis describes several clinical studies on the topic of intravenous myocardial 
contrast echocardiography, and an experimental study on the effect of ultrasound contrast on the 
cellular level. Chapter 1. describes ultrasound contrast agents and their unique properties that 
make them useful for ultrasound imaging and therapeutic purposes. Ultrasound contrast exists 
from microbubbles that can pass the lung and are relatively stable in blood. They produce non-
linear resonance under influence of ultrasound, which enables selective imaging of ultrasound 
contrast, and is the basis of contrast-enhanced imaging. With ultrasound of high intensity, 
microbubbles collapse, thereby causing microstreaming, shock waves, motion of fluid, and 
increased cell permeability. Microbubbles can function as carriers for drugs and genes. Using an 
intravenous injection of microbubbles with local application of ultrasound, drugs or genes can be 
released locally. Several studies demonstrated that microbubbles enhance gene uptake and 
expression. A second, intriguing issue is the development of targeted microbubbles. Biochemical 
properties of microbubbles create the possibility to incorporate ligands into the microbubble shell. 
Targeted microbubbles may selectively bind to specific cell types, inflamed tissue or activated 
endothelium, with the possibility of local treatment. A third field of interest is sonothrombolysis. 
Recent studies showed that the forceful collapse of microbubbles enhances lysis of blood clots. 
As a large part of cardiovascular diseases is caused by thrombotic disease, thrombolysis may 
become an important future technique for non-invasive recanalization of acutely occluded vessels, 
of which the first clinical studies have already proven the benefit. 
 
Chapter  2. of this thesis contains a study on the quanitification of myocardial perfusion. Previous 
studies demonstrated that, according to a model designed by Wei et al., a continuous infusion of 
ultrasound contrast allows absolute quantification of myocardial perfusion in an experimental and 
in vivo setting. We aimed to validate this technique in humans and compare myocardial contrast 
echocardiography (MCE) with the gold standard, positron emission tomography (PET). Sixteen 
healthy volunteers underwent rest and adenosine real-time MCE. Replenishment curves were 
calculated from end-systolic images and fitted to an exponential equation (y=A (1-e-βt)). The 
average myocardial blood flow per patient, estimated as the product of A and β (PEcorr), 
significantly increased from 1.43±0.35 IU s-1 at rest to 5.70±2.44 IU s-1 at stress (P<0.01) with 
MCE, resulting in a mean flow reserve of 3.94±1.31. PEcorr correlated significantly with MBFcorr. 
This correlation was found in all territories (left anterior descending artery: r=0.87, P<0.01; right 
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coronary artery: r=0.66, P<0.01; circumflexal artery: r=0.75, P<0.01). At rest only, no significant 
relations were demonstrated between PET and MCE. Heterogeneity was significantly larger for 
MCE (coefficient of variation 32±15%) than for PET (9±6%) measurements (P<0.01). The results 
of the present study indicate that, especially at stress, quantification of global MBF correlates well 
with PET. Accurate quantification of rest MBF and coronary flow reserve is more challenging. 
 
Chapter 3.1. provides a discussion about the safety of the use of contrast agents. The introduction 
of ultrasound contrast agents has led to a markable improvement of diagnostic capabilities in 
echocardiography. The occurrence of fatal adverse events, that were reported in a post marketing 
analysis of more than 150,000 studies of Sonovue® (0.002%), led to a temporary withdrawal, and 
the addition of several contra-indications for the use of this ultrasound contrast agent, although a 
causal relationship between the fatal cases and the use of Sonovue is debatable. The risk 
associated with the use of this ultrasound contrast agent should be judged carefully, taking into 
consideration the prevalence of adverse effects of other contrast media and diagnostic procedures 
used in cardiology. Large studies showed that fatal adverse events occurred in 0.0004% with 
GTPA (causal relation not clear), 0.0006% with ionic and non-ionic contrast media, and 0% in 
radiopharmaceuticals. When compared with exercise testing (0.005%) and dobutamine stress 
echocardiography (which has a relatively high serious adverse event rate of 0.43%), that have 
comparable values for assessment of coronary artery disease, administration of UCAs seems to be 
relatively safe. This manuscript stimulates the discussion about which risk is clinically acceptable 
for the diagnostic value of a specific test. 
  
In Chapter 3.2. a retrospective study is described. Previous studies suggested that during MCE, 
premature ventricular complexes (PVCs) occurred that were caused by a ‘flash’ of high intensity 
ultrasound, which is applied for destruction of microbubbles. As safety is an important issue for 
registration of ultrasound contrast for myocardial perfusion imaging, we aimed to assess the 
occurrence of  PVCs during real-time rest and adenosine MCE in a retrospective study in fifty 
healthy volunteers and twenty-six patients with stable coronary artery disease. The number of 
premature contractions was counted before contrast infusion, at rest, and at adenosine stress. 
Occasional premature contractions occurred following a flash. In healthy subjects, the occurrence 
of PVCs at baseline (0.04±0.23 PVCs/min) was similar at rest (0.04±0.23 PVCs/min, P=NS), and 
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adenosine stress (0.03±0.14, P=NS). In CAD patients, the occurrence of PVCs at baseline was 
0.30±0.76 PVC/min, compared to 0.29±0.74 at rest (P=NS), and 0.34±0.74 during adenosine 
stress (P=NS). The number of subjects demonstrating PVCs did not increase during MCE. The 
occurrence of premature atrial complexes during MCE was not increased compared to baseline in 
any of the study groups. We conclude that real-time MCE is safe with respect to the occurrence of 
premature contractions and arrhythmias. 
 
Chapter 4.1. reviews the current status of intravenous MCE. During the last 10 years, many 
studies have assessed the value of MCE for myocardial perfusion imaging. Several imaging 
modalities have been developed that make use of the non-linear resonance of microbubbles 
during insonification. These modalities can be divided in high-power and low-power, allowing 
triggered and real-time imaging (for simultaneous assessment of wall motion and perfusion) 
respectively. Both techniques can be used for (semi)-quantification of myocardial perfusion, 
whereas in humans only real-time MCE has been demonstrated to correlate well with the gold 
standard for assessment of myocardial perfusion, positron emission tomography. 
In patients with stable coronary artery disease, detection of significant coronary artery disease is 
currently performed with dobutamine stress echocardiography, and cardiac scintigraphy. Several 
studies show that the agreement of MCE with these contemporary techniques is high (65-92%). In 
addition, comparison of the latter techniques and MCE for detection of significant coronary artery 
disease with coronary angiography as gold standard, shows that the sensitivity of MCE is 
significantly higher compared with DSE/SPECT (85% versus 71%, p<0.001), with a similar 
specificity (74% versus 71% respectively, p=ns). Furthermore, in patients with unstable ischemic 
heart disease, MCE appears to be a sensitive tool for detection of impaired myocardial perfusion 
(82%), and thus can play an important role in the diagnosis of acute coronary syndromes. In 
addition, in patients after acute myocardial infarction, MCE accurately defines areas of (no)-
reflow, and the presence of adequate reperfusion, which is a predictor of functional recovery 
(presence of contrast predicts recovery with a sensivity of 82% at follow up), and death. Besides 
diagnostic value, MCE thus has important prognostic value in the setting of acute ischemic heart 
disease. This meta-analysis emphasizes the potential of MCE for routine clinical use.   
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Chapter 4.2. Previous studies assessed prediction of recovery of segmental function after acute 
myocardial infarction with rest MCE. As vasodilator stress may improve detection of collateral 
vasculature and residual intact microvascular function, we aimed to assess the value of adenosine 
stress MCE for prediction of functional recovery, and for estimating infarct size. 25 patients 
underwent rest and adenosine real-time MCE in the subacute phase after myocardial infarction. 
Residual perfusion as measured with rest and stress MCE correlated significantly with residual 
ST-elevation after reperfusion (r=0.86, p<0.01, versus r=0.66, p<0.01 respectively), and peak CK-
MB (r=0.76, p<0.01 versus r=0.85, p<0.01 respectively). The sensitivity for prediction of 
recovery was significantly higher with adenosine stress (97% versus 88%), with a similar 
specificity. All patients tolerated adenosine MCE well. We conclude that adenosine stress MCE is 
a safe and clinically feasible tool for prediction of recovery of function in the subacute phase after 
AMI, with additional value compared with rest MCE.  
 
Chapter 5.1. In the present study, we addressed the interactions between ultrasound, microbubbles 
and living cells as well as consequent arising bioeffects. We specifically investigated whether 
hydrogen peroxide (H2O2) is involved in transient permeabilization of cell membranes in vitro 
after ultrasound exposure at low diagnostic power, in the presence of stable oscillating 
microbubbles, by measuring the generation of H2O2 and Ca2+ influx. 
Ultrasound, in the absence or presence of SonoVueTM microbubbles, was applied to H9c2 cells at 
1.8 MHz with a mechanical index (MI) of 0.1 or MI 0.5 during ten seconds. This was repeated 
every minute for five times. The production of H2O2 was measured intracellularly with CM-
H2DCFDA. Cell membrane permeability was assessed by measuring real-time changes in 
intracellular Ca2+ with Fluo-4 using live-cell fluorescence microscopy.  
Ultrasound, in the presence of microbubbles, caused a significant increase in intracellular H2O2 at 
MI 0.1 of 50% and at MI 0.5 of 110% compared to control (p<0.001). Furthermore, intracellular 
Ca2 increases at both MI 0.1 and 0.5 in the presence of microbubbles, which was not detected in 
the absence of extracellular Ca2+. In addition, in the presence of catalase Ca2+ influx immediately 
after ultrasound exposure was completely blocked at MI 0.1 (p<0.01) and reduced by 50% at MI 
0.5 (p<0.001). Finally, cell viability was not significantly affected, not even 24 hours later. These 
results implicate a role for H2O2 in transient permeabilization of cell membranes induced by 
ultrasound-exposed microbubbles. 
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Chapter 5.2.  Although gene therapy has great potential as treatment for diseases, clinical trials 
are slowed down by the development of a safe and efficient gene delivery system. This part of the 
thesis reviews the viral and non-viral vehicles used for drug and gene delivery, and the different 
delivery techniques, thereby focusing on the delivery through ultrasound contrast agents. 
Currently, the mostly used viral vectors include retroviral-, lentiviral-, adenoviral-, and adeno-
associated viral vectors. Non-viral gene delivery techniques include micro-injection, the gene-
gun, magnetofection, micelles, liposomes, and electroporation. The current techniques mostly 
lack efficiency, whereas safety of viral vectors is doubtful. The development of ultrasound 
contrast agents, containing encapsulated microbubbles, has increased the possibilities for therapy. 
Microbubbles are safe, inert intravascular tracers. Their chemical composition allows binding or 
incorporating drugs, genes, and ligands in the bubble or the bubble shell. Ligands can be used to 
target the microbubbles to specific tissue. Destruction of the bubbles by ultrasound will result in 
local release of their contents, whereas ligands can be used to target the microbubbles to specific 
tissue. The results of several studies provide persuasive evidence, that a future role of 
microbubbles for gene delivery is promising.  
 
Future perspectives in myocardial contrast echocardiography 
As described in this thesis, many studies already have investigated the value of myocardial 
contrast echocardiography for clinical use in patients with coronary heart disease. Up to now, all 
these studies were performed as part of medical research, as a contrast agent that is registrated for 
myocardial perfusion imaging is still lacking. In the near future, contrast agents will become 
available for perfusion imaging in routine clinical care. Implementation of MCE requires 
availability of ultrasound equipment, and training of personnel. Provided these conditions are 
fullfilled, MCE probably has potential to compete with contemporary techniques for assessment 
of coronary artery disease.  
Recent developments in three-dimensional echocardiography have simplified image acquisition 
with use of a 3-dimensional matrix transducer. These transducers produce a homogeneous 
ultrasound field, which can increase image quality further. Although 3D-left ventricular 
opacification can be performed with the current ultrasound equipment, technical limitations 
preclude real-time imaging of myocardial perfusion in three dimensions. If these limitations can 
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be addressed adequately, 3D echocardiography has the potential to provide a simple and fast 
technique for assessment of perfusion.  
 
Future perspectives for therapeutic contrast echocardiography 
Future therapeutic applications of ultrasound contrast agents, can be grossly divided into two 
areas: the area of drug- and gene delivery, and the area of contrast enhanced thrombolysis.  
As the genetic basis of diseases is increasingly understood, gene delivery will gain importance in 
the near future. Many experimental animal studies show that microbubbles enhance delivery of 
genes. Although the results of these studies leave no doubt about the effectivity of microbubbles, 
the working mechanism remains unresolved. Future research should focus on assessment of the 
mechanism of gene delivery with microbubbles on the cellular level, the effect of variation of 
ultrasound parameters such as frequency, intensity and duration, and on the specific type of 
microbubbles. Unraveling the mechanism will enable us to potentiate the effect of contrast-
enhanced gene delivery, which is an fundamental condition, before this technique can be used in 
clinical studies. 
The second important area of interest is sonothrombolysis. In the Western society, thrombo-
occlusive diseases are responsible for the majority of disease-related mortality. Experimental 
studies showed that insonified ultrasound contrast has thrombolytic effect, both in vitro and in 
vivo. Recently, in patients with acute stroke, microbubbles were succesfully used as adjuvant 
therapy with thrombolysis. Although the majority of patients with acute myocardial infarction is 
currently treated with a percutaneous coronary intervention, many patients abroad still receive 
thrombolysis. In this patient group, adjuvant in-hospital therapy with contrast agents and 
ultrasound application could possibly speed up recanalization.  
According to the adage ‘time is muscle’, the speed of recanalization is an important predictor of 
outcome, also for patients with acute myocardial infarction that are treated with PCI. 
Recanalization of the occluded artery should begin before arrival of the patient in the hospital. 
With use of dedicated equipment, sonothrombolysis could provide a non-invasive, fast technique 
for timely restoration of the occluded vessel. 
As currently no patient-based studies on this topic have been performed, future research will need 
to focus on the effectivity of microbubble-enhanced sonothrombolysis in humans. 
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Chapter 7:  Samenvatting 
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Dit proefschrift beschrijft verscheidene klinische studies met als onderwerp intraveneuze 
myocardiale contrast echocardiografie (MCE), en een experimentele studie naar het effect van 
ultrageluidcontrastmiddelen op cellulair niveau. Hoofdstuk 1. beschrijft de unieke eigenschappen 
van ultrageluidcontrastmiddelen, die ze geschikt maken voor het gebruik in de echocardiografie, 
en voor therapeutische doeleinden. Ultrageluidcontrastmiddelen bestaan uit microbellen, met een 
schil van eiwit of fosfolipiden gevuld met een slecht oplosbaar gas. Ze kunnen het longvaatbed 
passeren, en zijn relatief stabiel in bloed. Onder invloed van ultrageluid met een matige 
intensiteit, produceren deze microbellen harmonische trillingen, welke gebruikt worden om 
selectief het contrast af te beelden. Het harmonisch trillen van microbellen vormt de basis van de 
contrastechocardiografie. Onder invloed van ultrageluid met een hoge intensiteit worden 
microbellen vernietigd, waarbij micro-jets, schokgolven, en beweging van vloeistof ontstaan. Op 
cellulair niveau veroorzaakt dit tevens een verhoogde celmembraanpermeabiliteit.  
Microbellen kunnen fungeren als ‘’carrier”, doordat medicatie of genen in de microbel 
geïncorporeerd, of aan de microbel gebonden kunnen worden. Met behulp van een intraveneuze 
injectie en locaal aanstralen met hoge intensiteit ultrageluid, kan op een gerichte plaats de inhoud 
van de microbel gedeponeerd worden. Verscheidene studies hebben reeds aangetoond dat 
microbellen op deze manier  de opname en expressie van genen verhogen. Een belangrijke 
ontwikkeling op dit gebied is de ontwikkeling van doelgerichte microbellen. De biochemische 
eigenschappen van microbellen maken het mogelijk in de schil van de microbel liganden aan te 
brengen die specifiek binden aan receptoren van een bepaald type weefsel. Deze liganden kunnen 
gericht zijn bepaalde celtypen, geactiveerd endotheel, of bloedstolsel. Door na binding van de 
ligand aan de receptor aan te stralen met ultrageluid, kan gericht een medicijn toegediend worden.  
Een belangrijk onderzoeksgebied wordt gevormd door ”sonothrombolyse”. In de Westerse 
maatschappij wordt een groot deel van de sterfte veroorzaakt door (vnl. thrombo-occlusieve) 
cardiovasculaire aandoeningen, waarbij een bloedstolsel een vat plotseling afsluit, met een hart- 
of herseninfarct tot gevolg. Recente studies hebben aangetoond dat ultrageluid 
bloedstolseloplossend vermogen heeft, wat versterkt wordt door het exploderen van microbellen, 
indien aanwezig. Microbellen in combinatie met ultrageluid kunnen om deze reden in de 
toekomst mogelijk behulpzaam zijn bij de niet-invasieve behandeling van cardiovasculaire 
aandoeningen. Enkele klinische studies hebben hiervan reeds het effect aangetoond.   
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Hoofdstuk 2. van dit proefschrift bevat een onderzoek naar de quantificatie van myocardiale 
perfusie met behulp van myocardiale contrast echocardiografie (MCE). Eerdere onderzoeken 
hebben gedemonstreerd dat, volgens een model dat ontworpen werd door Wei cum suis, met 
behulp van een continu intraveneus infuus van contrast, het mogelijk is om de bloeddoorstroming 
van het hart absoluut te bepalen, zowel in vitro, als in vivo. Het doel van dit onderzoek was om 
d.m.v. dit model de bloeddoorstroming van het hart te onderzoeken bij gezonde mensen, en dit te 
vergelijken met de gouden standaard, positron emissie tomografie (MBFcorr). Zestien gezonde 
vrijwilligers ondergingen real-time MCE in rust en tijdens adenosine. Contrast-vullingscurves 
werden berekend van eind-systolische beelden, en berekend volgens een exponentiele 
vergelijking (y=A (1-e-βt)). De gemiddelde bloedstroom door het hart per patient, geschat als het 
procuct van A en β (PEcorr), nam significant toe van rust (1.43±0.35 IU s-1) naar adenosine stress 
(5.70±2.44 IU s-1, P<0.01), met een gemiddelde reserve van 3.94±1.31. PEcorr correleerde 
significant met de MBFcorr. Deze correlatie werd gevonden in alle stroomgebieden (ramus 
descendens anterior: r=0.87, P<0.01; rechter coronair arterie: r=0.66, P<0.01; ramus 
circumflexus: r=0.75, P<0.01). In rust werden geen significante relaties aangetoond tussen PET 
en MCE. De heterogeniteit was groter voor MCE (variatie-coefficient 32±15%) dan voor PET 
(9±6%, P<0.01). De resultaten van dit onderzoek tonen aan dat, in het bijzonder tijdens adenosine 
stress, quantificatie van de bloedstroom door het hart d.m.v. MCE correleert met PET. De grotere 
heterogeniteit van MCE bemoeilijkt nauwkeurige quantificatie in rust. 
 
Hoofdstuk 3.1. bevat een discussie over de veiligheid van ultrageluidcontrastmiddelen. Het 
gebruik van ultrageluidcontrast heeft een belangrijke verbetering van de diagnostische 
mogelijkheden van echocardiografie bewerkstelligd. Het optreden van enkele fatale bijwerkingen, 
die werden gerapporteerd naar aanleiding van een post-marketing analyse van 150.000 studies 
met Sonovue (0.002%), leidde tot een tijdelijke terugtrekking van de markt, en een uitbreiding 
van contra-indicaties voor het gebruik van dit contrastmiddel, hoewel een causale relatie tussen 
het optreden van deze fatale bijwerkingen en het gebruik van Sonovue discutabel is. Het risico dat 
gepaard gaat met het gebruik van Sonovue dient daarom nauwkeurig bekeken worden, waarbij 
rekening gehouden moet worden met de frequentie van het optreden van bijwerkingen bij andere 
contrastmiddelen, en diagnostische procedures, die in de cardiologie gebruikt worden. Grote 
studies hebben aangetoond dat fatale bijwerkingen bij MRI-contrastmiddel GTPA in ca. 0.0004% 
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voorkwamen, in 0.0006% bij ionische en niet-ionische contrast media, en in 0% bij  
radiofarmaceutica. Vergeleken met een inspanningstest (0.005%) en dobutamine stress 
echocardiografie (wat een relatief hoog risico op ernstige bijwerkingen kent van 0.43%), welke 
een vergelijkbare waarde heeft voor detectie van coronaire hartziekten, lijkt het gebruik van 
ultrageluid contrast relatief veilig. Dit manuscript stimuleert  de discussie over welk risico in het 
algemeen acceptabel is voor het uitvoeren van een onderzoek met een bepaalde diagnostische 
waarde. 
  
In Hoofdstuk 3.2. wordt een retrospectief onderzoek beschreven. De resultaten van eerder 
onderzoek hebben gesuggereerd dat tijdens getriggerde MCE premature ventriculaire complexen 
optreden als gevolg van het toedienen van een geluidspuls met hoge intensiteit, die gebruikt wordt 
voor het vernietigen van contrast. Aangezien de veiligheid van ultrageluidcontrast een belangrijke 
voorwaarde is voor het verkrijgen van een registratie voor myocardiale perfusie, en over het 
optreden van PVCs bij real-time MCE niets bekend is, is het doel van deze studie het voorkomen 
van PVCs te onderzoeken. Vijftig gezonde vrijwilligers en zesentwintig patiënten met stabiel 
coronairlijden ondergingen real-time MCE in rust en tijdens adenosine. Het aantal premature 
ventriculaire complexen (PVCs) werd gescored voor contrastinfusie, tijdens de rustfase, en tijdens 
de stressfase. In een zeer beperkt aantal gevallen leidde de hoge ultrageluidpuls tot een PVC. Bij 
de gezonde proefpersonen was het aantal PVCs per minuut gelijk vooraf aan de contrastinfusie 
(0.04±0.23 PVCs/min), tijdens de rustfase (0.04±0.23 PVCs/min, P=NS), en tijdens adenosine 
stress (0.03±0.14, P=NS). Ook bij patienten met coronairlijden was het voorkomen van PVCs niet 
significant hoger tijdens de rust- of stressfase (0.29±0.74 PVCs/min en 0.34±0.74 PVCs/min 
respectievelijk) in vergelijking met de fase voor contrastinfusie (0.30±0.76 PVC/min). Ook het 
aantal onderzochte personen met PVCs nam niet toe tijdens MCE. Er werden geen belangrijke 
ritmestoornissen gezien. Wij concluderen dat real-time MCE veilig is met betrekking tot het 
optreden van premature contracties en overige ritmestoornissen. 
 
Hoofdstuk 4.1 is een overzichtsverhaal over de huidige status van intraveneuze MCE. De 
afgelopen 10 jaar hebben verscheidene studies, allen in het kader van medisch wetenschappelijk 
onderzoek, het belang van MCE voor het bepalen van de myocardiale perfusie onderzocht. Er zijn 
verschillende beeldvormende modaliteiten ontwikkeld, die alle gebruik maken van de 
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harmonische resonantie van microbellen tijdens aanstralen met ultrageluid. Deze modaliteiten 
worden onderverdeeld in die met een hoge (intermittent) en met een lage (real-time, voor 
beoordeling van perfusie en functie tegelijkertijd) geluidsintensiteit. Beide technieken kunnen 
worden gebruikt voor (semi-)quantificatie van de myocardiale perfusie. Bij mensen is alleen 
quantificatie van myocardiale perfusie d.m.v. real-time MCE vergeleken met de gouden 
standaard, positron emissie tomografie, waarbij een goede correlatie werd gezien. 
Bij patiënten met stabiel coronairlijden wordt het opsporen van een significante 
kransslagadervernauwing op dit moment verricht d.m.v. cardiale scintigrafie (SPECT) of 
dobutamine stress echocardiografie (DSE). Verscheidene onderzoeken hebben aangetoond dat de 
overeenkomst tussen deze technieken en MCE hoog is (65-92%). Een vergelijking van deze 
verschillende onderzoeken, waarbij het coronairangiogram als referentie diende, leert dat voor het 
opsporen van significant coronairlijden, de sensitiviteit van MCE hoger is dan die van 
SPECT/DSE (85% versus 71%, p<0.001), met een vergelijkbare specificiteit (74% versus 71%, 
p=ns).  
MCE blijkt ook een hoge sensitiviteit (82%) te hebben voor het detecteren van een verlaagde 
myocardiale perfusie bij patienten met instabiel ischemisch hartlijden, en kan hierdoor ook een rol 
spelen bij het diagnosticeren van het acuut coronair syndroom.  
Naast een belangrijke diagnostische functie, heeft MCE ook een prognostische functie. Bij 
patienten die een acuut myocardinfarct hebben doorgemaakt, definieert MCE nauwkeurig het 
gebied met (in)adequate reperfusie, wat een voorspeller is van functioneel herstel (de sensitiviteit 
van MCE voor het opsporen van functioneel herstel bij follow up is 81%) en dood. Naast 
diagnostische waarde, heeft MCE dus ook belangrijke prognostische waarde. Gezien de 
eenvoudige praktische uitvoering van dit onderzoek, heeft MCE groot potentieel voor de 
routinematige patiëntenzorg.  
 
Hoofdstuk 4.2. Eerder onderzoek bestudeerde de voorspellende waarde van MCE in rust voor het 
herstel van functie na het optreden van een hartinfarct. Aangezien vasodilatoire stress mogelijk 
het opsporen van residuele microvasculaire functie en collaterale bloedstroom vergemakkelijkt, is 
het doel van dit onderzoek de waarde te bepalen van adenosine stress MCE voor het voorspellen 
van functioneel herstel en het schatten van de grootte van de hartschade in de subacute fase van 
het hartinfarct. Vijfentwintig patiënten ondergingen real-time MCE in rust en tijdens adenosine 
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stress. De residuele myocardiale perfusie gemeten met MCE in rust en adenosine correleerde 
significant met de residuele ST-elevatie direct na recanalisatie (r=0.86, p<0.01, versus r=0.66, 
p<0.01 respectievelijk), en met de grootte van de enzymatisch hartschade, peak CK-MB (r=0.76, 
p<0.01 versus r=0.85, p<0.01 respectievelijk). De sensitiviteit voor het detecteren van herstel van 
functie was hoger tijdens adenosine dan tijdens rust, (97% versus 88%), met een gelijke 
specificiteit. Alle patiënten verdroegen het adenosine onderzoek goed. Uit dit onderzoek wordt 
geconcludeerd dat adenosine stress MCE een veilig en klinisch toepasbaar onderzoek is voor het 
opsporen van herstel van functie in de subacute fase van het hartinfarct, met toegevoegde waarde 
t.o.v. het MCE rust onderzoek. 
 
Hoofdstuk 5.1. In dit hoofdstuk, worden de interacties tussen ultrageluid, microbellen, en levende 
cellen onderzocht, evenals hieruitvolgende bioeffecten. Specifiek wordt onderzocht of 
waterstofperoxide (H2O2) betrokken is bij kortstondige verhoogde permeabiliteit van 
cellmembranen in vitro, na blootstelling van cellen aan ultrageluid in de aanwezigheid van 
microbellen, door de productie van H2O2 en de Ca2+ influx te meten. 
In de aan- en afwezigheid van microbellen (SonoVueTM), werden H9c2-cellen met ultrageluid 
aangestraald met een frequentie van 1.8 MHz en een mechanische index (MI) van 0.1 of 0.5 
gedurende 10 seconden. Dit werd elke minuut herhaald, gedurende 5 minuten. De productie van 
H2O2 werd intracellulair gemeten met CM-H2DCFDA. Celmembraanpermeabiliteit werd 
onderzocht door real-time metingen van intracellulair Ca2+ met Fluo-4 d.m.v. ‘live-cell 
fluorescentie microscopie’.  
Ultrageluid, in de aan- en afwezigheid van microbellen, veroorzaakte een significante stijging in 
intracellulair H2O2 bij een MI 0.1 van 50% en bij een MI 0.5 van 110% vergeleken met controle 
(p<0.001). De intracellulaire Ca2–concentratie neemt toe bij zowel MI 0.1 en 0.5 in de 
aanwezigheid van microbellen. Deze stijging werd niet waargenomen in bij afwezigheid van 
extracellulair calcium. In de aanwezigheid van een H2O2-scavenger, catalase, werd de influx van 
Ca2+ geblokkeerd bij MI 0.1 (p<0.01) en verminderd met 50% bij MI 0.5 (p<0.001). De vitaliteit 
van cellen veranderde niet significant, tot 24 uur na ultrageluidblootstelling. De resultaten van dit 
onderzoek wijzen op een rol van H2O2 bij de kortstondige permeabilisatie van de celmembraan 
die geïnduceerd wordt door ultrageluid-aangestraalde microbellen. 
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Hoofdstuk 5.2. bevat een overzichtsverhaal over virale en niet-virale technieken die gebruikt 
wordt voor gentherapie, met speciale aandacht voor het gebruik van ultrageluidcontrastmiddelen. 
Hoewel gentherapie waarschijnlijk een belangrijke toekomstige behandeling wordt voor een 
variëteit aan aandoeningen, worden het verrichten van klinische trials in dit onderzoeksgebied 
geremd door de trage ontwikkeling van een veilige en efficiënte manier om genen in het lichaam 
op de plaats van bestemming te krijgen. De belangrijkste virale vectoren zijn retrovirale, 
lentivirale, adenovirale, en adeno-gelijkende virale vectoren. Niet virale technieken omvatten 
ondermeer micro-injectie, de ‘gene-gun’, magnetofectie, micellen, liposomen en electroporatie. 
Deze huidige technieken zijn over het algemeen matig efficiënt, waarbij de laatste jaren ook de 
veiligheid van virale vectoren wordt betwijfeld. Ultrageluidcontrast is veilig, inert, en bestaat uit 
microbellen die puur intravasculair blijven. De chemische samenstelling maakt het mogelijk 
medicatie, genen en liganden in op op de microbel te binden. Dat laatste kan worden gebruikt om 
microbellen gericht naar een bepaald type weefsel te sturen. Gelocaliseerde destructie van 
microbellen door ultrageluid kan zo leiden tot locale afgifte van een specifiek gen in het weefsel 
van bestemming.  De resultaten van verscheidene studies wekken de verwachting dat microbellen 
in dit onderzoeksgebied een belangrijke rol kunnen spelen. 
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